

Canadian Pharmaceutical Industry Review

2016

http://imsbrogancapabilities.com/YIR_2016_FINAL

...the first of the ...

...the second of the ...

...the third of the ...

...the fourth of the ...

...the fifth of the ...

...the sixth of the ...

...the seventh of the ...

...the eighth of the ...

...the ninth of the ...

...the tenth of the ...

...the eleventh of the ...

...the twelfth of the ...

...the thirteenth of the ...

...the fourteenth of the ...

...the fifteenth of the ...

...the sixteenth of the ...

...the seventeenth of the ...

...the eighteenth of the ...

The Canadian Pharmaceutical Industry at a Glance

From leading companies and products, to the top molecules and classes, this 35th edition of the Canadian *Pharmaceutical Industry Review* provides an overview of market performance in Canada, as measured by QuintilesIMS information services.

The publication summarizes market performance and key industry metrics using four key databases that profile drug store and hospital purchases, prescription volume activity, diagnoses and treatment therapies, promotional activity and expenditures, and the generics market.

This publication also features an executive analysis of the Canadian pharmaceutical market performance. A brief description of the services that were used to generate this review can be found in the Appendix, as well as a list of manufacturer abbreviations and a glossary.

The information contained in Canadian Pharmaceutical Industry Review 2016 is reserved for the exclusive use of QuintilesIMS clients. All reproduction rights reserved.

Copyright© 2017, QuintilesIMS Incorporated

**Contact your representative to learn more about our offerings,
or visit our website:**

Montreal (514) 428-6000 | Ottawa (613) 599-0711 | Toronto (905) 816-5000

www.quintilesims.com

Relevant Data to Improve Commercial Performance in the Life Sciences Industry

Never has healthcare been nearer to the top of the world's agenda than it is today. Each part of the world is facing new challenges and addressing them differently. Developed markets will offset increased costs from new medicines with the use of generics and a greater focus on pricing and access measures, while pharmerging markets will struggle to live up to promised access expansions made when their economic outlooks were stronger.

In seeking to navigate these disparate environments, four major trends are impacting commercial business models in a significant way:

Market Dimensions and Measurement

- Product portfolios are very different today than in the past, driven by more direct connections with patients
- Transformative specialty products and biologics in non-traditional therapy areas require specialized distribution and dispensing channels
- Expanded data in developed markets, new data and methods in emerging markets
- Adoption of biosimilars and non-original biologics

Optimizing Patient Care

- Understanding the patient journey is increasingly important to improving healthcare delivery and patient outcomes
- Multiple types of data are captured at varying points along the patient's journey as they move from testing and diagnosis through to treatment
- Access to rich secondary data is essential given variations by country, by therapy area, across patient and physician segments
- Demonstrating health outcome benefits over time on utilization of therapies, not just efficacy at the time of product launch, is required

Shifting Face of Healthcare Professionals

- Rapid shifts occurring in the number, location, associations, and type of prescribers, including the growth of non-traditional prescribers
- An increasing number of influencers involved in drug selection, with a growing need to understand how they collectively influence treatment decisions

Proliferation of Communication Channels


- More information coming from more sources through more channels than ever before
- The rise of digital technologies, enabling the growth and diversification of vital communication channels is revolutionizing the commercial model
- Traditional approaches to inform and communicate with prescribers, patients, and stakeholders are no longer effective or affordable. More targeted, tailored, and orchestrated communications are vital

Make better decisions, faster

More than ever, the Life Sciences industry is relying on evolving insightful information to help drive more effective commercial performance.

As the leader in healthcare market intelligence, QuintilesIMS takes a vast array of healthcare data and facts and transforms them into actionable intelligence. We give companies a complete and consistent view of market dynamics through global, national, and local measures of product, patient, provider and payer insights, using market-defining methodologies. We continue to invest in new geography coverage, expanded data types and added granularity to help clinical and commercial functions keep pace with change and plan for ongoing success.


The world's largest and most diverse set of healthcare information, including anonymized patient-level data that provides rich insights while ensuring privacy compliance



QuintilesIMS experts can guide you in using Big Data to benefit commercial success:

- Compare market growth forecasts and track competitor moves
- Understand key drivers of product uptake and plan effectively for a successful launch with a view to recent market dynamics and longer-term trends
- Develop effective portfolio strategies from Early-Stage R&D to Loss of Exclusivity (LOE)
- Maximize the performance of your sales force and improve sales and promotional outcomes
- Improve performance at every level of your organization with detailed HCP and organizational insights


Orchestrate your business success – predictably, efficiently, safely and compliantly – across the product lifecycle



Through continual investments in next-generation market measures, QuintilesIMS is able to offer the most comprehensive and complete view of changing market dynamics — from increasingly complex supply chains and payer influences, to emerging specialty products, to real-world evidence and understanding of patients, treatments, outcomes and costs.

Table of Contents

	TABLE	PAGE
Executive Summary		9
Corporations and Manufacturers		13
Leading 50 Corporations by Total Ethical Purchases	1	15
Leading 50 Manufacturers by Share of Total Ethical Purchases, Drug Stores vs. Hospitals	2	18
Leading 50 Manufacturers by Ethical Drug Store Purchases	3	20
Leading 50 Manufacturers by Ethical Hospital Purchases	4	22
Leading 20 Manufacturers and Top Five Products by Ethical Purchases	5	24
Leading 50 Manufacturers by Total Ethical Prescriptions	6	28
Leading 20 Manufacturers and Top Five Products by Total Ethical Prescriptions	7	30
Leading 20 Manufacturers and Top Five Products by Detailing Activity	8	34
Leading 20 Manufacturers and Top Five Products by Journal Ad Expenditures	9	38
Products and Molecules		43
Top 50 Products by Total Ethical Purchases	10	44
Top 50 Products by Ethical Drug Store Purchases	11	46
Top 50 Products by Ethical Hospital Purchases	12	48
Top 25 Molecules by Total Ethical Purchases	13	50
Brand-Name Products Launched by Total Purchases	14	53
Top 50 Products by Total Prescriptions	15	54
Top 15 Products by Total Ethical Purchases, Canada vs. United States	16	56
Top 50 Molecules by Total Prescriptions	17	57
Top 50 Products by Total Promotional Dollars	18	59
Therapeutic Classes		61
Top 15 Therapeutic Classes and Leading Manufacturers by Total Ethical Purchases	19	62
Top 15 Therapeutic Classes and Leading Manufacturers by Ethical Drug Store Purchases	20	65
Top 15 Therapeutic Classes and Leading Manufacturers by Ethical Hospital Purchases	21	68
Top 15 Therapeutic Classes and Leading Brand-Name Manufacturers by Total Ethical Purchases	22	71
Top 15 Therapeutic Classes and Leading Generic Manufacturers by Total Ethical Purchases	23	75
Top 15 Therapeutic Classes and Leading Brand-Name Manufacturers by Total Prescriptions	24	79
Top 15 Therapeutic Classes and Leading Generic Manufacturers by Total Prescriptions	25	83
Top 15 Therapeutic Classes and Leading Corporations by Journal Ad Expenditures	26	87
Top 15 Therapeutic Classes and Leading Corporations by Detailing and Sampling Activity	27	90
Diagnoses and Therapies		93
Profile of Leading Diagnoses	28	94
Profile of Leading Recommended Drug Therapies	29	95
Generic Manufacturers		97
Leading 10 Generic Manufacturers and Top Five Products by Ethical Purchases	30	98
Leading 10 Brand and Generic Drug Manufacturers and Top 5 Provinces by Total Ethical Prescriptions	31	100
Share of Prescription Market by Province, Brand vs. Generic Manufacturers	32	104
Total Ethical Purchases for the Five Leading Brand and Generic Manufacturers by Province	33	105
Top 25 Generic Molecules and Top Five Products by Total Ethical Purchases	34	109
10 Fastest Growing Brand and Generic Manufacturers (larger than \$10 million) by Total Ethical Purchases	35	114
Appendix		115
Information Services		116
Manufacturer Abbreviations		118
Glossary		119





Executive Summary


2016 Market Headlines

Total Prescription Volume Grows +3.6% in 2016, Led Mainly by Generics Performance

Canadian retail pharmacies dispensed 650.3 million prescriptions* for the 12-month period ending December 2016, up +3.6% over 2015 (Figure 1). This is slower than the growth rates posted over the same period in 2015 and 2014 (+4.6% and +4.5% respectively) but consistent with the four-year (2011-2015) CAGR of +3.6%.

Total prescription performance in the current period was led mainly by volume growth of the generics sector of +5.9% – a slight slowdown from the +7.2% rate recorded over the same period last year. The brand sector slowed to -1.3%, down further from the -0.7% posted over the same period last year.

FIGURE 1: Total Prescriptions Volume Grows at +3.6% in 2016 (Down from +4.6% in 2015)
Brand's Performance Slows to -1.3%, Down Further from -0.7% in 2015
 Canadian Market, Total Prescription Volume and % Growth, 2006-2016



Source: QuintilesIMS, Canadian CompuScript, MAT December 2016

* Ethical market only; as at February 2017 data month.

Total Retail and Hospital Purchases

Combined retail and hospital purchases totaled \$25.71 billion in 2016 on growth of +3.2%. That is 3.2 percentage points slower than last year's +6.4% pace but slightly faster than the four-year (2011-2015) CAGR of +2.9%.

The brand sector contributed positively to total market growth in 2016 but at a slower rate than in 2014 and 2015 when the market saw unprecedented growth from a strong product pipeline, led by new hepatitis C therapies. Brand purchases tallied \$20.1 billion in 2016 and accounted for 78.0% of total sales, which is slightly down from last year's share (78.3%).


The generic sector accounted for the remaining 22.0% of market sales at \$5.7 billion in 2016. Generic purchases growth rose by +4.6% in 2016, a healthy increase from the +3.4% rate in the same period last year.

All Market Segments Post Positive Growth Rates in 2016

Market segments, including brands and generics, contributed positively to market performance in 2016 (Figure 2). Brand sales posted low-single-digit growth of +2.8% (down from a +7.3% rate in 2015). Growth was led largely by the contribution of the top three products (all biologics): Bayer's Eylea, Janssen's Remicade and AbbVie's Humira.

The generics sector showed continued improvement in 2016, when compared with 2015, posting growth of +4.6% (up from the +3.4% growth rate posted over the same period in 2015, +1.0% in 2014 and -3.6% in 2013).

FIGURE 2: All Market Segments Post Positive Growth Rates in 2016, Led by *Biologics, Diabetes and Oncology*
Canadian Market Performance by Segment (for select segments)



* The Brands market segment definition includes the Biologics and Oncology segments¹

** The Biologics market segment includes some oncology products. It excludes biosimilar products.

Source: QuintilesIMS, Canadian Drugstore and Hospital Audit. MAT December 2016

¹ The Brands and Generics market segments definition is supplied by QuintilesIMS to help clients split out brand and generic manufacturers in IMSight, using a file designed simply as an aid to customers. It does not reflect a formal definition of brand and generic manufacturers by QuintilesIMS. The file has been compiled based on feedback from customers and research through information in the public domain. Clients are free to employ this existing list or modify it to meet their specific business needs.



Corporations and Manufacturers

T1 | LEADING 50 CORPORATIONS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Rate
TOTAL ETHICAL MARKET						25,713,985	100.0%	3.2%	100	4%
					JANSSEN PHARMA	2,399,445	81.9%	15.3%	103	15%
					MCNEIL CONSUMER	286,647	9.8%	0.3%	89	0%
					LIFESCAN	172,355	5.9%	2.0%	91	-1%
					J&J	72,690	2.5%	1.1%	90	0%
					JANSSEN	17	0.0%	-	-	-
1	1	1	1	1	J & J Subtotal	2,931,155	12.3%	12.4%	109	11%
					NOVARTIS PHARMA	1,170,259	94.2%	-2.0%	100	8%
					NOVARTIS CONS HEALTH	57,899	4.7%	-8.7%	93	2%
					NOVARTIS NUTRITION	11,578	0.9%	11.4%	114	5%
					CIBA VISION OPTICS	1,972	0.2%	-19.8%	82	-14%
7	6	3	2	2	NOVARTIS Subtotal	1,241,708	5.2%	-2.2%	95	7%
					TEVA CANADA LTD	900,518	75.4%	-1.2%	102	-4%
					ACTAVIS PHARMA	225,577	18.9%	-3.7%	99	4%
					COBALT PHARMA	59,089	4.9%	-20.2%	82	-6%
					ROUGIER PHARMA	9,353	0.8%	-6.2%	97	-7%
					RATIOPHARM	5	0.0%	-84.9%	16	-65%
3	3	2	3	3	TEVA CANADA LTD Subtotal	1,194,541	5.0%	-2.9%	94	-3%
					APOTEX INC	1,192,097	100.0%	6.7%	100	-1%
5	4	5	4	4	APOTEX INC Subtotal	1,192,097	5.0%	6.7%	103	-1%
					MERCK CANADA INC	1,123,494	100.0%	13.5%	100	1%
6	5	6	7	5	MERCK CANADA INC Subtotal	1,123,494	4.7%	13.5%	110	1%
					PFIZER	875,090	89.9%	-3.2%	99	-13%
					PFIZER CPD	70,065	7.2%	-1.9%	100	-1%
					GENMED	28,662	2.9%	73.4%	177	9%
2	2	4	6	6	PFIZER Subtotal	973,817	4.1%	-1.8%	95	-12%
					ASTRAZENECA	931,327	100.0%	5.1%	100	-8%
4	8	9	9	7	ASTRAZENECA Subtotal	931,327	3.9%	5.1%	102	-8%
					ROCHE	883,751	100.0%	3.0%	100	4%
9	9	8	10	8	ROCHE Subtotal	883,751	3.7%	3.0%	100	4%
					GILEAD SCIENCES	880,134	100.0%	-18.3%	100	55%
33	27	19	5	9	GILEAD SCIENCES Subtotal	880,134	3.7%	-18.3%	79	55%

T 1 | LEADING 50 CORPORATIONS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Rate
					ABBVIE	864,522	100.0%	14.4%	100	14%
14	14	11	12	10	ABBVIE Subtotal	864,522	3.6%	14.4%	111	14%
					AMGEN	821,268	100.0%	3.4%	100	5%
10	10	10	11	11	AMGEN Subtotal	821,268	3.4%	3.4%	100	5%
					GLAXOSMITHKLINE	752,477	97.3%	-12.2%	101	-2%
					STIEFEL, A GSK CO	15,835	2.0%	-36.6%	73	-20%
					GSK CONSUMER	5,364	0.7%	-32.3%	78	-14%
8	7	7	8	12	GLAXOSMITHKLINE Subtotal	773,676	3.2%	-13.1%	84	-3%
					BAYER HEALTHCARE	680,423	89.2%	31.8%	103	20%
					BAYER CCD	82,717	10.8%	3.2%	81	2%
18	16	16	17	13	BAYER INC Subtotal	763,141	3.2%	28.0%	124	17%
					SANDOZ CANADA INC	738,692	100.0%	7.8%	100	6%
12	12	14	13	14	SANDOZ CANADA INC Subtotal	738,692	3.1%	7.8%	104	6%
					PHARMASCIENCE	522,356	79.5%	-0.4%	100	-1%
					PENDOPHARM	121,838	18.6%	4.2%	104	12%
					DOMINION PHARMACAL	12,476	1.9%	-16.5%	84	-4%
11	11	12	15	15	PHARMASCIENCE Subtotal	656,669	2.8%	0.0%	97	1%
					BMS PHARMA	503,931	84.3%	12.8%	104	21%
					MEAD JOHNSON	58,986	9.9%	-5.4%	87	2%
					BMS-SANOFI	28,973	4.8%	-17.3%	76	-31%
					WESTWOOD SQUIBB	3,679	0.6%	2.0%	94	11%
					LINSON PHARMA INC.	2,479	0.4%	-23.9%	70	-11%
16	18	17	18	16	BRISTOL-MYERS SQUIBB Subtotal	598,048	2.5%	8.5%	105	9%
					LILLY	547,915	100.0%	-18.4%	100	1%
13	13	13	14	17	LILLY Subtotal	547,915	2.3%	-18.4%	79	1%
					SANOFI-AVENTIS	520,561	98.6%	-12.1%	100	2%
					SANOFI-PASTEUR	5,181	1.0%	-0.6%	113	5%
					CHATTEM LABS	2,356	0.4%	-3.3%	110	-4%
15	15	15	16	18	SANOFI-AVENTIS Subtotal	528,098	2.2%	-11.9%	85	2%
					BOEHRINGER ING	428,181	100.0%	3.5%	100	1%
17	17	18	19	19	BOEHRINGER ING Subtotal	428,181	1.8%	3.5%	100	1%
					NOVO NORDISK CDA	413,473	100.0%	4.8%	100	6%
22	19	20	20	20	NOVO NORDISK CDA Subtotal	413,473	1.7%	4.8%	102	6%

T1 | LEADING 50 CORPORATIONS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Rate
					SANIS HEALTH INC	398,480	100.0%	27.2%	100	9%
23	25	26	22	21	SANIS HEALTH INC Subtotal	398,480	1.7%	27.2%	123	9%
					SERVIER LAB.	340,462	100.0%	9.7%	100	11%
27	24	24	23	22	SERVIER LAB. Subtotal	340,462	1.4%	9.7%	106	11%
					PURDUE PHARMA	340,031	100.0%	-0.1%	100	-3%
19	20	21	21	23	PURDUE PHARMA Subtotal	340,031	1.4%	-0.1%	97	-3%
					VALEANT PHARMA	313,288	100.0%	4.8%	100	-1%
21	21	23	24	24	VALEANT PHARMA Subtotal	313,288	1.3%	4.8%	102	-1%
					MYLAN PHARMA	282,226	100.0%	1.3%	100	-5%
20	23	25	25	25	MYLAN PHARMA Subtotal	282,226	1.2%	1.3%	98	-5%
					SHIRE CANADA INC	224,392	100.0%	13.0%	100	20%
41	36	34	29	26	SHIRE CANADA INC Subtotal	224,392	0.9%	13.0%	109	20%
					BIOGEN IDEC	207,141	100.0%	4.0%	100	17%
40	40	33	28	27	BIOGEN IDEC Subtotal	207,141	0.9%	4.0%	101	17%
					PRO DOC	206,664	100.0%	0.0%	100	6%
30	29	29	27	28	PRO DOC Subtotal	206,664	0.9%	0.0%	97	6%
					BGP PHARMA ULC	195,058	100.0%	0.0%	100	-4%
25	26	27	30	29	BGP PHARMA ULC Subtotal	195,058	0.8%	0.0%	97	-4%
					ASTELLAS PHARMA	192,559	100.0%	8.3%	100	15%
38	35	35	34	30	ASTELLAS PHARMA Subtotal	192,559	0.8%	8.3%	105	15%
					ALCON CANADA	178,130	100.0%	-0.6%	100	2%
29	30	30	33	31	ALCON CANADA Subtotal	178,130	0.7%	-0.6%	96	2%
					ABBOTT NUTRITION	123,070	69.5%	-2.0%	100	-2%
					ABBOTT DIABTC CARE	54,001	30.5%	-1.3%	101	1%
28	28	31	32	32	ABBOTT Subtotal	177,071	0.7%	-2.0%	95	-1%
					SIVEM PHARMA ULC	174,435	100.0%	-9.1%	100	105%
49	39	32	31	33	SIVEM PHARMA ULC Subtotal	174,435	0.7%	-9.1%	88	105%
					VIIV HEALTHCARE ULC	166,356	100.0%	21.7%	100	16%
45	46	45	38	34	VIIV HEALTHCARE ULC Subtotal	166,356	0.7%	21.7%	118	16%
					LUNDBECK CANADA INC	164,328	98.9%	6.0%	100	-9%
					LUNDBECK INC	1,759	1.1%	29.4%	122	0%
24	22	22	36	35	H LUNDBECK A/S Subtotal	166,087	0.7%	6.2%	103	-9%

T1 | LEADING 50 CORPORATIONS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Rate
					ASCENSIA DIABETES CA	163,118	100.0%	1.3%	100	0%
32	33	36	35	36	ASCENSIA DIABETES CA Subtotal	163,118	0.7%	1.3%	98	0%
					GENZYME CORP	161,232	100.0%	25.8%	100	107%
50	50	48	41	37	GENZYME CORP Subtotal	161,232	0.7%	25.8%	122	107%
					TAKEDA PHARMA NA	149,393	100.0%	-35.2%	100	3%
34	32	28	26	38	TAKEDA PHARMA NA Subtotal	149,393	0.6%	-35.2%	63	3%
					ALLERGAN	145,944	100.0%	8.0%	100	14%
46	45	41	39	39	ALLERGAN Subtotal	145,944	0.6%	8.0%	105	14%
					PALADIN	132,519	100.0%	-0.1%	100	0%
35	38	39	40	40	PALADIN Subtotal	132,519	0.6%	-0.1%	97	0%
					PRIVATE LABEL	132,434	100.0%	-5.7%	100	-5%
31	34	37	37	41	PRIVATE LABEL Subtotal	132,434	0.6%	-5.7%	91	-5%
					LEO PHARMA INC	122,441	100.0%	2.8%	100	3%
39	41	42	42	42	LEO PHARMA INC Subtotal	122,441	0.5%	2.8%	100	3%
					AA PHARMA INC	121,016	100.0%	3.0%	100	4%
42	42	40	43	43	AA PHARMA INC Subtotal	121,016	0.5%	3.0%	100	4%
					TARO PHARMACEUTICALS	94,480	90.2%	15.8%	102	15%
					TAROPHARMA	10,300	9.8%	-2.8%	86	-1%
48	49	50	49	44	TARO PHARM Subtotal	104,780	0.4%	13.6%	110	13%
					RANBAXY PHARMA CAN	102,815	100.0%	-11.6%	100	-17%
26	31	38	44	45	RANBAXY PHARMA CAN Subtotal	102,815	0.4%	-11.6%	86	-17%
					JAMIESON	98,994	100.0%	3.3%	100	7%
47	47	47	47	46	JAMIESON Subtotal	98,994	0.4%	3.3%	100	7%
					WARNER CHILCOTT	94,295	100.0%	4.7%	100	-1%
44	48	49	50	47	WARNER-LAMBERT Subtotal	94,295	0.4%	4.7%	101	-1%
					EMD CANADA INC	93,195	100.0%	-12.3%	100	-8%
36	37	43	45	48	EMD CANADA INC Subtotal	93,195	0.4%	-12.3%	85	-8%
					TEVA CDN INNOVATION	92,411	100.0%	-1.5%	100	-3%
43	44	46	48	49	TEVA CDN INNOVATION Subtotal	92,411	0.4%	-1.5%	95	-3%
					ROCHE DIAGNOSTICS	92,244	100.0%	-10.6%	100	-6%
37	43	44	46	50	ROCHE DIAGNOSTICS Subtotal	92,244	0.4%	-10.6%	87	-6%

T 2 | LEADING 50 MANUFACTURERS BY SHARE OF TOTAL ETHICAL PURCHASES, DRUG STORES VS. HOSPITALS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	Drug Stores % Share of Purchases	Drug Stores % Change	Evolution Index (Drug Stores)	Hospitals % Share of Purchases	Hospitals % Change	Evolution Index (Hospitals)
TOTAL ETHICAL MARKET						25,713,985	88.6%	3.4%	100	11.4%	1.7%	100
2	1	1	1	1	JANSSEN PHARMA	2,399,445	90.3%	16.9%	113	9.7%	1.8%	100
4	3	2	3	2	APOTEX INC	1,192,097	98.6%	6.5%	103	1.4%	17.8%	116
7	5	3	2	3	NOVARTIS PHARMA	1,170,259	88.6%	-2.2%	95	11.4%	-0.3%	98
5	4	4	5	4	MERCK CANADA INC	1,123,494	79.9%	4.6%	101	20.1%	71.3%	168
3	7	8	8	5	ASTRAZENECA	931,327	93.5%	5.9%	102	6.5%	-4.5%	94
6	6	6	6	6	TEVA CANADA LTD	900,518	95.5%	-0.1%	97	4.5%	-21.3%	77
9	9	7	9	7	ROCHE	883,751	22.8%	-6.0%	91	77.2%	6.0%	104
35	28	18	4	8	GILEAD SCIENCES	880,134	91.7%	-20.0%	77	8.3%	7.3%	106
1	2	5	7	9	PFIZER	875,090	90.1%	-3.4%	93	9.9%	-1.6%	97
14	13	11	12	10	ABBVIE	864,522	92.6%	18.5%	115	7.4%	-20.3%	78
10	10	10	11	11	AMGEN	821,268	84.7%	4.1%	101	15.3%	-0.4%	98
8	8	9	10	12	GLAXOSMITHKLINE	752,477	90.5%	-13.0%	84	9.5%	-3.8%	95
11	11	13	13	13	SANDOZ CANADA INC	738,692	82.5%	8.4%	105	17.5%	5.1%	103
20	18	17	17	14	BAYER HEALTHCARE	680,423	91.2%	27.5%	123	8.8%	101.0%	198
13	12	12	14	15	LILLY	547,915	86.6%	-17.7%	80	13.4%	-22.4%	76
12	14	15	16	16	PHARMASCIENCE	522,356	96.3%	0.2%	97	3.7%	-15.0%	84
15	15	14	15	17	SANOFI-AVENTIS	520,561	79.1%	1.6%	98	20.9%	-41.8%	57
25	23	20	18	18	BMS PHARMA	503,931	87.6%	25.8%	122	12.4%	-34.9%	64
16	16	16	19	19	BOEHRINGER ING	428,181	95.3%	2.9%	100	4.7%	18.0%	116
21	17	19	20	20	NOVO NORDISK CDA	413,473	99.2%	5.4%	102	0.8%	-36.0%	63
23	26	27	22	21	SANIS HEALTH INC	398,480	100.0%	27.2%	123	0.0%	3.6%	102
28	25	24	23	22	SERVIER LAB.	340,462	99.9%	9.8%	106	0.1%	-19.3%	79
17	19	21	21	23	PURDUE PHARMA	340,031	97.3%	-0.2%	96	2.7%	7.1%	105
19	20	23	24	24	VALEANT PHARMA	313,288	98.3%	4.9%	101	1.7%	-1.6%	97
22	22	25	25	25	MCNEIL CONSUMER	286,647	98.5%	0%	97	1.5%	22.3%	120
18	24	26	26	26	MYLAN PHARMA	282,226	96.8%	2.2%	99	3.2%	-20.0%	79
29	31	28	27	27	ACTAVIS PHARMA	225,577	95.3%	-7.8%	89	4.7%	788.9%	874
42	39	36	31	28	SHIRE CANADA INC	224,392	99.0%	12.9%	109	1.0%	17.0%	115
41	42	35	30	29	BIOGEN IDEC	207,141	98.5%	4.0%	101	1.5%	2.4%	101

T 2 | LEADING 50 MANUFACTURERS BY SHARE OF TOTAL ETHICAL PURCHASES, DRUG STORES VS. HOSPITALS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	Drug Stores % Share of Purchases	Drug Stores % Change	Evolution Index (Drug Stores)	Hospitals % Share of Purchases	Hospitals % Change	Evolution Index (Hospitals)
32	29	31	29	30	PRO DOC	206,664	100.0%	0.1%	97	0.0%	-72.4%	27
26	27	29	32	31	BGP PHARMA ULC	195,058	98.2%	1.7%	98	1.8%	-47.9%	51
39	38	37	35	32	ASTELLAS PHARMA	192,559	68.4%	1.8%	98	31.6%	25.6%	124
31	30	32	34	33	ALCON CANADA	178,130	94.7%	-0.6%	96	5.3%	-1.9%	97
49	41	33	33	34	SIVEM PHARMA ULC	174,435	99.5%	-9.3%	88	0.5%	30.9%	129
30	32	34	36	35	LIFESCAN	172,355	99.9%	2.0%	99	0.1%	0.2%	99
44	46	46	40	36	VIIV HEALTHCARE ULC	166,356	68.3%	18.9%	115	31.7%	28.4%	126
24	21	22	38	37	LUNDBECK CANADA INC	164,328	65.2%	3.7%	100	34.8%	10.8%	109
34	35	38	37	38	ASCENSIA DIABETES CA	163,118	99.7%	1.4%	98	0.3%	-10.4%	88
50	50	49	43	39	GENZYME CORP	161,232	84.0%	35.0%	131	16.0%	-7.4%	91
37	34	30	28	40	TAKEDA PHARMA NA	149,393	99.5%	-35.1%	63	0.5%	-49.2%	50
45	45	44	41	41	ALLERGAN	145,944	96.0%	7.2%	104	4.0%	31.9%	130
38	40	42	42	42	PALADIN	132,519	94.1%	0.4%	97	5.9%	-6.9%	92
33	36	39	39	43	PRIVATE LABEL	132,434	99.7%	-5.7%	91	0.3%	2.7%	101
36	37	41	44	44	ABBOTT NUTRITION	123,070	93.4%	-2.2%	95	6.6%	0.4%	99
40	43	45	45	45	LEO PHARMA INC	122,441	91.9%	2.8%	99	8.1%	2.8%	101
46	47	47	47	46	PENDOPHARM	121,838	87.6%	4.0%	101	12.4%	5.6%	104
43	44	43	46	47	AA PHARMA INC	121,016	95.6%	2.7%	99	4.4%	8.5%	107
27	33	40	48	48	RANBAXY PHARMA CAN	102,815	99.1%	-11.4%	86	0.9%	-29.2%	70
47	48	48	49	49	JAMIESON	98,994	99.6%	3.3%	100	0.4%	-4.2%	94
48	49	50	50	50	TARO PHARMACEUTICALS	94,480	96.2%	16.8%	113	3.8%	-4.4%	94

T3 | LEADING 50 MANUFACTURERS BY ETHICAL DRUG STORE PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Drug Store Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Growth
TOTAL ETHICAL DRUG STORE PURCHASES						22,786,456	100.0%	3.4%	100	4%
4	1	1	1	1	JANSSEN PHARMA	2,167,635	9.5%	16.9%	113	15%
2	3	2	2	2	APOTEX INC	1,175,033	5.2%	6.5%	103	-1%
8	6	4	3	3	NOVARTIS PHARMA	1,037,425	4.6%	-2.2%	95	8%
6	4	5	6	4	MERCK CANADA INC	897,127	3.9%	4.6%	101	1%
3	7	7	7	5	ASTRAZENECA	871,230	3.8%	5.9%	102	-8%
5	5	6	5	6	TEVA CANADA LTD	860,269	3.8%	-0.1%	97	-4%
38	36	18	4	7	GILEAD SCIENCES	806,771	3.5%	-20.0%	77	55%
13	11	10	10	8	ABBVIE	800,927	3.5%	18.5%	115	14%
1	2	3	8	9	PFIZER	788,115	3.5%	-3.4%	93	-13%
9	9	9	11	10	AMGEN	695,910	3.1%	4.1%	101	5%
7	8	8	9	11	GLAXOSMITHKLINE	680,652	3.0%	-13.0%	84	-2%
19	17	15	15	12	BAYER HEALTHCARE	620,554	2.7%	27.5%	123	20%
12	13	12	13	13	SANDOZ CANADA INC	609,074	2.7%	8.4%	105	6%
10	10	13	14	14	PHARMASCIENCE	502,863	2.2%	0.2%	97	-1%
11	12	11	12	15	LILLY	474,703	2.1%	-17.7%	80	1%
29	26	23	19	16	BMS PHARMA	441,498	1.9%	25.8%	122	21%
20	16	16	16	17	SANOFI-AVENTIS	411,984	1.8%	1.6%	98	2%
18	15	17	18	18	NOVO NORDISK CDA	410,173	1.8%	5.4%	102	6%
14	14	14	17	19	BOEHRINGER ING	408,256	1.8%	2.9%	100	1%
22	25	25	21	20	SANIS HEALTH INC	398,440	1.7%	27.2%	123	9%
26	22	21	22	21	SERVIER LAB.	340,075	1.5%	9.8%	106	11%
15	18	19	20	22	PURDUE PHARMA	330,746	1.5%	-0.2%	96	-3%
17	19	20	23	23	VALEANT PHARMA	307,992	1.4%	4.9%	101	-1%
21	20	22	24	24	MCNEIL CONSUMER	282,396	1.2%	0%	97	0%
16	23	26	25	25	MYLAN PHARMA	273,091	1.2%	2.2%	99	-5%
39	37	35	30	26	SHIRE CANADA INC	222,145	1.0%	12.9%	109	20%
28	29	28	26	27	ACTAVIS PHARMA	214,982	0.9%	-7.8%	89	4%
31	28	31	29	28	PRO DOC	206,663	0.9%	0.1%	97	6%
40	41	36	31	29	BIOGEN IDEC	204,130	0.9%	4.0%	101	17%

T3 | LEADING 50 MANUFACTURERS BY ETHICAL DRUG STORE PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Drug Store Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Growth
27	24	27	28	30	ROCHE	201,669	0.9%	-6.0%	91	4%
24	27	29	33	31	BGP PHARMA ULC	191,525	0.8%	1.7%	98	-4%
49	38	33	32	32	SIVEM PHARMA ULC	173,576	0.8%	-9.3%	88	105%
30	31	34	35	33	LIFESCAN	172,100	0.8%	2.0%	99	-1%
33	30	32	34	34	ALCON CANADA	168,618	0.7%	-0.6%	96	2%
34	34	37	36	35	ASCENSIA DIABETES CA	162,640	0.7%	1.4%	98	0%
35	33	30	27	36	TAKEDA PHARMA NA	148,579	0.7%	-35.1%	63	3%
44	44	44	38	37	ALLERGAN	140,077	0.6%	7.2%	104	14%
50	50	50	47	38	GENZYME CORP	135,381	0.6%	35.0%	131	107%
32	35	38	37	39	PRIVATE LABEL	132,096	0.6%	-5.7%	91	-5%
45	45	43	39	40	ASTELLAS PHARMA	131,625	0.6%	1.8%	98	15%
36	40	42	40	41	PALADIN	124,634	0.5%	0.4%	97	0%
41	42	41	43	42	AA PHARMA INC	115,734	0.5%	2.7%	99	4%
37	39	40	41	43	ABBOTT NUTRITION	114,915	0.5%	-2.2%	95	-2%
48	49	49	48	44	VIIV HEALTHCARE ULC	113,668	0.5%	18.9%	115	16%
42	43	45	44	45	LEO PHARMA INC	112,551	0.5%	2.8%	99	3%
23	21	24	45	46	LUNDBECK CANADA INC	107,107	0.5%	3.7%	100	-9%
47	48	48	46	47	PENDOPHARM	106,680	0.5%	4.0%	101	12%
25	32	39	42	48	RANBAXY PHARMA CAN	101,918	0.4%	-11.4%	86	-17%
46	46	46	49	49	JAMIESON	98,564	0.4%	3.3%	100	7%
43	47	47	50	50	WARNER CHILCOTT	93,696	0.4%	4.7%	101	-1%

T 4 | LEADING 50 MANUFACTURERS BY ETHICAL HOSPITAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Hospital Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Growth Rate
TOTAL ETHICAL HOSPITAL PURCHASES						2,927,529	100.0%	1.7%	100	4%
1	1	1	1	1	ROCHE	682,082	23.3%	6.0%	104	4%
2	2	2	2	2	JANSSEN PHARMA	231,810	7.9%	1.8%	100	15%
8	5	5	5	3	MERCK CANADA INC	226,366	7.7%	71.3%	168	1%
5	4	4	4	4	NOVARTIS PHARMA	132,834	4.5%	-0.3%	98	8%
4	6	7	7	5	SANDOZ CANADA INC	129,618	4.4%	5.1%	103	6%
7	7	6	6	6	AMGEN	125,358	4.3%	-0.4%	98	5%
3	3	3	3	7	SANOFI-AVENTIS	108,577	3.7%	-41.8%	57	2%
6	8	8	10	8	PFIZER	86,975	3.0%	-1.6%	97	-13%
16	15	15	13	9	GILEAD SCIENCES	73,363	2.5%	7.3%	106	55%
12	10	10	9	10	LILLY	73,212	2.5%	-22.4%	76	1%
11	9	11	12	11	GLAXOSMITHKLINE	71,825	2.5%	-3.8%	95	-2%
10	13	12	11	12	ABBVIE	63,595	2.2%	-20.3%	78	14%
15	12	9	8	13	BMS PHARMA	62,433	2.1%	-34.9%	64	21%
17	17	17	17	14	ASTELLAS PHARMA	60,934	2.1%	25.6%	124	15%
9	11	13	14	15	ASTRAZENECA	60,097	2.1%	-4.5%	94	-8%
25	26	25	20	16	BAYER HEALTHCARE	59,869	2.0%	101.0%	198	20%
43	20	16	15	17	LUNDBECK CANADA INC	57,221	2.0%	10.8%	109	-9%
19	18	19	19	18	VIIV HEALTHCARE ULC	52,688	1.8%	28.4%	126	16%
13	14	14	18	19	HOSPIRA	44,648	1.5%	-6.8%	92	-4%
14	16	18	16	20	TEVA CANADA LTD	40,249	1.4%	-21.3%	77	-4%
21	22	22	23	21	HLS THERAPEUTICS,INC	27,727	0.9%	11.1%	109	3%
46	37	20	21	22	GENZYME CORP	25,851	0.9%	-7.4%	91	107%
22	24	24	22	23	ID BIOMEDICAL CORP	25,268	0.9%	-2.9%	95	4%
35	28	28	26	24	STERIMAX INC	21,098	0.7%	16.0%	114	38%
24	25	27	27	25	BOEHRINGER ING	19,924	0.7%	18.0%	116	1%
23	21	23	25	26	PHARMASCIENCE	19,493	0.7%	-15.0%	84	-1%
18	19	21	24	27	BMS-GILEAD	19,134	0.7%	-16.8%	82	-10%
20	23	26	28	28	APOTEX INC	17,064	0.6%	17.8%	116	-1%
31	29	31	29	29	PENDOPHARM	15,158	0.5%	5.6%	104	12%

T 4 | LEADING 50 MANUFACTURERS BY ETHICAL HOSPITAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Hospital Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Growth Rate
26	27	30	30	30	LUITPOLD PHARMA	13,009	0.4%	3.1%	101	0%
45	43	40	35	31	CUBIST PHARMA INC	11,588	0.4%	21.6%	120	27%
50	50	46	32	32	ALVEDA PHARMA INC	11,488	0.4%	9.0%	107	113%
38	35	37	37	33	FRESENIUS KABI CDN	10,965	0.4%	24.4%	122	17%
49	49	50	50	34	ACTAVIS PHARMA	10,595	0.4%	788.9%	874	4%
41	41	41	39	35	PHARMA PARTNERS	10,323	0.4%	17.6%	116	14%
29	33	33	34	36	LEO PHARMA INC	9,890	0.3%	2.8%	101	3%
37	39	39	33	37	ALCON CANADA	9,512	0.3%	-1.9%	97	2%
32	36	36	40	38	PURDUE PHARMA	9,286	0.3%	7.1%	105	-3%
28	31	32	31	39	MYLAN PHARMA	9,135	0.3%	-20.0%	79	-5%
30	34	38	42	40	ABBOTT NUTRITION	8,155	0.3%	0.4%	99	-2%
40	42	43	44	41	FERRING	8,121	0.3%	5.7%	104	4%
36	40	42	43	42	BAXTER CANADA INC	7,925	0.3%	1.5%	100	0%
33	38	34	41	43	PALADIN	7,884	0.3%	-6.9%	92	0%
34	30	29	36	44	NOVARTIS VACCINES	7,821	0.3%	-13.7%	85	-5%
27	32	35	38	45	EMD CANADA INC	7,553	0.3%	-14.0%	85	-8%
42	44	44	45	46	OMEGA	7,479	0.3%	10.4%	109	8%
48	48	49	48	47	OTSUKA	7,183	0.2%	49.7%	147	128%
47	47	48	49	48	ALLERGAN	5,867	0.2%	31.9%	130	14%
39	45	45	46	49	VALEANT PHARMA	5,296	0.2%	-1.6%	97	-1%
44	46	47	47	50	AA PHARMA INC	5,283	0.2%	8.5%	107	4%

T5 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY ETHICAL PURCHASES

		Ethical Purchases (\$000s)	% Share of Market	% Change
TOTAL ETHICAL MARKET		25,713,985	100.0%	3.2%
	REMICADE : JAN : 06/01	1,037,163	43.2%	13.8%
	STELARA : JAN : 01/09	195,537	8.1%	33.4%
	CONCERTA : JAN : 08/03	156,823	6.5%	10.0%
	INVEGA SUSTENNA : JAN : 08/10	139,282	5.8%	18.5%
	SIMPONI : JAN : 06/09	122,542	5.1%	16.4%
1	JANSSEN PHARMA Subtotal	2,399,445	9.3%	15.3%
	APO-ATORVASTATIN : ATX : 05/10	101,345	8.5%	4.0%
	APO-ESOMEPRAZOLE : ATX : 03/11	60,956	5.1%	-31.9%
	APO-ROSUVASTATIN : ATX : 04/12	45,531	3.8%	11.0%
	APO-MOMETASONE : ATX : 03/13	40,834	3.4%	4.7%
	APO-OMEPRAZOLE : ATX : 02/04	35,066	2.9%	3.8%
2	APOTEX INC Subtotal	1,192,097	4.6%	6.7%
	LUCENTIS : NVR : 08/07	347,964	29.7%	-26.0%
	XOLAIR : NVR : 02/05	109,836	9.4%	25.5%
	GILENYA : NVR : 04/11	94,678	8.1%	16.0%
	SANDOSTATIN LAR : NVR : 01/99	86,545	7.4%	5.1%
	GLEEVEC : NVR : 10/01	53,189	4.5%	-5.2%
3	NOVARTIS PHARMA Subtotal	1,170,259	4.6%	-2.0%
	JANUMET : M-F : 10/09	184,545	16.4%	17.2%
	JANUVIA : M-F : 01/08	167,701	14.9%	6.2%
	ZOSTAVAX II : M-F : 05/14	88,987	7.9%	35.4%
	OLMETEC : M-F : 03/09	54,123	4.8%	16.9%
	GARDASIL : M-F : 08/06	53,275	4.7%	9.3%
4	MERCK CANADA INC Subtotal	1,123,494	4.4%	13.5%
	SYMBICORT : AZN : 02/02	211,172	22.7%	5.3%
	CRESTOR : AZN : 02/03	145,125	15.6%	0.3%
	NEXIUM : AZN : 08/01	76,212	8.2%	-14.0%
	ONGLYZA : AZN : 11/09	64,230	6.9%	-3.3%
	ZOLADEX LA : AZN : 01/90	47,077	5.1%	-0.8%
5	ASTRAZENECA Subtotal	931,327	3.6%	5.1%

T5 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY ETHICAL PURCHASES

		Ethical Purchases (\$000s)	% Share of Market	% Change
	TEVA-VENLAFAXINE XR : TEV : 12/06	38,767	4.3%	4.6%
	TEVA-FENTANYL : TEV : 08/06	34,060	3.8%	-8.8%
	TEVA-ROSUVASTATIN : TEV : 04/12	28,386	3.2%	-27.8%
	TEVA-CEPHALEXIN : TEV : 02/80	27,821	3.1%	26.0%
	RATIO-OXYCOCET : TEV : 04/84	25,041	2.8%	3.3%
6	TEVA CANADA LTD Subtotal	900,518	3.5%	-1.2%
	RITUXAN : ROC : 04/00	247,934	28.1%	5.0%
	HERCEPTIN : ROC : 08/99	185,401	21.0%	0.9%
	AVASTIN : ROC : 11/05	107,324	12.1%	-2.4%
	PERJETA & HERCEPTIN : ROC : 05/13	73,929	8.4%	50.7%
	ACTEMRA : ROC : 05/10	43,992	5.0%	16.6%
7	ROCHE Subtotal	883,751	3.4%	3.0%
	HARVONI : GS- : 10/14	416,541	47.3%	-33.9%
	SOVALDI : GS- : 01/14	155,205	17.6%	-16.4%
	TRUVADA : GS- : 04/06	104,017	11.8%	2.5%
	VIREAD : GS- : 03/04	79,040	9.0%	4.2%
	STRIBILD : GS- : 12/12	50,268	5.7%	8.3%
8	GILEAD SCIENCES Subtotal	880,134	3.4%	-18.3%
	FRAGMIN : PFZ : 03/95	108,058	12.3%	4.6%
	PRISTIQ : PFZ : 03/09	65,577	7.5%	7.0%
	EPIPEN : PFZ : 09/85	65,436	7.5%	-4.7%
	LIPITOR : PFZ : 03/97	65,224	7.5%	-6.3%
	VIAGRA : PFZ : 03/99	45,813	5.2%	-1.7%
9	PFIZER Subtotal	875,090	3.4%	-3.2%
	HUMIRA : AV1 : 07/06	668,580	77.3%	15.0%
	LUPRON DEPOT : AV1 : 04/85	65,604	7.6%	6.5%
	HOLKIRA PAK : AV1 : 01/15	60,308	7.0%	138.5%
	SYNAGIS : AV1 : 02/08	33,544	3.9%	-29.7%
	SEVORANE : AV1 : 12/95	11,081	1.3%	-13.9%
10	ABBVIE Subtotal	864,522	3.4%	14.4%

T5 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY ETHICAL PURCHASES

		Ethical Purchases (\$'000s)	% Share of Market	% Change
	ENBREL : AAI : 03/01	346,988	42.3%	-0.1%
	NEUPOGEN : AAI : 03/92	130,085	15.8%	-1.4%
	ARANESP : AAI : 08/02	113,867	13.9%	5.7%
	PROLIA : AAI : 08/10	99,612	12.1%	24.8%
	NEULASTA : AAI : 04/04	66,451	8.1%	-3.7%
11	AMGEN Subtotal	821,268	3.2%	3.4%
	FLOVENT HFA : GSK : 02/02	125,977	16.7%	-1.4%
	ADVAIR 250 : GSK : 10/99	114,284	15.2%	-6.1%
	ADVAIR 250 DISKUS : GSK : 10/99	89,775	11.9%	-8.5%
	ADVAIR 500 DISKUS : GSK : 10/99	77,512	10.3%	-11.5%
	ADVAIR 125 : GSK : 10/99	32,041	4.3%	-5.3%
12	GLAXOSMITHKLINE Subtotal	752,477	2.9%	-12.2%
	SANDOZ PANTOPRAZOLE : SDZ : 06/08	32,664	4.4%	13.9%
	SANDOZ-RABEPRAZOLE : SDZ : 09/08	29,997	4.1%	4.6%
	SANDOZ-AMLODIPINE : SDZ : 07/09	22,649	3.1%	-17.4%
	SANDOZ-METFORMIN FC : SDZ : 12/97	20,101	2.7%	24.6%
	SANDOZ VALSARTAN : SDZ : 02/11	19,228	2.6%	5.0%
13	SANDOZ CANADA INC Subtotal	738,692	2.9%	7.8%
	EYLEA : BAY : 12/13	246,329	36.2%	154.1%
	XARELTO : BAY : 10/08	179,886	26.4%	19.3%
	ADALAT XL : BAY : 04/92	64,324	9.5%	0.1%
	MIRENA : BAY : 02/01	53,577	7.9%	4.3%
	BETASERON : BAY : 11/95	15,515	2.3%	-15.8%
14	BAYER HEALTHCARE Subtotal	680,423	2.6%	31.8%
	CYMBALTA : LLY : 01/08	166,881	30.5%	-37.7%
	CIALIS : LLY : 11/03	107,475	19.6%	-12.3%
	HUMALOG : LLY : 11/96	71,597	13.1%	5.0%
	ALIMTA : LLY : 08/04	48,013	8.8%	-28.6%
	FORTEO : LLY : 07/04	23,400	4.3%	24.8%
15	LILLY Subtotal	547,915	2.1%	-18.4%

T5 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY ETHICAL PURCHASES

		Ethical Purchases (\$000s)	% Share of Market	% Change
	PMS-PREGABALIN : P8I : 02/13	31,853	6.1%	43.9%
	PMS-ZOPICLONE : P8I : 09/99	21,404	4.1%	-23.3%
	PMS-CETIRIZINE : P8I : 12/08	20,832	4.0%	-12.4%
	PMS-VALACYCLOVIR : P8I : 05/08	20,591	3.9%	195.3%
	PMS-HYDROMORPHONE : P8I : 07/91	16,530	3.2%	2.2%
16	PHARMASCIENCE Subtotal	522,356	2.0%	-0.4%
	LANTUS SOLOSTAR : S.A : 01/08	157,899	30.3%	9.4%
	LANTUS : S.A : 02/05	89,791	17.2%	-4.0%
	LOVENOX : S.A : 02/93	54,126	10.4%	-2.7%
	ELIGARD : S.A : 04/04	40,631	7.8%	6.1%
	TOUJEO SOLOSTAR : S.A : 07/15	17,794	3.4%	859.7%
17	SANOFI-AVENTIS Subtotal	520,561	2.0%	-12.1%
	ABILIFY : BMS : 10/09	162,248	32.2%	14.9%
	ELIQUIS : BMS : 02/12	138,823	27.5%	66.9%
	ORENCIA : BMS : 03/07	64,672	12.8%	19.1%
	SPRYCEL : BMS : 04/07	49,620	9.8%	11.1%
	REYATAZ : BMS : 01/04	28,622	5.7%	-24.6%
18	BMS PHARMA Subtotal	503,931	2.0%	12.8%
	SPIRIVA : B.I : 01/03	154,889	36.2%	-19.6%
	PRADAXA : B.I : 08/08	79,706	18.6%	-6.7%
	TRAJENTA : B.I : 09/11	49,590	11.6%	22.7%
	JARDIANCE : B.I : 09/15	25,847	6.0%	>999.9%
	ATROVENT HFA : B.I : 10/04	19,713	4.6%	-4.0%
19	BOEHRINGER ING Subtotal	428,181	1.7%	3.5%
	VICTOZA : N-N : 05/10	98,401	23.8%	10.0%
	NOVORAPID : N-N : 01/02	67,405	16.3%	-8.9%
	LEVEMIR : N-N : 01/06	60,421	14.6%	-11.3%
	VAGIFEM 10 : N-N : 11/10	49,404	11.9%	9.5%
	NOVOLIN GE NPH : N-N : 08/93	23,605	5.7%	-8.3%
20	NOVO NORDISK CDA Subtotal	413,473	1.6%	4.8%

T6 | LEADING 50 MANUFACTURERS BY TOTAL ETHICAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Growth Rate
TOTAL ETHICAL PRESCRIPTIONS						649,746	100.0%	3.7%	100	4%
1	1	1	1	1	APOTEX INC	89,878	13.8%	4.0%	100	0%
2	2	2	2	2	TEVA CANADA LTD	75,373	11.6%	6.1%	102	1%
3	3	3	3	3	PHARMASCIENCE	50,225	7.7%	5.4%	102	5%
4	4	4	4	4	SANDOZ CANADA INC	45,363	7.0%	9.2%	105	12%
6	5	5	5	5	PRO DOC	36,467	5.6%	1.2%	98	9%
11	8	6	6	6	SANIS HEALTH INC	29,572	4.6%	22.2%	118	21%
7	7	9	8	7	BGP PHARMA ULC	20,691	3.2%	5.6%	102	3%
47	10	8	7	8	SIVEM PHARMA ULC	18,781	2.9%	-15.5%	82	166%
26	22	11	10	9	JAMP PHARMA	18,481	2.8%	23.2%	119	41%
10	11	13	12	10	MYLAN PHARMA	14,402	2.2%	10.2%	106	-2%
5	6	7	9	11	PFIZER	13,735	2.1%	-10.6%	86	-15%
15	16	12	11	12	ACTAVIS PHARMA	12,426	1.9%	-11.0%	86	6%
9	9	10	13	13	MERCK CANADA INC	10,830	1.7%	-0.4%	96	-9%
8	14	15	15	14	ASTRAZENECA	10,460	1.6%	2.3%	99	-13%
17	17	17	16	15	TARO PHARMACEUTICALS	10,232	1.6%	5.2%	102	7%
12	13	14	14	16	GLAXOSMITHKLINE	8,840	1.4%	-15.4%	82	-6%
18	19	21	21	17	RIVA	8,799	1.4%	13.4%	109	5%
22	20	19	17	18	SERVIER LAB.	8,649	1.3%	2.8%	99	9%
-	50	34	22	19	MALLINCKRODT	8,418	1.3%	20.8%	117	-
14	15	18	19	20	AA PHARMA INC	8,242	1.3%	4.4%	101	-4%
16	18	20	18	21	JANSSEN PHARMA	7,741	1.2%	-2.2%	94	-2%
13	12	16	20	22	RANBAXY PHARMA CAN	6,937	1.1%	-10.8%	86	-11%
23	24	25	24	23	PURDUE PHARMA	6,394	1.0%	4.2%	101	2%
24	25	26	27	24	PENDOPHARM	5,859	0.9%	2.0%	98	4%
21	23	24	26	25	BAYER HEALTHCARE	5,683	0.9%	-3.8%	93	-3%
19	21	22	25	26	VALEANT PHARMA	5,521	0.8%	-7.7%	89	-6%
20	26	28	29	27	BOEHRINGER ING	5,258	0.8%	2.5%	99	-5%
34	32	31	31	28	BMS PHARMA	5,076	0.8%	18.5%	114	15%
25	27	29	30	29	ALCON CANADA	4,705	0.7%	-4.5%	92	0%

T6 | LEADING 50 MANUFACTURERS BY TOTAL ETHICAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Growth Rate
27	28	27	28	30	LILLY	4,524	0.7%	-17.9%	79	-1%
30	29	23	23	31	TAKEDA PHARMA NA	4,030	0.6%	-41.7%	56	6%
43	42	43	37	32	MINT PHARMACEUTICALS	3,658	0.6%	38.9%	134	38%
32	35	30	32	33	COBALT PHARMA	3,456	0.5%	-15.6%	81	2%
29	30	32	33	34	SANOFI-AVENTIS	3,435	0.5%	0.7%	97	1%
31	31	33	34	35	PALADIN	3,418	0.5%	5.2%	101	2%
48	49	50	49	36	AURO PHARMA INC	3,289	0.5%	120.9%	213	119%
49	48	44	38	37	MARCAN PHARMA INC	3,258	0.5%	26.2%	122	285%
28	33	36	35	38	NOVARTIS PHARMA	3,031	0.5%	-2.5%	94	-5%
33	34	35	36	39	NOVO NORDISK CDA	3,010	0.5%	-0.6%	96	0%
42	44	45	42	40	WEBBER	2,740	0.4%	19.9%	116	26%
46	46	49	47	41	MANTRA PHARMA	2,619	0.4%	62.2%	157	42%
38	40	41	43	42	WARNER CHILCOTT	2,394	0.4%	5.4%	102	2%
39	41	42	41	43	ALLERGAN	2,382	0.4%	4.1%	100	9%
35	36	37	40	44	TRITON PHARMA INC	2,194	0.3%	-7.6%	89	-3%
41	39	38	39	45	DOMINION PHARMACAL	2,076	0.3%	-19.4%	78	6%
37	37	39	45	46	LEO PHARMA INC	2,060	0.3%	1.7%	98	-2%
44	45	47	46	47	SHIRE CANADA INC	2,023	0.3%	14.2%	110	21%
36	38	40	44	48	JAMIESON	1,995	0.3%	-3.3%	93	-4%
40	43	46	48	49	MCNEIL CONSUMER	1,737	0.3%	11.7%	108	1%
45	47	48	50	50	WAMPOLE	1,400	0.2%	3.4%	100	19%

T7 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY TOTAL ETHICAL PRESCRIPTIONS

		# of Rx (000s)	% Share of Market	% Change
TOTAL ETHICAL PRESCRIPTIONS		649,746	100.0%	3.7%
	APO-ATORVASTATIN : ATX : 05/10	5,913	6.6%	6.6%
	APO-FUROSEMIDE : ATX : 06/76	3,498	3.9%	7.0%
	APO-ROSUVASTATIN : ATX : 04/12	3,442	3.8%	11.6%
	APO-METOPROLOL : ATX : 10/84	2,255	2.5%	-6.9%
	APO-AMOXI : ATX : 08/84	2,118	2.4%	-2.8%
1	APOTEX INC Subtotal	89,878	13.8%	4.0%
	TEVA-FUROSEMIDE : TEV : 08/76	3,732	5.0%	14.1%
	TEVA-VENLAFAXINE XR : TEV : 12/06	3,263	4.3%	11.2%
	TEVA-SALBUTAMOL HFA : TEV : 01/10	2,781	3.7%	25.0%
	RATIO-LENOLTEC #3 : TEV : 11/85	2,701	3.6%	8.9%
	TEVA-ROSUVASTATIN : TEV : 04/12	2,685	3.6%	-15.5%
2	TEVA CANADA LTD Subtotal	75,373	11.6%	6.1%
	PMS-CLONAZEPAM-R : P8I : 03/96	2,272	4.5%	3.1%
	PMS-HYDROCHLOROTHIAZDE : P8I : 10/04	2,179	4.3%	8.6%
	PMS-HYDROMORPHONE : P8I : 07/91	1,722	3.4%	8.0%
	PMS-METOPROLOL-L : P8I : 10/97	1,675	3.3%	80.4%
	PMS-ZOPICLONE : P8I : 09/99	1,652	3.3%	-10.5%
3	PHARMASCIENCE Subtotal	50,225	7.7%	5.4%
	SANDOZ-BISOPROLOL : SDZ : 08/03	3,675	8.1%	18.3%
	SANDOZ-METFORMIN FC : SDZ : 12/97	3,638	8.0%	50.4%
	SANDOZ PANTOPRAZOLE : SDZ : 06/08	2,473	5.5%	15.0%
	SANDOZ-RABEPRAZOLE : SDZ : 09/08	2,248	5.0%	3.3%
	SANDOZ-AMLODIPINE : SDZ : 07/09	2,102	4.6%	-9.1%
4	SANDOZ CANADA INC Subtotal	45,363	7.0%	9.2%
	ATORVASTATIN : PDO : 08/10	2,171	6.0%	-4.4%
	PRO-AAS EC-80 : PDO : 11/08	2,053	5.6%	-3.8%
	PANTOPRAZOLE : PDO : 05/09	1,582	4.3%	-3.3%
	AMLODIPINE : PDO : 09/09	1,562	4.3%	0.9%
	PRO-METFORMIN : PDO : 05/09	1,541	4.2%	0.1%
5	PRO DOC Subtotal	36,467	5.6%	1.2%

T7 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY TOTAL ETHICAL PRESCRIPTIONS

		# of Rx (000s)	% Share of Market	% Change
	ROSUVASTATIN : S1H : 09/13	2,076	7.0%	89.5%
	ATORVASTATIN : S1H : 06/10	1,680	5.7%	3.9%
	ZOPICLONE : S1H : 08/10	1,320	4.5%	54.7%
	RAMIPRIL : S1H : 01/12	1,304	4.4%	77.9%
	AMLODIPINE : S1H : 02/11	1,243	4.2%	55.0%
6	SANIS HEALTH INC Subtotal	29,572	4.6%	22.2%
	SYNTHROID : BGP : 01/57	17,887	86.4%	5.3%
	MAVIK : BGP : 01/98	1,233	6.0%	6.8%
	INFLUVAC : BGP : 10/05	263	1.3%	122.7%
	KADIAN : BGP : 08/96	229	1.1%	5.1%
	ANDROGEL : BGP : 05/02	215	1.0%	3.3%
7	BGP PHARMA ULC Subtotal	20,691	3.2%	5.6%
	AMLODIPINE : SVM : 10/12	1,175	6.3%	-21.2%
	ATORVASTATIN : SVM : 12/12	1,103	5.9%	-39.8%
	METFORMIN FC : SVM : 10/12	893	4.8%	-31.6%
	PANTOPRAZOLE-40 : SVM : 11/14	851	4.5%	-29.0%
	ROSUVASTATIN : SVM : 12/12	802	4.3%	-36.7%
8	SIVEM PHARMA ULC Subtotal	18,781	2.9%	-15.5%
	JAMP-VITAMIN D : JMP : 05/12	2,977	16.1%	28.1%
	JAMP VITAMIN B12 : JMP : 02/07	2,489	13.5%	6.9%
	CALCIUM : JMP : 03/07	2,059	11.1%	5.4%
	JAMP-VITAMIN D3 : JMP : 08/09	1,540	8.3%	1.4%
	SENNOSIDES : JMP : 10/08	842	4.6%	-0.8%
9	JAMP PHARMA Subtotal	18,481	2.8%	23.2%
	MYLAN-BUPROPION XL : MYN : 10/13	2,048	14.2%	13.8%
	MYLAN-PANTOPRAZOLE T : MYN : 10/15	1,297	9.0%	668.3%
	MYLAN-NIFEDIPINE : MYN : 01/09	1,045	7.3%	-21.7%
	MYLAN-BUPRENORPH/NALOXON : MYN : 01/15	709	4.9%	103.5%
	MYLAN-NITRO PATCH : MYN : 11/13	533	3.7%	-2.6%
10	MYLAN PHARMA Subtotal	14,402	2.2%	10.2%

T7 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY TOTAL ETHICAL PRESCRIPTIONS

		# of Rx (000s)	% Share of Market	% Change
	ATIVAN : PFZ : 04/77	1,846	13.4%	-6.9%
	ALESSE : PFZ : 01/98	1,503	10.9%	-12.2%
	PREMARIN : PFZ : 02/42	1,082	7.9%	-7.3%
	DILANTIN SODIUM : PFZ : 01/52	1,036	7.5%	-3.6%
	VIAGRA : PFZ : 03/99	703	5.1%	-2.1%
11	PFIZER Subtotal	13,735	2.1%	-10.6%
	ACT AMLODIPINE : AAV : 07/09	1,314	10.6%	24.0%
	ACT ATORVASTATIN : AAV : 05/10	1,078	8.7%	8.7%
	ACT QUETIAPINE : AAV : 09/08	907	7.3%	9.2%
	ACT METFORMIN : AAV : 11/04	749	6.0%	-25.9%
	ACT RAMIPRIL : AAV : 12/07	697	5.6%	-56.1%
12	ACTAVIS PHARMA Subtotal	12,426	1.9%	-11.0%
	JANUMET : M-F : 10/09	1,746	16.1%	17.0%
	JANUVIA : M-F : 01/08	1,615	14.9%	10.0%
	OLMETEC : M-F : 03/09	1,071	9.9%	12.1%
	MARVELON : M-F : 07/93	683	6.3%	-13.7%
	OLMETEC PLUS : M-F : 03/09	669	6.2%	8.9%
13	MERCK CANADA INC Subtotal	10,830	1.7%	-0.4%
	SYMBICORT : AZN : 02/02	1,915	18.3%	3.5%
	CRESTOR : AZN : 02/03	1,644	15.7%	-5.6%
	ONGLYZA : AZN : 11/09	1,023	9.8%	2.0%
	OMNARIS : AZN : 04/08	790	7.6%	6.5%
	VIMOVO : AZN : 02/11	699	6.7%	5.7%
14	ASTRAZENECA Subtotal	10,460	1.6%	2.3%
	TARO-WARFARIN : TAR : 10/00	2,893	28.3%	-8.2%
	TARO-DOCUSATE : TAR : 12/86	1,922	18.8%	13.6%
	BETADERM : TAR : 08/79	1,409	13.8%	9.8%
	HYDERM : TAR : 11/79	711	7.0%	-8.5%
	CLOTRIMADERM : TAR : 06/89	568	5.5%	6.7%
15	TARO PHARMACEUTICALS Subtotal	10,232	1.6%	5.2%

T7 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY TOTAL ETHICAL PRESCRIPTIONS

	# of Rx (000s)	% Share of Market	% Change
FLOVENT HFA : GSK : 02/02	1,946	22.0%	-0.7%
VENTOLIN HFA : GSK : 01/02	1,428	16.2%	-29.5%
AVAMYS : GSK : 10/07	1,041	11.8%	8.0%
ADVAIR 250 DISKUS : GSK : 10/99	688	7.8%	-10.3%
ADVAIR 250 : GSK : 10/99	616	7.0%	-5.7%
16 GLAXOSMITHKLINE Subtotal	8,840	1.4%	-15.4%
D-TABS : RVA : 06/94	3,201	36.4%	6.2%
RIVA-PANTOPRAZOLE : RVA : 12/08	710	8.1%	56.0%
CALCITE + D 400 : RVA : 08/02	583	6.6%	-12.9%
RIVA-VENLAFAXINE XR : RVA : 06/08	457	5.2%	5.8%
RIVA-METFORMIN : RVA : 04/00	416	4.7%	1.7%
17 RIVA Subtotal	8,799	1.4%	13.4%
COVERSYL : SVR : 11/94	6,099	70.5%	10.8%
COVERSYL PLUS HD : SVR : 05/09	954	11.0%	16.5%
COVERSYL PLUS : SVR : 12/02	790	9.1%	7.2%
DIAMICRON MR : SVR : 04/01	738	8.5%	-43.6%
LOZIDE : SVR : 10/82	23	0.3%	1.4%
18 SERVIER LAB. Subtotal	8,649	1.3%	2.8%
METHADOSE : MKR : 02/13	8,418	100.0%	20.8%
19 MALLINCKRODT Subtotal	8,418	1.3%	20.8%
ZYLOPRIM : AA1 : 02/09	765	9.3%	-13.5%
METRONIDAZOLE : AA1 : 03/09	705	8.5%	10.7%
AVENTYL : AA1 : 06/14	665	8.1%	10.4%
KETOROLAC : AA1 : 04/14	598	7.3%	5.6%
ELAVIL : AA1 : 02/09	508	6.2%	-45.7%
20 AA PHARMA INC Subtotal	8,242	1.3%	4.4%

T8 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY DETAILING ACTIVITY

	# of Details (000s)	% Share of Market	% Change
TOTAL NUMBER OF DETAILS	2,877	100.0%	-22.6%
SYMBICORT : AZN : 02/02	80	23.1%	19.4%
FORXIGA : AZN : 01/15	57	16.5%	-10.4%
TUDORZA GENUAIR : AZN : 10/13	33	9.4%	-8.7%
XIGDUO : AZN : 02/16	28	8.1%	-
VIMOVO : AZN : 02/11	26	7.4%	-39.0%
1 ASTRAZENECA Subtotal	348	12.1%	-3.2%
BREO ELLIPTA : GSK : 12/13	99	41.2%	-0.8%
INCRUSE ELLIPTA : GSK : 09/15	47	19.5%	-
ANORO ELLIPTA : GSK : 04/14	36	14.8%	-28.0%
AVAMYS : GSK : 10/07	23	9.5%	-33.3%
ARNUITY ELLIPTA : GSK : 02/16	10	4.0%	-
2 GLAXOSMITHKLINE Subtotal	241	8.4%	-4.9%
JANUMET XR : M-F : 01/14	29	13.5%	7.9%
ZENHALE : M-F : 04/11	29	13.1%	-31.7%
JANUMET : M-F : 10/09	27	12.3%	18.3%
OLMETEC : M-F : 03/09	23	10.4%	-14.7%
JANUVIA : M-F : 01/08	20	9.1%	-19.9%
3 MERCK CANADA INC Subtotal	218	7.6%	-19.3%
VIACORAM : SVR : 04/16	79	39.1%	-
COVERSYL : SVR : 11/94	78	38.5%	-30.2%
COVERSYL PLUS HD : SVR : 05/09	17	8.6%	-40.0%
COVERSYL PLUS : SVR : 12/02	15	7.7%	-58.8%
GENERAL DISCUSSION : SVR : N/A	7	3.6%	99.4%
4 SERVIER LAB. Subtotal	202	7.0%	-1.5%
INSPIOLTO RESPIMAT : B.I : 06/15	38	20.2%	89.6%
JARDIANCE : B.I : 09/15	37	19.8%	196.5%
SPIRIVA RESPIMAT : B.I : 01/15	29	15.4%	-31.3%
PRADAXA : B.I : 08/08	28	15.1%	4.4%
TRAJENTA : B.I : 09/11	16	8.3%	11.8%
5 BOEHRINGER ING Subtotal	187	6.5%	5.0%

T8 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY DETAILING ACTIVITY

		# of Details (000s)	% Share of Market	% Change
	TOVIAZ : PFZ : 05/12	26	15.3%	1.5%
	ELIQUIS (CPA) : PFZ : N/A	24	14.2%	-20.5%
	PRISTIQ : PFZ : 03/09	21	12.7%	-54.0%
	VIAGRA : PFZ : 03/99	18	10.5%	-0.2%
	EPIPEN : PFZ : 09/85	11	6.3%	-2.1%
6	PFIZER Subtotal	168	5.8%	-37.4%
	JUBLIA : VLT : 07/14	30	22.6%	24.6%
	LODALIS : VLT : 02/12	22	16.6%	-27.5%
	GLUMETZA : VLT : 11/05	21	16.0%	7.7%
	TIAZAC XC : VLT : 08/04	14	10.1%	26.2%
	BENZACLIN : VLT : 05/04	7	5.4%	-28.1%
7	VALEANT PHARMA Subtotal	134	4.6%	-24.5%
	XARELTO : BAY : 10/08	70	66.3%	8.4%
	JAYDESS : BAY : 11/13	12	11.0%	-32.5%
	MIRENA : BAY : 02/01	9	8.2%	-29.3%
	GENERAL DISCUSSION : BAY : N/A	6	5.4%	70.1%
	YAZ : BAY : 01/09	4	3.5%	-25.3%
8	BAYER HEALTHCARE Subtotal	106	3.7%	-19.6%
	INVOKANA : JAN : 05/14	56	53.3%	-24.0%
	CONCERTA : JAN : 08/03	19	17.8%	-14.1%
	GENERAL DISCUSSION : JAN : N/A	6	5.5%	-24.2%
	INVEGA SUSTENNA : JAN : 08/10	5	4.5%	-41.5%
	INVOKAMET : JAN : 07/16	4	3.9%	-
9	JANSSEN PHARMA Subtotal	104	3.6%	-24.8%
	JARDIANCE (CPA) : LLY : N/A	20	24.1%	177.9%
	CYMBALTA : LLY : 01/08	12	14.6%	-57.1%
	TRULICITY : LLY : 02/16	12	13.6%	>999.9%
	CIALIS : LLY : 11/03	10	11.8%	-50.4%
	JENTADUETO (CPA) : LLY : N/A	6	7.7%	-35.3%
10	LILLY Subtotal	85	2.9%	-22.8%

T8 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY DETAILING ACTIVITY

		# of Details (000s)	% Share of Market	% Change
	ULTIBRO BREEZHALER : NVR : 03/14	24	31.1%	-34.4%
	XOLAIR : NVR : 02/05	17	21.6%	75.3%
	ENTRESTO : NVR : 11/15	13	16.8%	>999.9%
	SEEBRI BREEZHALER : NVR : 02/13	10	12.3%	-55.2%
	ONBREZ BREEZHALER : NVR : 03/12	5	5.9%	-62.3%
11	NOVARTIS PHARMA Subtotal	77	2.7%	-19.7%
	MAVIK : BGP : 01/98	32	51.7%	-37.1%
	CREON : BGP : 10/92	10	15.7%	-11.1%
	ANDROGEL : BGP : 05/02	6	10.3%	-38.2%
	KADIAN : BGP : 08/96	6	10.2%	-
	DICETEL : BGP : 05/79	3	5.2%	-71.0%
12	BGP PHARMA ULC Subtotal	62	2.1%	-35.3%
	DEXILANT : TAK : 08/10	34	55.7%	-32.3%
	ULORIC : TAK : 10/10	9	14.5%	-24.5%
	NESINA : TAK : 06/14	7	11.3%	-33.2%
	KAZANO : TAK : 10/14	6	9.2%	45.8%
	GENERAL DISCUSSION : TAK : N/A	2	3.3%	-40.4%
13	TAKEDA PHARMA NA Subtotal	62	2.1%	-43.1%
	TRINTELLIX : LUN : 12/14	47	80.0%	-25.7%
	GENERAL DISCUSSION : LUN : N/A	3	5.2%	23.2%
	ABILIFY MAINTENA (CPA) : LUN : N/A	3	5.1%	425.5%
	CIPRALEX : LUN : 02/05	3	4.9%	-74.9%
	SAPHRIS(CPA) : LUN : N/A	2	4.1%	-34.9%
14	LUNDBECK CANADA INC Subtotal	59	2.0%	-34.2%
	VICTOZA : N-N : 05/10	24	41.9%	5.9%
	SAXENDA : N-N : 08/15	12	21.3%	267.9%
	VAGIFEM : N-N : 05/02	4	7.6%	-55.9%
	GENERAL DISCUSSION : N-N : N/A	4	6.5%	46.7%
	LEVEMIR FLEXTOUCH : N-N : 11/13	3	5.3%	-66.4%
15	NOVO NORDISK CDA Subtotal	57	2.0%	-7.7%

T8 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY DETAILING ACTIVITY

	# of Details (000s)	% Share of Market	% Change
TOUJEO SOLOSTAR : S.A : 07/15	20	38.2%	62.7%
PRALUENT : S.A : 05/16	6	12.5%	-
LANTUS : S.A : 02/05	6	11.5%	7.5%
GENERAL DISCUSSION : S.A : N/A	5	9.9%	13.2%
APIDRA : S.A : 01/09	4	8.8%	3.4%
16 SANOFI-AVENTIS Subtotal	51	1.8%	-4.5%
ABILIFY : BMS : 10/09	20	47.1%	-32.5%
ELIQUIS : BMS : 02/12	18	41.0%	5.2%
GENERAL DISCUSSION : BMS : N/A	2	5.3%	-14.6%
ORENCIA : BMS : 03/07	2	3.6%	-4.5%
DAKLINZA : BMS : 09/15	0	0.9%	108.2%
17 BMS PHARMA Subtotal	43	1.5%	-18.1%
BIPHENTIN : PUF : 08/06	13	31.1%	-13.4%
BUTRANS : PUF : 05/10	12	29.0%	-53.6%
TARGIN : PUF : 10/10	7	16.0%	-58.5%
OXYNEO : PUF : 02/12	5	12.5%	-55.0%
GENERAL DISCUSSION : PUF : N/A	2	4.8%	-66.1%
18 PURDUE PHARMA Subtotal	42	1.5%	-47.3%
PROLIA : AAI : 08/10	20	47.9%	-44.6%
REPATHA : AAI : 09/15	18	41.8%	258.3%
GENERAL DISCUSSION : AAI : N/A	2	4.9%	-21.5%
ENBREL : AAI : 03/01	2	4.2%	-22.7%
XGEVA : AAI : 06/11	0	0.7%	-42.0%
19 AMGEN Subtotal	42	1.5%	-13.1%
CONSTELLA (CPA) : ALL : N/A	21	52.2%	308.6%
LOLO (CPA) : ALL : N/A	12	30.0%	881.1%
BOTOX : ALL : 06/91	5	11.3%	13.8%
GENERAL DISCUSSION : ALL : N/A	1	3.0%	12.2%
ASACOL 800 (CPA) : ALL : N/A	1	1.7%	-
20 ALLERGAN Subtotal	40	1.4%	237.0%

T9 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY JOURNAL AD EXPENDITURES

	Journal Advertising Expenditures (\$'000s)	% Share of Market	% Change
TOTAL JOURNAL AD EXPENDITURES	12,465	100.0%	-1.3%
BREO ELLIPTA : GSK : 12/13	658	48.1%	18.1%
ANORO ELLIPTA : GSK : 04/14	342	25.0%	-6.8%
BEXSERO : GSK : 03/14	201	14.7%	3.9%
INCRUSE ELLIPTA : GSK : 09/15	128	9.3%	-
FLONASE : GSK : 09/93	40	2.9%	-
1 GLAXOSMITHKLINE Subtotal	1,369	11.0%	17.5%
XIGDUO : AZN : 02/16	284	22.3%	-
FORXIGA : AZN : 01/15	264	20.7%	-38.6%
BYDUREON : AZN : 02/16	204	16.0%	-
BRILINTA : AZN : 06/11	153	12.0%	-54.1%
DUAKLIR GENUAIR : AZN : 08/15	127	9.9%	67.4%
2 ASTRAZENECA Subtotal	1,274	10.2%	-35.7%
PRISTIQ : PFZ : 03/09	455	45.0%	16.9%
EFFEXOR XR : PFZ : 03/98	163	16.1%	273.5%
TOVIAZ : PFZ : 05/12	86	8.5%	-42.2%
INSTITUTIONAL : PFZ : N/A	85	8.4%	137.9%
XELJANZ : PFZ : 06/14	60	5.9%	-41.4%
3 PFIZER Subtotal	1,012	8.1%	18.4%
JARDIANCE : B.I : 09/15	239	26.5%	72.2%
INSPIOLTO RESPIMAT : B.I : 06/15	239	26.5%	103.5%
JENTADUETO : B.I : 05/13	145	16.0%	-3.0%
TRAJENTA : B.I : 09/11	136	15.1%	-7.0%
INSTITUTIONAL : B.I : N/A	57	6.3%	-68.5%
4 BOEHRINGER ING Subtotal	902	7.2%	-32.3%
JANUMET : M-F : 10/09	494	59.5%	>999.9%
ZENHALE : M-F : 04/11	189	22.8%	265.7%
PNEUMOVAX 23 : M-F : 01/00	50	6.0%	-
ASMANEX TWISTHALER : M-F : 12/11	40	4.9%	7.2%
INSTITUTIONAL : M-F : N/A	30	3.6%	-64.3%
5 MERCK CANADA INC Subtotal	831	6.7%	222.3%

T9 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY JOURNAL AD EXPENDITURES

	Journal Advertising Expenditures (\$000s)	% Share of Market	% Change
INSTITUTIONAL : PUF : N/A	261	33.0%	23.6%
TARGIN : PUF : 10/10	249	31.4%	-5.3%
BUTRANS : PUF : 05/10	181	22.8%	-45.1%
BIPHENTIN : PUF : 08/06	73	9.2%	-68.2%
OXYNEO : PUF : 02/12	20	2.5%	-
6 PURDUE PHARMA Subtotal	792	6.4%	-23.3%
TRULICITY : LLY : 02/16	395	69.4%	>999.9%
INSTITUTIONAL : LLY : N/A	106	18.5%	-18.7%
TALTZ : LLY : 08/16	69	12.1%	-
7 LILLY Subtotal	569	4.6%	189.4%
TRINTELLIX : LUN : 12/14	447	81.4%	30.7%
TREANDA : LUN : 09/12	59	10.7%	75.1%
TRISENOX : LUN : 09/13	43	7.9%	123.7%
8 LUNDBECK CANADA INC Subtotal	549	4.4%	39.0%
TOUJEO SOLOSTAR : S.A : 07/15	365	72.3%	132.2%
PRALUENT : S.A : 05/16	78	15.5%	-
SUPRAX : S.A : 01/90	35	6.9%	-
INSTITUTIONAL : S.A : N/A	26	5.2%	-43.3%
9 SANOFI-AVENTIS Subtotal	505	4.0%	147.7%
MYRBETRIQ : AES : 03/13	373	90.7%	50.3%
XTANDI : AES : 06/13	38	9.3%	-59.8%
10 ASTELLAS PHARMA Subtotal	411	3.3%	19.8%
ULTIBRO BREEZHALER : NVR : 03/14	150	38.8%	231.8%
ENTRESTO : NVR : 11/15	63	16.2%	-
COSENTYX : NVR : 04/15	45	11.7%	-23.3%
VOLTAREN : NVR : 09/80	36	9.4%	-
INSTITUTIONAL : NVR : N/A	32	8.3%	-
11 NOVARTIS PHARMA Subtotal	386	3.1%	35.4%

T9 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY JOURNAL AD EXPENDITURES

	Journal Advertising Expenditures (\$000s)	% Share of Market	% Change
REPATHA : AAI : 09/15	171	45.9%	-
PROLIA : AAI : 08/10	94	25.1%	-26.3%
XGEVA : AAI : 06/11	56	14.9%	-25.6%
NEULASTA : AAI : 04/04	27	7.2%	53.9%
ENBREL : AAI : 03/01	26	6.9%	-
12 AMGEN Subtotal	372	3.0%	69.9%
VIACORAM : SVR : 04/16	202	57.7%	-
COVERSYL : SVR : 11/94	126	35.9%	-10.6%
COVERSYL PLUS HD : SVR : 05/09	22	6.4%	-22.4%
13 SERVIER LAB. Subtotal	350	2.8%	86.7%
DEXILANT : TAK : 08/10	194	58.5%	-18.9%
NESINA : TAK : 06/14	106	31.8%	100.3%
ONDISSOLVE ODF : TAK : 02/13	32	9.6%	64.3%
14 TAKEDA PHARMA NA Subtotal	332	2.7%	-24.4%
INVOKANA : JAN : 05/14	125	45.2%	-31.6%
ZYTIGA : JAN : 08/11	69	25.0%	-
STELARA : JAN : 01/09	56	20.4%	-
SIMPONI : JAN : 06/09	26	9.3%	-76.6%
15 JANSSEN PHARMA Subtotal	276	2.2%	-35.0%
HUMIRA : AV1 : 07/06	269	100.0%	-8.3%
16 ABBVIE Subtotal	269	2.2%	-14.2%
VYVANSE : S/C : 01/10	149	56.5%	17.7%
INSTITUTIONAL : S/C : N/A	95	36.2%	-
INTUNIV XR : S/C : 10/13	19	7.3%	-21.1%
17 SHIRE CANADA INC Subtotal	263	2.1%	74.8%
CONSTELLA : F/S : 05/14	181	100.0%	-53.5%
18 FOREST LAB CANADA Subtotal	181	1.5%	-53.5%

T9 | LEADING 20 MANUFACTURERS AND TOP FIVE PRODUCTS BY JOURNAL AD EXPENDITURES

	Journal Advertising Expenditures (\$000s)	% Share of Market	% Change
ROSIVER : GLD : 07/15	62	42.2%	38.9%
TACTUPUMP : GLD : 05/11	30	20.5%	-57.1%
TACTUPUMP FORTE : GLD : 01/16	30	20.5%	-
CETAPHIL : GLD : 12/76	17	11.4%	-8.8%
EXCIPIAL U10 HEALNG THPY : GLD : 02/16	8	5.5%	-
19 GALDERMA Subtotal	148	1.2%	-41.5%
CONSTELLA (CPA) : ALL : N/A	80	55.7%	-
LOLO (CPA) : ALL : N/A	59	41.4%	-
INSTITUTIONAL : ALL : N/A	4	2.8%	-77.8%
20 ALLERGAN Subtotal	143	1.1%	681.3%



Products and Molecules

T10 | TOP 50 PRODUCTS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Growth Rate
TOTAL ETHICAL MARKET						25,713,985	100.0%	3.2%	100	4%
1	1	1	1	1	REMICADE : JAN : 06/01	1,037,163	4.0%	13.8%	110	16%
3	2	2	3	2	HUMIRA : AV1 : 07/06	668,580	2.6%	15.0%	111	16%
-	-	47	2	3	HARVONI : GS- : 10/14	416,541	1.6%	-33.9%	64	-
5	3	3	4	4	LUCENTIS : NVR : 08/07	347,964	1.4%	-26.0%	72	5%
4	4	4	5	5	ENBREL : AAI : 03/01	346,988	1.3%	-0.1%	97	2%
6	5	6	7	6	RITUXAN : ROC : 04/00	247,934	1.0%	5.0%	102	5%
-	44	46	38	7	EYLEA : BAY : 12/13	246,329	1.0%	154.1%	246	-
12	10	8	8	8	COVERSYL : SVR : 11/94	233,836	0.9%	11.0%	108	12%
10	9	10	9	9	SYMBICORT : AZN : 02/02	211,172	0.8%	5.3%	102	6%
31	31	26	16	10	STELARA : JAN : 01/09	195,537	0.8%	33.4%	129	32%
8	8	9	12	11	HERCEPTIN : ROC : 08/99	185,401	0.7%	0.9%	98	2%
35	30	17	14	12	JANUMET : M-F : 10/09	184,545	0.7%	17.2%	114	42%
40	36	25	15	13	XARELTO : BAY : 10/08	179,886	0.7%	19.3%	116	72%
13	11	11	13	14	JANUVIA : M-F : 01/08	167,701	0.7%	6.2%	103	5%
9	6	5	6	15	CYMBALTA : LLY : 01/08	166,881	0.6%	-37.7%	60	-1%
30	29	21	20	16	ABILIFY : BMS : 10/09	162,248	0.6%	14.9%	111	25%
28	26	19	18	17	LANTUS SOLOSTAR : S.A : 01/08	157,899	0.6%	9.4%	106	20%
19	17	15	19	18	CONCERTA : JAN : 08/03	156,823	0.6%	10.0%	107	9%
-	-	13	11	19	SOVALDI : GS- : 01/14	155,205	0.6%	-16.4%	81	-
7	7	7	10	20	SPIRIVA : B.I : 01/03	154,889	0.6%	-19.6%	78	-5%
2	13	12	17	21	CRESTOR : AZN : 02/03	145,125	0.6%	0.3%	97	-23%
36	33	33	26	22	INVEGA SUSTENNA : JAN : 08/10	139,282	0.5%	18.5%	115	36%
42	43	44	44	23	ELIQUIS : BMS : 02/12	138,823	0.5%	66.9%	162	711%
17	15	16	21	24	NEUPOGEN : AAI : 03/92	130,085	0.5%	-1.4%	96	2%
41	41	38	28	25	CONTOUR NEXT : AS8 : 12/10	127,747	0.5%	15.6%	112	111%
14	14	18	22	26	FLOVENT HFA : GSK : 02/02	125,977	0.5%	-1.4%	96	-1%
26	20	22	25	27	HYDROMORPH CONTIN : PUF : 01/86	122,664	0.5%	1.8%	99	7%
32	34	36	32	28	SIMPONI : JAN : 06/09	122,542	0.5%	16.4%	113	23%
34	37	39	39	29	VYVANSE : S/C : 01/10	120,933	0.5%	26.4%	122	27%

T10 | TOP 50 PRODUCTS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Growth Rate
21	18	20	24	30	ADVAIR 250 : GSK : 10/99	114,284	0.4%	-6.1%	91	2%
20	21	29	30	31	ARANESP : AAI : 08/02	113,867	0.4%	5.7%	102	1%
37	38	41	43	32	XOLAIR : NVR : 02/05	109,836	0.4%	25.5%	122	32%
27	28	32	34	33	FRAGMIN : PFZ : 03/95	108,058	0.4%	4.6%	101	5%
24	23	23	23	34	CIALIS : LLY : 11/03	107,475	0.4%	-12.3%	85	2%
23	22	28	29	35	AVASTIN : ROC : 11/05	107,324	0.4%	-2.4%	95	2%
25	25	31	35	36	TRUVADA : GS- : 04/06	104,017	0.4%	2.5%	99	3%
18	19	27	33	37	EPREX : JAN : 03/90	101,545	0.4%	-2.0%	95	-3%
16	27	34	37	38	APO-ATORVASTATIN : ATX : 05/10	101,345	0.4%	4.0%	101	-5%
-	-	48	48	39	INVOKANA : JAN : 05/14	100,333	0.4%	62.9%	158	-
39	40	42	46	40	PROLIA : AAI : 08/10	99,612	0.4%	24.8%	121	43%
15	16	24	31	41	OXYNEO : PUF : 02/12	98,564	0.4%	-7.5%	90	-7%
33	35	37	41	42	VICTOZA : N-N : 05/10	98,401	0.4%	10.0%	107	17%
-	-	49	49	43	TRIUMEQ : VII : 10/14	97,070	0.4%	234.6%	324	-
11	12	14	27	44	ONE TOUCH ULTRA : LFS : 03/01	96,274	0.4%	-14.5%	83	-12%
38	39	40	45	45	GILENYA : NVR : 04/11	94,678	0.4%	16.0%	112	35%
-	42	43	42	46	TECFIDERA : BGE : 05/13	94,087	0.4%	7.0%	104	-
-	-	50	50	47	IMBRUVICA : JAN : 11/14	94,036	0.4%	295.4%	383	-
29	32	35	40	48	LANTUS : S.A : 02/05	89,791	0.3%	-4.0%	93	6%
22	24	30	36	49	ADVAIR 250 DISKUS : GSK : 10/99	89,775	0.3%	-8.5%	89	-4%
-	-	45	47	50	ZOSTAVAX II : M-F : 05/14	88,987	0.3%	35.4%	131	-

T11 | TOP 50 PRODUCTS BY ETHICAL DRUG STORE PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Drug Store Purchases (\$'000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Growth Rate
TOTAL ETHICAL MARKET						22,786,456	100.0%	3.4%	100	4%
1	1	1	1	1	REMICADE : JAN : 06/01	1,024,103	4.5%	15.7%	112	17%
3	2	2	3	2	HUMIRA : AV1 : 07/06	665,937	2.9%	14.9%	111	16%
-	-	48	2	3	HARVONI : GS- : 10/14	402,365	1.8%	-35.1%	63	-
4	4	4	5	4	ENBREL : AAI : 03/01	345,775	1.5%	-0.1%	97	2%
5	3	3	4	5	LUCENTIS : NVR : 08/07	327,180	1.4%	-26.2%	71	6%
11	7	7	7	6	COVERSYL : SVR : 11/94	233,561	1.0%	11.0%	107	12%
-	46	47	35	7	EYLEA : BAY : 12/13	216,059	0.9%	145.9%	238	-
9	8	8	8	8	SYMBICORT : AZN : 02/02	205,765	0.9%	5.2%	102	6%
27	28	21	13	9	STELARA : JAN : 01/09	195,275	0.9%	33.4%	129	32%
35	25	14	11	10	JANUMET : M-F : 10/09	184,335	0.8%	17.2%	113	42%
41	36	22	14	11	XARELTO : BAY : 10/08	174,632	0.8%	19.4%	115	73%
12	9	9	12	12	JANUVIA : M-F : 01/08	164,235	0.7%	6.0%	103	5%
8	5	5	6	13	CYMBALTA : LLY : 01/08	164,179	0.7%	-37.8%	60	-1%
30	27	18	18	14	ABILIFY : BMS : 10/09	157,249	0.7%	15.2%	111	26%
16	15	13	17	15	CONCERTA : JAN : 08/03	156,558	0.7%	10.1%	106	9%
25	21	16	16	16	LANTUS SOLOSTAR : S.A : 01/08	155,296	0.7%	8.9%	105	20%
7	6	6	9	17	SPIRIVA : B.I : 01/03	150,230	0.7%	-19.5%	78	-5%
-	-	11	10	18	SOVALDI : GS- : 01/14	150,128	0.7%	-17.4%	80	-
2	11	10	15	19	CRESTOR : AZN : 02/03	144,909	0.6%	0.3%	97	-23%
44	45	45	42	20	ELIQUIS : BMS : 02/12	134,081	0.6%	66.6%	161	715%
43	42	35	23	21	CONTOUR NEXT : AS8 : 12/10	127,534	0.6%	15.6%	112	111%
31	32	31	26	22	SIMPONI : JAN : 06/09	122,371	0.5%	16.4%	113	23%
38	34	32	27	23	INVEGA SUSTENNA : JAN : 08/10	122,055	0.5%	18.5%	115	38%
14	13	15	19	24	FLOVENT HFA : GSK : 02/02	121,578	0.5%	-1.2%	96	-1%
34	37	36	31	25	VYVANSE : S/C : 01/10	119,971	0.5%	26.3%	122	27%
22	17	19	21	26	HYDROMORPH CONTIN : PUF : 01/86	117,077	0.5%	1.6%	98	8%
37	39	42	37	27	XOLAIR : NVR : 02/05	109,744	0.5%	25.4%	121	32%
18	16	17	20	28	CIALIS : LLY : 11/03	107,361	0.5%	-12.3%	85	2%
19	19	23	24	29	ADVAIR 250 : GSK : 10/99	101,931	0.4%	-5.5%	91	2%

T11 | TOP 50 PRODUCTS BY ETHICAL DRUG STORE PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Drug Store Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Growth Rate
15	23	28	30	30	APO-ATORVASTATIN : ATX : 05/10	100,985	0.4%	4.0%	101	-5%
-	-	49	48	31	INVOKANA : JAN : 05/14	100,083	0.4%	62.7%	157	-
40	41	43	43	32	PROLIA : AAI : 08/10	98,790	0.4%	24.8%	121	43%
33	33	34	32	33	VICTOZA : N-N : 05/10	98,069	0.4%	10.0%	106	17%
13	14	20	25	34	OXYNEO : PUF : 02/12	97,817	0.4%	-7.4%	90	-7%
23	26	26	29	35	NEUPOGEN : AAI : 03/92	96,536	0.4%	-0.9%	96	3%
10	10	12	22	36	ONE TOUCH ULTRA : LFS : 03/01	96,057	0.4%	-14.5%	83	-12%
39	40	39	40	37	GILENYA : NVR : 04/11	94,608	0.4%	15.9%	112	35%
-	44	44	36	38	TECFIDERA : BGE : 05/13	94,041	0.4%	7.0%	104	-
17	18	24	28	39	ADVAIR 250 DISKUS : GSK : 10/99	89,390	0.4%	-8.5%	88	-4%
26	29	33	33	40	LANTUS : S.A : 02/05	84,594	0.4%	-4.2%	93	6%
20	22	30	41	41	COPAXONE : TVI : 09/97	83,697	0.4%	3.2%	100	-2%
29	31	38	44	42	TRUVADA : GS- : 04/06	78,984	0.3%	6.7%	103	6%
24	20	27	38	43	PRADAXA : B.I : 08/08	78,809	0.3%	-6.6%	90	-2%
28	30	37	45	44	FRAGMIN : PFZ : 03/95	77,006	0.3%	4.3%	101	5%
6	12	25	34	45	NEXIUM : AZN : 08/01	75,896	0.3%	-14.0%	83	-22%
36	38	41	46	46	VIREAD : GS- : 03/04	75,782	0.3%	5.3%	102	15%
21	24	29	39	47	ADVAIR 500 DISKUS : GSK : 10/99	74,867	0.3%	-11.3%	86	-4%
32	35	40	47	48	SANDOSTATIN LAR : NVR : 01/99	74,326	0.3%	5.7%	102	9%
42	43	46	49	49	ONE TOUCH VERIO : LFS : 10/11	72,625	0.3%	36.6%	132	64%
-	-	50	50	50	TRIUMEQ : VII : 10/14	70,652	0.3%	191.6%	282	-

T12 | TOP 50 PRODUCTS BY ETHICAL HOSPITAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Hospital Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Growth Rate
TOTAL ETHICAL MARKET						2,927,529	100.0%	1.7%	100	4%
1	1	1	1	1	RITUXAN : ROC : 04/00	198,616	6.8%	2.7%	101	3%
2	2	2	2	2	HERCEPTIN : ROC : 08/99	184,961	6.3%	1.0%	99	2%
4	3	3	3	3	AVASTIN : ROC : 11/05	99,526	3.4%	-1.4%	97	2%
-	37	18	10	4	PERJETA & HERCEPTIN : ROC : 05/13	73,929	2.5%	50.8%	148	-
7	7	8	8	5	ARANESP : AAI : 08/02	56,892	1.9%	4.7%	103	3%
6	6	6	6	6	EPREX : JAN : 03/90	56,723	1.9%	-1.3%	97	-4%
35	23	10	12	7	TREANDA : LUN : 09/12	49,991	1.7%	12.5%	111	176%
23	16	14	15	8	GARDASIL : M-F : 08/06	49,082	1.7%	52.2%	150	29%
12	9	7	5	9	ALIMTA : LLY : 08/04	47,895	1.6%	-28.6%	70	11%
5	5	5	7	10	VELCADE : JAN : 02/05	41,665	1.4%	-24.8%	74	-11%
-	-	43	49	11	ZOSTAVAX II : M-F : 05/14	40,507	1.4%	>999.9%	1,209	-
11	10	12	13	12	NEUPOGEN : AAI : 03/92	33,550	1.1%	-2.9%	96	0%
8	17	15	11	13	SYNAGIS : AVI : 02/08	33,504	1.1%	-29.8%	69	-4%
9	11	13	14	14	LOVENOX : S.A : 02/93	33,191	1.1%	-3.0%	95	-3%
-	-	47	48	15	IMBRUVICA : JAN : 11/14	32,443	1.1%	814.9%	900	-
16	15	17	16	16	FRAGMIN : PFZ : 03/95	31,052	1.1%	5.2%	103	4%
-	42	45	43	17	EYLEA : BAY : 12/13	30,270	1.0%	233.2%	328	-
17	19	21	23	18	CLOZARIL : HLT : 04/91	27,727	0.9%	11.1%	109	4%
21	24	23	22	19	CATHFLO : ROC : 09/02	27,214	0.9%	7.7%	106	7%
-	-	48	45	20	TRIUMEQ : VII : 10/14	26,417	0.9%	452.4%	543	-
13	12	16	17	21	TRUVADA : GS : 04/06	25,033	0.9%	-8.9%	90	-5%
30	28	27	25	22	ZYTIGA : JAN : 08/11	23,369	0.8%	9.1%	107	26%
38	42	49	20	23	FLUVIRAL S/F : IBO : 10/01	21,727	0.7%	-15.3%	83	-
15	8	9	18	24	LUCENTIS : NVR : 08/07	20,784	0.7%	-22.1%	77	-9%
28	27	28	30	25	ACTIVASE : ROC : 02/88	20,257	0.7%	16.5%	115	10%
19	25	25	26	26	PROGRAF : AES : 04/96	19,166	0.7%	-1.5%	97	-2%
14	14	19	24	27	ATRIPLA : BMG : 10/07	19,134	0.7%	-16.8%	82	-11%
-	41	39	31	28	KADCYLA : ROC : 10/13	18,244	0.6%	8.1%	106	-
22	26	29	29	29	TNKASE : ROC : 10/01	18,055	0.6%	2.7%	101	0%

T12 | TOP 50 PRODUCTS BY ETHICAL HOSPITAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Hospital Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-yr Avg Compound Growth Rate
33	18	11	9	30	YERVOY : BMS : 11/11	18,004	0.6%	-63.8%	36	38%
-	40	41	44	31	XTANDI : AES : 06/13	17,939	0.6%	135.4%	232	-
36	38	38	40	32	JAKAVI : NVR : 08/12	17,753	0.6%	30.0%	128	235%
32	34	35	37	33	INVEGA SUSTENNA : JAN : 08/10	17,227	0.6%	18.8%	117	24%
10	13	24	27	34	GLEEVEC : NVR : 10/01	17,092	0.6%	-7.7%	91	-18%
26	29	32	35	35	ELIGARD : S.A : 04/04	16,739	0.6%	11.1%	109	4%
29	33	30	32	36	VECTIBIX : AAI : 07/08	16,708	0.6%	3.3%	102	14%
20	21	22	21	37	KIVEXA : VII : 08/05	16,321	0.6%	-35.5%	63	-6%
27	30	36	38	38	ZOLADEX LA : AZN : 01/90	16,272	0.6%	13.5%	112	4%
-	-	-	50	39	KEYTRUDA : M-F : 06/15	15,780	0.5%	>999.9%	11,017	-
38	39	40	41	40	STRIBILD : GS- : 12/12	15,370	0.5%	14.5%	113	-
37	35	37	39	41	SPRYCEL : BMS : 04/07	15,338	0.5%	11.3%	109	346%
3	4	4	4	42	ELOXATIN : S.A : 07/07	15,292	0.5%	-84.4%	15	-37%
31	32	34	33	43	PREZISTA : JAN : 08/06	15,276	0.5%	-1.2%	97	14%
18	22	26	28	44	REYATAZ : BMS : 01/04	14,686	0.5%	-18.9%	80	-10%
-	-	46	42	45	HARVONI : GS- : 10/14	14,176	0.5%	33.7%	132	-
25	31	33	36	46	SUTENT : PFZ : 06/06	13,300	0.5%	-11.2%	87	-3%
-	-	44	46	47	XOFIGO : BAY : 05/14	13,194	0.5%	224.9%	320	-
34	36	31	34	48	AFINITOR : NVR : 02/10	13,151	0.4%	-13.2%	85	31%
-	-	42	47	49	PROQUAD : M-F : 05/14	13,120	0.4%	246.4%	341	-
24	20	20	19	50	REMICADE : JAN : 06/01	13,059	0.4%	-50.9%	48	-7%

T13 | TOP 25 MOLECULES BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
TOTAL ETHICAL PURCHASES						25,713,985	100.0%	3.2%	100	4%
					REMICADE : JAN : 06/01	1,037,163	99.6%	13.8%	100	16%
					INFLECTRA : HO& : 02/15	3,786	0.4%	529.3%	552	-
2	1	1	1	1	INFLIXIMAB Subtotal	1,040,948	4.0%	14.1%	111	17%
					HUMIRA : AV1 : 07/06	668,580	100.0%	15.0%	100	16%
5	3	3	3	2	ADALIMUMAB Subtotal	668,580	2.6%	15.0%	111	16%
					CONTOUR NEXT : AS8 : 12/10	127,747	23.3%	15.6%	117	111%
					ONE TOUCH ULTRA : LFS : 03/01	96,274	17.5%	-14.5%	87	-12%
					ONE TOUCH VERIO : LFS : 10/11	72,657	13.2%	36.5%	139	64%
					ACCU-CHEK AVIVA : R-D : 05/05	69,286	12.6%	0.9%	102	4%
					FREESTYLE LITE : AO+ : 12/07	41,800	7.6%	-1.4%	100	4%
1	2	2	4	3	NON PHARMACEUTICAL INGREDIENT Subtotal	548,865	2.1%	-1.6%	95	-1%
					HARVONI : GS- : 10/14	416,541	100.0%	-33.9%	100	-
-	-	25	2	4	LEDIPASVIR:SOFOBUVIR Subtotal	416,541	1.6%	-33.9%	64	-
					LUCENTIS : NVR : 08/07	347,964	100.0%	-26.0%	100	5%
9	4	4	5	5	RANIBIZUMAB Subtotal	347,964	1.4%	-26.0%	72	5%
					ENBREL : AAI : 03/01	346,988	100.0%	-0.1%	100	2%
8	6	6	6	6	ETANERCEPT Subtotal	347,010	1.3%	0%	97	2%
					ADVAIR 250 : GSK : 10/99	114,284	36.1%	-6.1%	102	2%
					ADVAIR 250 DISKUS : GSK : 10/99	89,775	28.3%	-8.5%	100	-4%
					ADVAIR 500 DISKUS : GSK : 10/99	77,512	24.5%	-11.5%	96	-3%
					ADVAIR 125 : GSK : 10/99	32,041	10.1%	-5.3%	103	-1%
					ADVAIR 100 DISKUS : GSK : 10/99	3,262	1.0%	-6.3%	102	-21%
6	5	5	7	7	FLUTICASONE:SALMETEROL Subtotal	316,873	1.2%	-8.1%	89	-2%
					CRESTOR : AZN : 02/03	145,125	47.9%	0.3%	96	-23%
					APO-ROSUVASTATIN : ATX : 04/12	45,531	15.0%	11.0%	106	5%
					ROSUVASTATIN : SH : 09/13	30,448	10.1%	120.6%	211	-
					TEVA-ROSUVASTATIN : TEV : 04/12	28,386	9.4%	-27.8%	69	2%
					PMS-ROSUVASTATIN : P8I : 04/12	8,594	2.8%	5.6%	101	-10%
3	8	7	8	8	ROSUVASTATIN Subtotal	302,882	1.2%	4.4%	101	-13%

T13 | TOP 25 MOLECULES BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate	
						APO-ATORVASTATIN : ATX : 05/10	101,345	36.1%	4.0%	104	-5%
						LIPITOR : PFZ : 03/97	65,224	23.2%	-6.3%	94	-10%
						ATORVASTATIN : SIH : 06/10	26,854	9.6%	2.7%	103	-5%
						ATORVASTATIN : PDO : 08/10	17,223	6.1%	-6.9%	93	-6%
						ACT ATORVASTATIN : AAV : 05/10	15,243	5.4%	-4.9%	96	-12%
4	7	8	9	9		ATORVASTATIN Subtotal	280,793	1.1%	-0.4%	96	-10%
						LANTUS SOLOSTAR : S.A : 01/08	157,899	59.3%	9.4%	98	20%
						LANTUS : S.A : 02/05	89,791	33.7%	-4.0%	86	6%
						TOUJEO SOLOSTAR : S.A : 07/15	17,794	6.7%	859.7%	863	-
18	14	13	12	10		INSULIN GLARGINE Subtotal	266,480	1.0%	11.2%	108	16%
						RITUXAN : ROC : 04/00	247,934	100.0%	5.0%	100	5%
11	11	11	13	11		RITUXIMAB Subtotal	247,934	1.0%	5.0%	102	5%
						EYLEA : BAY : 12/13	246,329	100.0%	154.1%	100	-
-	24	24	25	12		AFLIBERCEPT Subtotal	246,329	1.0%	154.1%	246	-
						COVERSYL : SVR : 11/94	233,836	100.0%	11.0%	100	12%
17	16	14	14	13		PERINDOPRIL Subtotal	233,836	0.9%	11.0%	108	12%
						JANUMET : M-F : 10/09	184,545	86.6%	17.2%	93	42%
						JANUMET XR : M-F : 01/14	28,446	13.4%	128.4%	182	-
22	21	20	21	14		METFORMIN:SITAGLIPTIN Subtotal	212,991	0.8%	25.4%	121	47%
						CONCERTA : JAN : 08/03	156,823	73.7%	10.0%	100	9%
						BIPHENTIN : PUF : 08/06	38,316	18.0%	15.6%	105	14%
						TEVA-METHYLPHENIDATE ER : TEV : 01/10	7,685	3.6%	-12.3%	80	-8%
						PMS-METHYLPHENIDATE : P8I : 07/90	2,090	1.0%	-16.1%	76	-3%
						APO-METHYLPHENIDATE SR : ATX : 04/06	1,471	0.7%	-4.0%	88	2%
16	18	17	17	15		METHYLPHENIDATE Subtotal	212,796	0.8%	9.7%	106	8%
						SYMBICORT : AZN : 02/02	211,172	100.0%	5.3%	100	6%
15	15	16	16	16		BUDESONIDE:FORMOTEROL Subtotal	211,172	0.8%	5.3%	102	6%
						CYMBALTA : LLY : 01/08	166,881	82.9%	-37.7%	83	-1%
14	12	10	11	17		DULOXETINE Subtotal	201,187	0.8%	-24.9%	73	4%

T13 | TOP 25 MOLECULES BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					SANDOZ PANTOPRAZOLE : SDZ : 06/08	32,664	16.4%	13.9%	160	8%
					TECTA : TAK : 02/09	18,695	9.4%	-86.2%	19	-29%
					APO-PANTOPRAZOLE : ATX : 03/08	17,923	9.0%	8.9%	153	-3%
					PANTOLOC : TAK : 03/97	15,214	7.6%	-8.8%	128	-18%
					TEVA-PANTOPRAZOLE : TEV : 04/08	13,887	7.0%	-0.6%	140	-21%
10	9	9	10	18	PANTOPRAZOLE Subtotal	199,366	0.8%	-29.0%	69	-7%
					ABILIFY : BMS : 10/09	162,248	81.5%	14.9%	89	25%
					ABILIFY MAINTENA : OTS : 04/14	36,928	18.5%	173.0%	212	-
20	20	21	22	19	ARIPIPRAZOLE Subtotal	199,176	0.8%	28.7%	125	32%
					STELARA : JAN : 01/09	195,537	100.0%	33.4%	100	32%
21	22	23	24	20	USTEKINUMAB Subtotal	195,537	0.8%	33.4%	129	32%
					HERCEPTIN : ROC : 08/99	185,401	100.0%	0.9%	100	2%
12	13	15	18	21	TRASTUZUMAB Subtotal	185,401	0.7%	0.9%	98	2%
					XARELTO : BAY : 10/08	179,886	100.0%	19.3%	100	72%
23	23	22	23	22	RIVAROXABAN Subtotal	179,886	0.7%	19.3%	116	72%
					HYDROMORPH CONTIN : PUF : 01/86	122,664	68.8%	1.8%	98	7%
					PMS-HYDROMORPHONE : P81 : 07/91	16,530	9.3%	2.2%	98	3%
					HYDROMORPHONE HCL : SDZ : 06/95	14,540	8.2%	44.6%	139	39%
					DILAUDID : PUF : 03/70	7,887	4.4%	-0.8%	95	1%
					HYDROMORPHONE HP FORTE : SDZ : 12/01	2,963	1.7%	-27.8%	69	92%
19	19	19	20	23	HYDROMORPHONE Subtotal	178,278	0.7%	3.9%	101	9%
					FLOVENT HFA : GSK : 02/02	125,977	72.8%	-1.4%	99	-1%
					AVAMYS : GSK : 10/07	27,524	15.9%	9.8%	110	13%
					APO-FLUTICASON : ATX : 05/07	8,965	5.2%	12.2%	112	17%
					FLOVENT DISKUS : GSK : 05/98	6,336	3.7%	-5.3%	95	-4%
					FLONASE : GSK : 09/93	2,707	1.6%	1.0%	101	-19%
13	17	18	19	24	FLUTICASON Subtotal	173,014	0.7%	0.1%	97	0%
					NEXIUM : AZN : 08/01	76,212	45.2%	-14.0%	105	-22%
					APO-ESOMEPRAZOLE : ATX : 03/11	60,956	36.1%	-31.9%	83	-13%
					MYLAN-ESOMEPRAZOLE : MYN : 08/12	12,025	7.1%	22.3%	150	62%
					ESOMEPRAZOLE : S1H : 12/14	6,974	4.1%	-23.9%	93	-
					ESOMEPRAZOLE : PDO : 10/13	4,224	2.5%	-45.0%	67	-
7	10	12	15	25	ESOMEPRAZOLE Subtotal	168,634	0.7%	-18.2%	79	-15%

T14 | BRAND-NAME PRODUCTS LAUNCHED BY TOTAL PURCHASES

		Total Purchases (\$000s)	Average Monthly Purchases (\$000s)
14000 : ANTIHISTAMINES, SYSTEMIC	BLEXTEN : AZH : 12/16	4	0
15000 : ANTI-INFECTIVES	ZERBAXA : M-F : 01/16	501	42
20000 : NEUROLOGICAL DISORDERS, MISC	BRIVLERA : UC. : 06/16	209	17
28000 : RESPIRATORY THERAPY	ARNUIITY ELLIPTA : GSK : 02/16	247	21
	NUCALA : GSK : 03/16	6,900	575
30000 : ONCOLOGY	ALECSAR : ROC : 10/16	137	11
	COTELLIC : ROC : 04/16	437	36
	IBRANCE : PFZ : 05/16	5,677	473
	KYPROLIS : AAI : 04/16	1,417	118
	LENVIMA : EIS : 04/16	892	74
	LYNPARZA : AZN : 05/16	4,770	398
	TAGRISSE : AZN : 07/16	2,778	232
	VENCLEXTA : AV1 : 10/16	12	1
	VIDAZA : CC5 : 04/16	356	30
31000 : CARDIOVASCULARS	UPTRAVI : A9N : 04/16	3,265	272
32000 : ANTIHYPERLIPIDEMIC AGENTS	PRALUENT : S.A : 05/16	210	18
39000 : DIABETES THERAPY	TRULICITY : LLY : 02/16	6,446	537
78000 : MISCELLANEOUS ETHICAL	BRIDION : M-F : 03/16	501	42
	ELELYSO : PFZ : 03/16	520	43
	PRAXBIND : B.I : 06/16	1,636	136
81000 : ANTI-VIRALS	DESCOVY : GS- : 06/16	1,782	148
	EPCLUSA : GS- : 08/16	19,620	1,635
	GENVOYA : GS- : 02/16	16,749	1,396
	ZEPATIER : M-F : 01/16	8,572	714
86000 : IMMUNOLOGIC AGENTS	SYLVANT : J-C : 02/16	17	1
	TALTZ : LLY : 08/16	797	66

T15 | TOP 50 PRODUCTS BY TOTAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
TOTAL ETHICAL MARKET						649,746	3.7%	100	4%
1	1	1	1	1	SYNTHROID : BGP : 01/57	17,887	5.3%	102	5%
-	45	6	2	2	METHADOSE : MKR : 02/13	8,418	20.8%	117	-
4	4	3	4	3	COVERSYL : SVR : 11/94	6,099	10.8%	107	12%
2	2	2	3	4	APO-ATORVASTATIN : ATX : 05/10	5,913	6.6%	103	2%
22	33	37	5	5	TEVA-FUROSEMIDE : TEV : 08/76	3,732	14.1%	110	19%
18	14	11	9	6	SANDOZ-BISOPROLOL : SDZ : 08/03	3,675	18.3%	114	16%
38	41	44	17	7	SANDOZ-METFORMIN FC : SDZ : 12/97	3,638	50.4%	145	51%
3	3	4	6	8	APO-FUROSEMIDE : ATX : 06/76	3,498	7.0%	103	-5%
26	15	9	10	9	APO-ROSUVASTATIN : ATX : 04/12	3,442	11.6%	108	22%
9	9	10	12	10	TEVA-VENLAFAXINE XR : TEV : 12/06	3,263	11.2%	107	4%
10	7	7	11	11	D-TABS : RVA : 06/94	3,201	6.2%	102	5%
40	39	24	13	12	DEXILANT : TAK : 08/10	3,125	19.6%	115	64%
-	-	38	20	13	JAMP-VITAMIN D : JMP : 05/12	2,977	28.1%	124	-
7	5	5	8	14	TARO-WARFARIN : TAR : 10/00	2,893	-8.2%	89	0%
33	31	19	23	15	TEVA-SALBUTAMOL HFA : TEV : 01/10	2,781	25.0%	121	25%
14	16	20	14	16	RATIO-LENOLTEC #3 : TEV : 11/85	2,701	8.9%	105	6%
29	8	8	7	17	TEVA-ROSUVASTATIN : TEV : 04/12	2,685	-15.5%	81	20%
-	46	31	19	18	JAMP VITAMIN B12 : JMP : 02/07	2,489	6.9%	103	-
34	37	42	28	19	SANDOZ PANTOPRAZOLE : SDZ : 06/08	2,473	15.0%	111	23%
27	24	23	27	20	TEVA-TRAZODONE : TEV : 02/95	2,322	7.7%	104	14%
21	23	26	24	21	PMS-CLONAZEPAM-R : P8I : 03/96	2,272	3.1%	100	5%
19	22	22	16	22	APO-METOPROLOL : ATX : 10/84	2,255	-6.9%	90	4%
35	35	34	26	23	SANDOZ-RABEPRAZOLE : SDZ : 09/08	2,248	3.3%	100	23%
16	20	21	30	24	RATIO-OXYCOCET : TEV : 04/84	2,217	4.7%	101	1%
24	26	28	33	25	PMS-HYDROCHLOROTHIAZDE : P8I : 10/04	2,179	8.6%	105	6%
12	12	13	18	26	ELTROXIN : T4T : 01/51	2,176	-7.6%	89	-3%
20	19	16	22	27	ATORVASTATIN : PDO : 08/10	2,171	-4.4%	92	3%
23	25	25	25	28	APO-AMOXI : ATX : 08/84	2,118	-2.8%	94	4%
6	11	15	32	29	TEVA-AMOXICILLIN : TEV : 01/79	2,115	2.1%	98	-8%

T15 | TOP 50 PRODUCTS BY TOTAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
39	30	29	21	30	SANDOZ-AMLODIPINE : SDZ : 07/09	2,102	-9.1%	88	41%
5	6	12	15	31	APO-HYDRO : ATX : 10/74	2,100	-13.6%	83	-10%
-	44	48	49	32	ROSUVASTATIN : S1H : 09/13	2,076	89.5%	183	-
36	36	35	36	33	CALCIUM : JMP : 03/07	2,059	5.4%	102	25%
15	18	17	29	34	PRO-AAS EC-80 : PDO : 11/08	2,053	-3.8%	93	-1%
-	47	45	39	35	MYLAN-BUPROPION XL : MYN : 10/13	2,048	13.8%	110	-
28	28	18	37	36	SANDOZ-TAMSULOSIN CR : SDZ : 01/11	1,978	6.0%	102	10%
42	42	46	43	37	XARELTO : BAY : 10/08	1,977	18.6%	114	97%
17	21	30	35	38	FLOVENT HFA : GSK : 02/02	1,946	-0.7%	96	-2%
13	17	27	31	39	APO-LORAZEPAM : ATX : 11/85	1,943	-7.1%	90	-5%
37	38	41	41	40	ABILIFY : BMS : 10/09	1,927	13.6%	110	25%
32	29	39	42	41	TARO-DOCUSATE : TAR : 12/86	1,922	13.6%	110	13%
25	27	33	38	42	SYMBICORT : AZN : 02/02	1,915	3.5%	100	5%
30	32	36	40	43	HYDROMORPH CONTIN : PUF : 01/86	1,905	7.2%	103	12%
-	-	-	46	44	APO-GLICLAZIDE MR : ATX : 06/08	1,849	16.6%	113	-
8	10	14	34	45	ATIVAN : PFZ : 04/77	1,846	-6.9%	90	-10%
-	43	43	44	46	APO-MOMETASONE : ATX : 03/13	1,817	9.8%	106	-
31	34	40	47	47	TEVA-SPIRONOLACTONE : TEV : 02/84	1,791	13.9%	110	11%
43	48	49	50	48	ELIQUIS : BMS : 02/12	1,760	70.4%	164	779%
41	40	47	48	49	JANUMET : M-F : 10/09	1,746	17.0%	113	49%
11	13	32	45	50	APO-SALVENT CFC FREE : ATX : 08/02	1,745	7.5%	104	-9%

T16 | TOP 15 PRODUCTS BY TOTAL ETHICAL PURCHASES, CANADA VS. UNITED STATES

	Ethical Purchases (\$000s)	% Change	# of Rx (000s)	% Change
Canada				
TOTAL ETHICAL MARKET	25,713,985	3.2%	649,760	3.7%
REMICADE : JAN : 06/01	1,037,163	13.8%	227	17.7%
HUMIRA : AV1 : 07/06	668,580	15.0%	348	12.5%
HARVONI : GS- : 10/14	416,541	-33.9%	53	-26.2%
LUCENTIS : NVR : 08/07	347,964	-26.0%	200	-28.5%
ENBREL : AAI : 03/01	346,988	-0.1%	181	-0.4%
RITUXAN : ROC : 04/00	247,934	5.0%	11	18.4%
EYLEA : BAY : 12/13	246,329	154.1%	83	116.3%
COVERSYL : SVR : 11/94	233,836	11.0%	6,099	10.8%
SYMBICORT : AZN : 02/02	211,172	5.3%	1,915	3.5%
STELARA : JAN : 01/09	195,537	33.4%	44	30.9%
HERCEPTIN : ROC : 08/99	185,401	0.9%	0	-70.2%
JANUMET : M-F : 10/09	184,545	17.2%	1,746	17.0%
XARELTO : BAY : 10/08	179,886	19.3%	1,977	18.6%
JANUVIA : M-F : 01/08	167,701	6.2%	1,615	10.0%
CYMBALTA : LLY : 01/08	166,881	-37.7%	1,615	-35.7%
United States*				
TOTAL ETHICAL MARKET	450,271,340	5.0%	4,460,227	2.0%
HUMIRA : AV1 : 01/03	12,929,246	27.6%	2,554	10.4%
HARVONI : GS- : 10/14	9,959,780	-30.1%	268	-35.7%
ENBREL : AAI : 11/98	7,362,086	11.2%	1,541	-5.5%
LANTUS SOLOSTAR : S.A : 07/07	5,698,444	-1.6%	11,781	2.6%
REMICADE : JAN : 09/98	5,309,321	6.6%	82	6.8%
JANUVIA : M-F : 10/06	4,787,767	15.2%	9,767	4.7%
ADVAIR DISKUS : GSK : 03/01	4,657,658	-0.9%	11,874	-9.5%
LYRICA : PFZ : 08/05	4,395,804	15.0%	10,452	2.1%
CRESTOR : AZN : 08/03	4,240,379	-32.2%	12,031	-40.7%
NEULASTA : AAI : 03/02	4,237,673	3.2%	39	-9.7%
COPAXONE : TVN : 03/97	4,137,266	-5.8%	637	-5.6%
RITUXAN : ROC : 04/00	3,913,944	6.6%	12	21.8%
TECFIDERA : BGE : 04/13	3,666,714	6.0%	445	-4.8%
XARELTO : JAN : 07/11	3,589,899	27.2%	8,443	14.0%
LANTUS : S.A : 05/01	3,337,220	-11.6%	7,720	-10.2%

* US numbers are derived from retail and mail order channels, long-term care facilities, clinics, HMO's, non-federal hospitals and other federal facilities.

Data source: National Sales Perspectives, National Prescription Audit Plus.

Note - US numbers and growth rates may not correlate with previous years due to corrections to the market made after publication.

T17 | TOP 50 MOLECULES BY TOTAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
TOTAL ETHICAL PRESCRIPTIONS						649,746	100.0%	3.7%	100	4%
1	1	1	1	1	LEVOTHYROXINE	20,063	3.1%	3.7%	100	4%
5	4	3	3	2	PANTOPRAZOLE	17,797	2.7%	6.7%	103	12%
2	2	2	2	3	ATORVASTATIN	17,680	2.7%	0.7%	97	1%
3	3	4	4	4	ROSUVASTATIN	16,528	2.5%	6.0%	102	7%
6	6	6	5	5	AMLODIPINE	13,607	2.1%	5.7%	102	7%
4	5	5	6	6	METFORMIN	12,782	2.0%	-0.1%	96	0%
16	12	7	7	7	CHOLECALCIFEROL	12,019	1.8%	10.7%	107	17%
9	9	9	8	8	FUROSEMIDE	9,206	1.4%	3.8%	100	4%
50	50	39	14	9	METHADONE	8,760	1.3%	20.6%	116	110%
7	7	8	9	10	RAMIPRIL	8,458	1.3%	-2.5%	94	-3%
12	10	11	11	11	QUETIAPINE	8,353	1.3%	2.6%	99	4%
8	8	10	10	12	METOPROLOL	8,260	1.3%	1.2%	98	1%
14	14	13	13	13	VENLAFAXINE	7,773	1.2%	4.0%	100	3%
10	11	12	12	14	LORAZEPAM	7,642	1.2%	0.4%	97	1%
23	19	17	18	15	BISOPROLOL	7,411	1.1%	9.0%	105	10%
13	15	14	15	16	CITALOPRAM	7,310	1.1%	2.0%	98	1%
15	16	15	16	17	SALBUTAMOL	7,218	1.1%	2.7%	99	2%
11	13	16	17	18	HYDROCHLOROTHIAZIDE	6,551	1.0%	-4.4%	92	-3%
20	18	19	19	19	ZOPICLONE	6,191	1.0%	1.1%	98	4%
26	24	24	23	20	PERINDOPRIL	6,099	0.9%	10.8%	107	12%
17	17	18	20	21	AMOXICILLIN	5,952	0.9%	3.2%	100	1%
22	22	21	22	22	CLONAZEPAM	5,616	0.9%	1.8%	98	2%
21	20	20	21	23	DOCUSATE	5,607	0.9%	-1.3%	95	1%
27	27	27	26	24	IRON FERROUS	5,426	0.8%	9.9%	106	9%
43	38	30	28	25	PREGABALIN	5,388	0.8%	14.9%	111	17%
25	25	26	27	26	TRAZODONE	5,094	0.8%	5.9%	102	6%
35	28	25	24	27	CALCIUM	5,081	0.8%	1.1%	98	12%
49	49	37	31	28	CYANOCOBALAMIN	5,036	0.8%	16.1%	112	26%
19	23	22	25	29	ACETAMINOPHEN:CAFFEINE:CODEINE	4,785	0.7%	-3.2%	93	-3%

T17 | TOP 50 MOLECULES BY TOTAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
41	34	31	30	30	HYDROMORPHONE	4,750	0.7%	8.4%	105	12%
32	33	32	32	31	TAMSULOSIN	4,462	0.7%	6.6%	103	7%
36	31	28	34	32	ESCITALOPRAM	4,347	0.7%	5.1%	101	8%
39	35	34	33	33	GLICLAZIDE	4,280	0.7%	2.7%	99	9%
44	42	38	37	34	GABAPENTIN	4,269	0.7%	10.3%	106	10%
18	21	23	29	35	WARFARIN	4,262	0.7%	-8.8%	88	-7%
31	32	33	35	36	NAPROXEN	4,147	0.6%	2.9%	99	4%
48	48	48	43	37	SERTRALINE	3,980	0.6%	15.5%	111	13%
37	40	40	40	38	CALCIUM:ERGOCALCIFEROL	3,892	0.6%	8.4%	105	5%
24	26	29	36	39	RABEPRAZOLE SODIUM	3,825	0.6%	-4.5%	92	-4%
28	30	35	38	40	CLOPIDOGREL	3,803	0.6%	0.1%	97	0%
42	43	44	41	41	ACETAMINOPHEN	3,789	0.6%	6.7%	103	6%
34	39	41	42	42	FLUTICASONE	3,567	0.5%	1.5%	98	1%
29	29	36	39	43	ETHINYLESTRADIOL:LEVONORGESTREL	3,520	0.5%	-2.5%	94	-1%
47	47	49	48	44	METHYLPHENIDATE	3,492	0.5%	8.9%	105	8%
45	45	46	47	45	BUPROPION	3,434	0.5%	6.1%	102	6%
38	41	45	46	46	AMITRIPTYLINE	3,373	0.5%	3.3%	100	2%
33	37	43	44	47	RISPERIDONE	3,338	0.5%	0.3%	97	-1%
40	44	47	49	48	MOMETASONE	3,221	0.5%	3.7%	100	2%
30	36	42	45	49	ATENOLOL	3,190	0.5%	-4.1%	92	-3%
46	46	50	50	50	ALLOPURINOL	3,181	0.5%	5.2%	101	5%

T18 | TOP 50 PRODUCTS BY TOTAL PROMOTIONAL DOLLARS

		Promotional Expenditures (\$000s)	# of Ad Pages	# of Details (000s)	# of Details with Samples (000s)	% of Details with Samples	# of Samples (000s)	# of Detail Minutes (000s)
TOTAL ETHICAL MARKET		421,434	2,066	2,877	1,415	49.2%	9,864	18,417
1	BREO ELLIPTA : GSK : 12/13	13,994	96	99	70	70.1%	361	582
2	XARELTO : BAY : 10/08	11,898	13	70	37	52.9%	329	460
3	VIACORAM : SVR : 04/16	11,436	45	79	52	65.6%	225	555
4	SYMBICORT : AZN : 02/02	11,142	-	80	67	83.5%	519	461
5	COVERSYL : SVR : 11/94	10,737	18	78	56	72.0%	441	404
6	TRINTELLIX : LUN : 12/14	8,900	60	47	25	53.4%	277	400
7	INVOKANA : JAN : 05/14	8,701	21	56	38	67.9%	288	326
8	FORXIGA : AZN : 01/15	8,218	26	57	31	54.8%	212	366
9	INCRUSE ELLIPTA : GSK : 09/15	6,219	17	47	26	54.1%	112	317
10	JARDIANCE : B.I : 09/15	5,679	25	37	20	54.8%	160	266
11	MYRBETRIQ : AES : 03/13	5,612	73	32	22	69.2%	187	195
12	DEXILANT : TAK : 08/10	5,460	31	34	25	72.0%	289	157
13	INSPiOLTO RESPiMAT : B.I : 06/15	4,848	26	38	21	55.9%	87	186
14	MAVIK : BGP : 01/98	4,809	-	32	21	65.8%	179	147
15	ANORO ELLIPTA : GSK : 04/14	4,608	66	36	20	57.1%	97	201
16	PRADAXA : B.I : 08/08	4,113	12	28	15	53.8%	81	148
17	JUBLIA : VLT : 07/14	4,069	20	30	2	7.2%	6	160
18	ABILIFY : BMS : 10/09	3,983	-	20	6	28.1%	41	171
19	PRISTIQ : PFZ : 03/09	3,927	67	21	11	52.5%	158	171
20	JANUMET XR : M-F : 01/14	3,800	1	29	13	44.1%	86	176
21	ZENHALE : M-F : 04/11	3,776	57	29	15	51.4%	91	183
22	TUDORZA GENUAIR : AZN : 10/13	3,737	-	33	18	55.1%	89	216
23	ULTIBRO BREEZHALER : NVR : 03/14	3,625	19	24	7	28.5%	35	136
24	SPIRIVA RESPiMAT : B.I : 01/15	3,615	-	29	16	56.3%	74	158
25	VICTOZA : N-N : 05/10	3,580	-	24	11	44.4%	58	151
26	TOUJEO SOLOSTAR : S.A : 07/15	3,578	82	20	1	5.2%	4	149
27	XIGDUO : AZN : 02/16	3,534	32	28	15	54.6%	77	194
28	VYVANSE : S/C : 01/10	3,464	22	18	0	0.4%	0	151
29	JANUMET : M-F : 10/09	3,406	104	27	10	37.6%	63	188
30	PROLIA : AAI : 08/10	3,335	12	20	0	0.8%	0	128

T18 | TOP 50 PRODUCTS BY TOTAL PROMOTIONAL DOLLARS

		Promotional Expenditures (\$000s)	# of Ad Pages	# of Details (000s)	# of Details with Samples (000s)	% of Details with Samples	# of Samples (000s)	# of Detail Minutes (000s)
31	TOVIAZ : PFZ : 05/12	3,325	14	26	17	64.4%	125	138
32	ELIQUIS (CPA) : PFZ : N/A	3,322	-	24	12	49.3%	99	169
33	ELIQUIS : BMS : 02/12	3,301	1	18	8	43.6%	82	141
34	CONCERTA : JAN : 08/03	3,113	-	19	0	0.8%	1	160
35	LODALIS : VLT : 02/12	3,092	-	22	14	61.4%	104	118
36	XOLAIR : NVR : 02/05	3,069	-	17	0	0.0%	0	183
37	JARDIANCE (CPA) : LLY : N/A	3,037	-	20	9	42.8%	59	121
38	VIMOVO : AZN : 02/11	3,024	-	26	24	93.0%	220	100
39	GENERAL DISCUSSION : AZN : N/A	2,968	-	16	0	0.0%	0	171
40	REPATHA : AAI : 09/15	2,843	20	18	0	0.0%	0	174
41	AVAMYS : GSK : 10/07	2,741	-	23	22	95.4%	211	80
42	BIPHENTIN : PUF : 08/06	2,666	10	13	0	1.2%	0	127
43	OLMETEC : M-F : 03/09	2,635	-	23	11	47.3%	80	85
44	GLUMETZA : VLT : 11/05	2,539	-	21	11	52.1%	65	131
45	DUAKLIR GENUAIR : AZN : 08/15	2,538	17	23	13	54.5%	56	109
46	GENERAL DISCUSSION : M-F : N/A	2,522	-	13	0	0.0%	0	143
47	CONSTELLA (CPA) : ALL : N/A	2,328	9	21	14	66.6%	112	110
48	JANUVIA : M-F : 01/08	2,229	2	20	7	36.0%	48	125
49	TRULICITY : LLY : 02/16	2,225	55	12	3	24.3%	9	98
50	LATUDA : S8R : 09/12	2,121	-	11	4	35.5%	34	150



Therapeutic Classes

T19 | TOP 15 THERAPEUTIC CLASSES AND LEADING MANUFACTURERS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
TOTAL ETHICAL MARKET						25,713,985	100.0%	3.2%	100	4%
					JANSSEN PHARMA	1,166,336	45.6%	14.1%	103	17%
					ABBVIE	668,580	26.2%	15.0%	104	16%
					AMGEN	346,988	13.6%	-0.1%	90	2%
					BMS PHARMA	64,672	2.5%	19.1%	107	21%
					APOTEX INC	47,759	1.9%	11.3%	100	9%
3	2	1	1	1	09000:ANTIARTHRITICS Subtotal	2,555,754	9.9%	10.8%	107	11%
					JANSSEN PHARMA	352,841	16.4%	9.2%	106	12%
					LILLY	191,749	8.9%	-35.3%	63	-3%
					SHIRE CANADA INC	183,219	8.5%	13.0%	109	21%
					BMS PHARMA	163,527	7.6%	13.9%	110	24%
					TEVA CANADA LTD	147,660	6.9%	-5.3%	92	-7%
1	1	2	2	2	64000:PSYCHOTHERAPEUTICS Subtotal	2,148,879	8.4%	3.3%	100	3%
					ROCHE	674,965	33.9%	5.3%	101	7%
					JANSSEN PHARMA	249,807	12.5%	42.2%	136	26%
					NOVARTIS PHARMA	227,624	11.4%	11.9%	107	8%
					BMS PHARMA	78,876	4.0%	-25.1%	72	22%
					SANOFI-AVENTIS	67,616	3.4%	-54.2%	44	-17%
4	3	3	3	3	30000:ONCOLOGY Subtotal	1,993,331	7.8%	4.6%	101	8%
					SERVIER LAB.	330,309	20.1%	12.3%	110	13%
					SANDOZ CANADA INC	159,165	9.7%	-3.0%	95	2%
					PFIZER	126,490	7.7%	-4.1%	94	-5%
					APOTEX INC	113,423	6.9%	0.5%	99	-13%
					MERCK CANADA INC	102,062	6.2%	9.7%	108	-1%
2	4	4	5	4	31000:CARDIOVASCULARS Subtotal	1,645,713	6.4%	1.7%	99	-2%
					MERCK CANADA INC	380,692	24.1%	16.1%	102	20%
					NOVO NORDISK CDA	313,224	19.9%	-0.3%	87	5%
					SANOFI-AVENTIS	278,784	17.7%	10.7%	97	16%
					ASTRAZENECA	131,968	8.4%	33.6%	117	46%
					LILLY	129,573	8.2%	7.3%	94	3%
9	7	6	6	5	39000:DIABETES THERAPY Subtotal	1,577,598	6.1%	13.9%	110	13%

T19 | TOP 15 THERAPEUTIC CLASSES AND LEADING MANUFACTURERS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate	
						GILEAD SCIENCES	877,783	56.7%	-18.5%	95	55%
						VIIV HEALTHCARE ULC	166,356	10.7%	21.7%	142	16%
						ABBVIE	111,789	7.2%	18.2%	138	11%
						BMS-GILEAD	64,240	4.1%	-18.3%	95	-10%
						GLAXOSMITHKLINE	18,122	1.2%	-85.3%	17	1%
11	11	8	4	6		81000:ANTI-VIRALS Subtotal	1,549,439	6.0%	-14.0%	83	18%
						GLAXOSMITHKLINE	513,003	38.6%	-0.8%	96	0%
						ASTRAZENECA	295,277	22.2%	6.1%	103	7%
						BOEHRINGER ING	198,452	14.9%	-8.8%	89	-2%
						NOVARTIS PHARMA	154,013	11.6%	27.3%	124	43%
						MERCK CANADA INC	48,465	3.6%	9.2%	106	6%
7	6	5	7	7		28000:RESPIRATORY THERAPY Subtotal	1,328,662	5.2%	2.9%	100	4%
						APOTEX INC	157,127	14.9%	-9.4%	102	-8%
						SANDOZ CANADA INC	112,921	10.7%	8.8%	123	4%
						TAKEDA PHARMA NA	102,457	9.7%	-51.6%	55	-5%
						ASTRAZENECA	94,312	8.9%	-12.6%	99	-20%
						NOVARTIS PHARMA	86,912	8.2%	4.8%	118	8%
5	5	7	8	8		23000:GASTROINTESTINAL/ GENITOURINARY Subtotal	1,057,966	4.1%	-11.5%	86	-6%
						NOVARTIS PHARMA	349,600	34.8%	-25.9%	71	5%
						BAYER HEALTHCARE	246,329	24.5%	154.1%	243	-
						ALLERGAN	132,612	13.2%	6.8%	102	15%
						ALCON CANADA	129,591	12.9%	-0.4%	95	1%
						BAUSCH & LOMB	19,209	1.9%	9.2%	104	5%
13	13	11	10	9		61000:OPHTHALMICS Subtotal	1,004,950	3.9%	4.7%	101	13%
						PURDUE PHARMA	269,013	27.7%	-1.9%	99	-5%
						TEVA CANADA LTD	121,571	12.5%	0.3%	101	1%
						SANDOZ CANADA INC	95,206	9.8%	4.0%	105	10%
						MCNEIL CONSUMER	66,452	6.8%	-11.0%	90	-5%
						APOTEX INC	55,908	5.8%	3.8%	104	5%
10	10	9	9	10		02000:ANALGESICS Subtotal	971,124	3.8%	-0.7%	96	0%

T19 | TOP 15 THERAPEUTIC CLASSES AND LEADING MANUFACTURERS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$'000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					NOVARTIS PHARMA	133,669	14.4%	8.9%	105	16%
					BIOGEN IDEC	106,039	11.4%	7.3%	103	168%
					TEVA CDN INNOVATION	90,938	9.8%	-1.2%	95	-3%
					PHARMASCIENCE	88,492	9.5%	5.5%	101	9%
					APOTEX INC	80,720	8.7%	4.9%	101	0%
8	9	12	11	11	20000:NEUROLOGICAL DISORDERS, MISC Subtotal	930,980	3.6%	4.0%	101	-1%
					AMGEN	123,341	13.8%	19.1%	115	39%
					MERCK CANADA INC	76,382	8.5%	-21.5%	76	-11%
					TEVA CANADA LTD	65,865	7.4%	21.5%	117	6%
					PFIZER	58,391	6.5%	12.4%	108	6%
					NOVO NORDISK CDA	52,317	5.9%	10.1%	106	15%
12	12	13	12	12	52000:HORMONES Subtotal	893,756	3.5%	3.9%	101	3%
					JANSSEN PHARMA	195,537	23.1%	33.4%	110	32%
					ASTELLAS PHARMA	102,127	12.1%	6.8%	88	8%
					BIOGEN IDEC	101,101	11.9%	0.8%	83	-2%
					NOVARTIS PHARMA	90,540	10.7%	26.9%	104	12%
					EMD CANADA INC	58,564	6.9%	-8.1%	76	-11%
15	15	15	15	13	86000:IMMUNOLOGIC AGENTS Subtotal	847,059	3.3%	21.7%	118	11%
					BAYER HEALTHCARE	179,886	22.0%	19.3%	107	71%
					BMS PHARMA	141,508	17.3%	63.8%	147	137%
					PFIZER	110,690	13.6%	3.9%	93	4%
					BOEHRINGER ING	87,287	10.7%	-7.2%	83	-3%
					SANOFI-AVENTIS	63,944	7.8%	-3.1%	87	0%
14	14	14	14	14	11000:HEMOSTATIC MODIFIERS Subtotal	816,436	3.2%	11.4%	108	9%
					APOTEX INC	174,809	22.4%	5.7%	105	-3%
					ASTRAZENECA	145,125	18.6%	0.3%	100	-23%
					SANIS HEALTH INC	68,580	8.8%	37.4%	137	10%
					PFIZER	66,161	8.5%	-6.1%	94	-10%
					TEVA CANADA LTD	63,680	8.2%	-12.5%	87	-8%
6	8	10	13	15	32000:ANTIHYPERTENSIVE AGENTS Subtotal	779,892	3.0%	0.4%	97	-13%

T20 | TOP 15 THERAPEUTIC CLASSES AND LEADING MANUFACTURERS BY ETHICAL DRUG STORE PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Drug Store Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
TOTAL ETHICAL MARKET						22,786,456	100.0%	3.4%	100	4%
					JANSSEN PHARMA	1,153,106	45.5%	15.9%	104	18%
					ABBVIE	665,937	26.3%	14.9%	103	16%
					AMGEN	345,775	13.6%	-0.1%	90	2%
					BMS PHARMA	64,299	2.5%	19.3%	107	21%
					APOTEX INC	46,647	1.8%	11.2%	100	9%
3	1	1	1	1	09000:ANTIARTHRITICS Subtotal	2,534,833	11.1%	11.6%	108	11%
					JANSSEN PHARMA	329,192	16.0%	9.1%	106	12%
					LILLY	188,568	9.2%	-35.4%	63	-3%
					SHIRE CANADA INC	182,005	8.8%	12.9%	109	21%
					BMS PHARMA	158,345	7.7%	14.2%	110	25%
					APOTEX INC	155,775	7.6%	19.2%	115	3%
1	2	2	2	2	64000:PSYCHOTHERAPEUTICS Subtotal	2,058,999	9.0%	3.4%	100	3%
					SERVIER LAB.	330,016	20.5%	12.3%	110	13%
					SANDOZ CANADA INC	148,096	9.2%	-3.1%	95	3%
					PFIZER	125,050	7.8%	-4.1%	94	-5%
					APOTEX INC	111,985	7.0%	0.4%	99	-13%
					MERCK CANADA INC	101,778	6.3%	9.8%	108	-1%
2	3	3	3	3	31000:CARDIOVASCULARS Subtotal	1,609,159	7.1%	1.8%	98	-2%
					MERCK CANADA INC	376,990	24.2%	16.1%	102	20%
					NOVO NORDISK CDA	310,816	20.0%	0.3%	88	5%
					SANOFI-AVENTIS	270,888	17.4%	10.7%	97	16%
					ASTRAZENECA	130,953	8.4%	33.9%	117	46%
					LILLY	124,975	8.0%	7.2%	94	3%
7	6	4	5	4	39000:DIABETES THERAPY Subtotal	1,555,450	6.8%	14.1%	110	13%
					GILEAD SCIENCES	804,718	61.6%	-20.2%	95	63%
					VIIV HEALTHCARE ULC	113,668	8.7%	18.9%	141	16%
					ABBVIE	71,336	5.5%	79.2%	213	33%
					JANSSEN PHARMA	50,937	3.9%	-6.6%	111	8%
					BMS-GILEAD	45,106	3.5%	-19.0%	96	-10%
11	12	9	4	5	81000:ANTI-VIRALS Subtotal	1,305,721	5.7%	-15.7%	81	22%

T20 | TOP 15 THERAPEUTIC CLASSES AND LEADING MANUFACTURERS BY ETHICAL DRUG STORE PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Drug Store Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					GLAXOSMITHKLINE	488,288	38.4%	-0.3%	97	0%
					ASTRAZENECA	287,595	22.6%	6.2%	103	7%
					BOEHRINGER ING	188,228	14.8%	-8.7%	88	-1%
					NOVARTIS PHARMA	152,718	12.0%	27.1%	123	43%
					MERCK CANADA INC	47,876	3.8%	8.9%	105	6%
6	5	6	6	6	28000:RESPIRATORY THERAPY Subtotal	1,272,220	5.6%	3.2%	100	4%
					APOTEX INC	156,299	15.3%	-9.5%	103	-8%
					SANDOZ CANADA INC	102,430	10.0%	10.5%	125	6%
					TAKEDA PHARMA NA	102,038	10.0%	-51.7%	55	-5%
					ASTRAZENECA	93,877	9.2%	-12.6%	99	-20%
					NOVARTIS PHARMA	74,688	7.3%	5.5%	119	9%
5	4	5	7	7	23000:GASTROINTESTINAL/ GENITOURINARY Subtotal	1,022,520	4.5%	-11.7%	85	-6%
					NOVARTIS PHARMA	327,636	35.0%	-26.2%	71	6%
					BAYER HEALTHCARE	216,059	23.1%	145.9%	238	-
					ALLERGAN	129,786	13.9%	6.7%	103	15%
					ALCON CANADA	122,718	13.1%	-0.1%	97	1%
					SANDOZ CANADA INC	25,528	2.7%	53.2%	148	83%
12	11	11	9	8	61000:OPHTHALMICS Subtotal	935,771	4.1%	3.2%	100	13%
					PURDUE PHARMA	261,976	28.7%	-2.0%	99	-5%
					TEVA CANADA LTD	120,388	13.2%	0.6%	102	1%
					MCNEIL CONSUMER	66,282	7.3%	-11.0%	90	-5%
					SANDOZ CANADA INC	56,183	6.1%	-4.2%	97	7%
					APOTEX INC	54,956	6.0%	3.7%	105	5%
9	9	7	8	9	02000:ANALGESICS Subtotal	913,767	4.0%	-1.4%	95	0%
					NOVARTIS PHARMA	130,437	14.4%	9.2%	105	16%
					BIOGEN IDEC	105,957	11.7%	7.3%	103	168%
					TEVA CDN INNOVATION	90,443	10.0%	-1.0%	95	-3%
					PHARMASCIENCE	86,809	9.6%	5.7%	102	9%
					APOTEX INC	79,477	8.7%	5.8%	102	0%
8	8	10	10	10	20000:NEUROLOGICAL DISORDERS, MISC Subtotal	908,445	4.0%	4.0%	101	-1%

T20 | TOP 15 THERAPEUTIC CLASSES AND LEADING MANUFACTURERS BY ETHICAL DRUG STORE PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Drug Store Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					AMGEN	119,069	14.1%	19.6%	115	40%
					MERCK CANADA INC	74,081	8.8%	-21.9%	75	-11%
					TEVA CANADA LTD	64,724	7.7%	24.0%	119	7%
					NOVO NORDISK CDA	52,211	6.2%	10.1%	106	15%
					PFIZER	48,174	5.7%	9.0%	105	6%
10	10	12	11	11	52000:HORMONES Subtotal	844,097	3.7%	4.0%	101	4%
					NOVARTIS PHARMA	157,430	19.9%	12.5%	96	7%
					JANSSEN PHARMA	139,654	17.7%	72.6%	147	66%
					ROCHE	73,492	9.3%	-2.8%	83	4%
					ASTRAZENECA	65,515	8.3%	10.7%	95	-6%
					ABBVIE	57,202	7.2%	7.2%	92	7%
13	13	13	13	12	30000:ONCOLOGY Subtotal	790,873	3.5%	17.1%	113	11%
					APOTEX INC	174,144	22.4%	5.7%	105	-3%
					ASTRAZENECA	144,909	18.6%	0.3%	100	-23%
					SANIS HEALTH INC	68,579	8.8%	37.4%	137	10%
					PFIZER	66,113	8.5%	-6.1%	93	-10%
					TEVA CANADA LTD	63,310	8.1%	-12.4%	87	-8%
4	7	8	12	13	32000:ANTIHYPERLIPIDEMIC AGENTS Subtotal	777,515	3.4%	0.5%	97	-13%
					JANSSEN PHARMA	195,275	25.4%	33.4%	107	32%
					BIOGEN IDEC	98,173	12.8%	0.7%	81	-2%
					GENZYME CORP	86,370	11.2%	52.7%	123	-
					NOVARTIS PHARMA	72,475	9.4%	37.7%	111	18%
					ASTELLAS PHARMA	71,616	9.3%	8.6%	87	9%
14	14	14	14	14	86000:IMMUNOLOGIC AGENTS Subtotal	767,835	3.4%	24.3%	120	13%
					BAYER HEALTHCARE	174,632	27.0%	19.4%	106	73%
					BMS PHARMA	136,748	21.1%	63.4%	145	135%
					BOEHRINGER ING	86,220	13.3%	-7.1%	82	-3%
					PFIZER	78,072	12.1%	3.9%	92	4%
					ASTRAZENECA	30,004	4.6%	28.2%	114	101%
15	15	15	15	15	11000:HEMOSTATIC MODIFIERS Subtotal	646,771	2.8%	12.9%	109	12%

T21 | TOP 15 THERAPEUTIC CLASSES AND LEADING MANUFACTURERS BY ETHICAL HOSPITAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Hospital Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
TOTAL ETHICAL MARKET						2,927,529	100.0%	1.7%	100	4%
					ROCHE	601,473	50.0%	6.4%	109	7%
					JANSSEN PHARMA	110,153	9.2%	16.2%	119	8%
					NOVARTIS PHARMA	70,194	5.8%	10.6%	113	9%
					LILLY	57,805	4.8%	-24.8%	77	6%
					LUNDBECK CANADA INC	55,484	4.6%	12.3%	115	184%
1	1	1	1	1	30000:ONCOLOGY Subtotal	1,202,458	41.1%	-2.2%	96	7%
					GILEAD SCIENCES	73,065	30.0%	6.9%	111	18%
					VIIV HEALTHCARE ULC	52,688	21.6%	28.4%	133	15%
					ABBVIE	40,453	16.6%	-26.1%	77	-6%
					JANSSEN PHARMA	21,750	8.9%	5.0%	109	14%
					BMS-GILEAD	19,134	7.9%	-16.8%	86	-11%
2	2	2	2	2	81000:ANTI-VIRALS Subtotal	243,718	8.3%	-3.5%	95	4%
					MERCK CANADA INC	137,537	63.9%	149.6%	159	41%
					GLAXOSMITHKLINE	44,452	20.6%	3.3%	66	4%
					ID BIOMEDICAL CORP	25,268	11.7%	-2.9%	62	5%
					NOVARTIS VACCINES	7,821	3.6%	-13.7%	55	-5%
					SANOFI-PASTEUR	154	0.1%	-21.1%	50	-8%
6	6	5	5	3	27000:BIOLOGICALS Subtotal	215,290	7.4%	56.6%	154	19%
					AMGEN	101,444	54.6%	-1.3%	99	2%
					JANSSEN PHARMA	56,723	30.5%	-1.3%	99	-4%
					LUITPOLD PHARMA	13,009	7.0%	3.1%	104	-3%
					SANOFI-AVENTIS	11,241	6.1%	4.4%	105	18%
					APOTEX INC	1,088	0.6%	>999.9%	2,078	53%
3	3	3	3	4	48000:HEMATINICS Subtotal	185,737	6.3%	-0.5%	98	0%
					ROCHE	65,526	38.6%	8.8%	103	6%
					SANOFI-AVENTIS	34,339	20.2%	-2.4%	92	-3%
					PFIZER	32,618	19.2%	4.0%	98	3%
					LEO PHARMA INC	8,026	4.7%	1.0%	95	-4%
					BAYER HEALTHCARE	5,255	3.1%	15.4%	109	39%
4	4	4	4	5	11000:HEMOSTATIC MODIFIERS Subtotal	169,665	5.8%	6.1%	104	2%

T21 | TOP 15 THERAPEUTIC CLASSES AND LEADING MANUFACTURERS BY ETHICAL HOSPITAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Hospital Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					SANDOZ CANADA INC	26,743	21.3%	2.9%	105	-2%
					MERCK CANADA INC	23,275	18.6%	13.8%	116	6%
					STERIMAX INC	13,818	11.0%	2.5%	105	17%
					CUBIST PHARMA INC	11,588	9.2%	21.6%	124	27%
					ASTELLAS PHARMA	11,096	8.8%	13.9%	116	8%
5	5	6	6	6	15000:ANTI-INFECTIVES Subtotal	125,414	4.3%	-2.0%	96	-4%
					HLS THERAPEUTICS,INC	27,727	30.8%	11.1%	108	4%
					JANSSEN PHARMA	23,648	26.3%	9.7%	107	8%
					SANDOZ CANADA INC	7,418	8.3%	-5.8%	92	-14%
					BMS PHARMA	5,182	5.8%	4.1%	101	11%
					OTSUKA	3,933	4.4%	91.4%	186	-
7	7	7	7	7	64000:PSYCHOTHERAPEUTICS Subtotal	89,881	3.1%	2.7%	101	0%
					ASTELLAS PHARMA	30,511	38.5%	2.9%	102	5%
					NOVARTIS PHARMA	18,065	22.8%	-3.5%	95	-1%
					SANOFI-AVENTIS	7,524	9.5%	30.5%	129	7%
					PFIZER	6,421	8.1%	-3.8%	95	0%
					MERCK CANADA INC	3,356	4.2%	-9.8%	89	-5%
8	8	8	8	8	86000:IMMUNOLOGIC AGENTS Subtotal	79,223	2.7%	1.4%	100	-2%
					BAYER HEALTHCARE	30,270	43.8%	233.2%	257	-
					NOVARTIS PHARMA	21,964	31.8%	-21.5%	60	-9%
					ALCON CANADA	6,873	9.9%	-4.8%	73	7%
					ALLERGAN	2,826	4.1%	10.1%	85	18%
					BAUSCH & LOMB	2,576	3.7%	10.9%	85	9%
13	12	10	11	9	61000:OPHTHALMICS Subtotal	69,179	2.4%	29.9%	128	12%
					ASTRAZENECA	20,744	31.8%	-14.0%	92	-14%
					ABBVIE	10,918	16.7%	-13.9%	93	-7%
					ALVEDA PHARMA INC	5,545	8.5%	-6.6%	100	108%
					HOSPIRA	5,355	8.2%	12.1%	121	15%
					PHARMASCIENCE	4,424	6.8%	-26.0%	80	23%
9	9	9	9	10	04000:ANESTHETICS Subtotal	65,222	2.2%	-7.0%	91	-2%

T21 | TOP 15 THERAPEUTIC CLASSES AND LEADING MANUFACTURERS BY ETHICAL HOSPITAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Hospital Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					SANDOZ CANADA INC	39,022	68.0%	18.6%	105	13%
					PURDUE PHARMA	7,038	12.3%	3.1%	91	-1%
					PHARMASCIENCE	2,247	3.9%	-0.9%	87	1%
					PALADIN	1,537	2.7%	-2.7%	86	0%
					TEVA CANADA LTD	1,183	2.1%	-19.7%	71	-7%
14	13	13	12	11	02000:ANALGESICS Subtotal	57,357	2.0%	13.4%	112	8%
					GLAXOSMITHKLINE	24,715	43.8%	-10.4%	93	-4%
					BOEHRINGER ING	10,225	18.1%	-10.1%	93	-5%
					ASTRAZENECA	7,682	13.6%	3.9%	108	6%
					ROCHE	4,571	8.1%	8.6%	113	8%
					TEVA CANADA LTD	3,665	6.5%	34.4%	140	19%
10	10	11	10	12	28000:RESPIRATORY THERAPY Subtotal	56,442	1.9%	-3.7%	95	-1%
					PFIZER	10,217	20.6%	31.3%	129	10%
					FERRING	5,872	11.8%	4.3%	102	3%
					AMGEN	4,271	8.6%	4.9%	103	19%
					EMD CANADA INC	4,023	8.1%	-14.1%	84	-13%
					LILLY	3,245	6.5%	-3.1%	95	-13%
11	11	12	13	13	52000:HORMONES Subtotal	49,659	1.7%	1.9%	100	-4%
					GENZYME CORP	11,536	26.3%	-2.6%	93	-
					PALADIN	3,895	8.9%	-5.6%	91	-7%
					LILLY	3,809	8.7%	-12.0%	84	-1%
					SANOVI-AVENTIS	3,544	8.1%	4.4%	100	1%
					HOSPIRA	3,403	7.8%	23.5%	118	7%
15	15	14	14	14	78000:MISCELLANEOUS ETHICAL Subtotal	43,862	1.5%	4.2%	103	8%
					SANDOZ CANADA INC	11,069	30.3%	-1.6%	101	-10%
					HOSPIRA	3,519	9.6%	14.6%	117	5%
					BAYER HEALTHCARE	2,778	7.6%	3.8%	106	-3%
					FRESENIUS KABI CDN	1,915	5.2%	8.3%	111	24%
					AA PHARMA INC	1,660	4.5%	16.3%	119	28%
12	14	15	15	15	31000:CARDIOVASCULARS Subtotal	36,553	1.2%	-2.3%	96	-5%

T 22 | TOP 15 THERAPEUTIC CLASSES AND LEADING BRAND-NAME MANUFACTURERS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
TOTAL ETHICAL MARKET						25,713,985	100.0%	3.2%	100	4%
					JANSSEN PHARMA	1,166,336	49.0%	14.1%	102	17%
					ABBVIE	668,580	28.1%	15.0%	103	16%
					AMGEN	346,988	14.6%	-0.1%	90	2%
					BMS PHARMA	64,672	2.7%	19.1%	107	21%
					ROCHE	45,001	1.9%	14.9%	103	22%
					Brand Manufacturers Subtotal	2,380,702	93.2%	11.6%	101	11%
3	2	1	1	1	09000:ANTIARTHRITICS Subtotal	2,555,754	9.9%	10.8%	107	11%
					JANSSEN PHARMA	352,841	25.8%	9.2%	109	12%
					LILLY	191,749	14.0%	-35.3%	64	-3%
					SHIRE CANADA INC	183,219	13.4%	13.0%	112	21%
					BMS PHARMA	163,527	11.9%	13.9%	113	24%
					PFIZER	111,791	8.2%	1.9%	101	3%
					Brand Manufacturers Subtotal	1,370,238	63.8%	0.6%	97	3%
1	1	2	2	2	64000:PSYCHOTHERAPEUTICS Subtotal	2,148,879	8.4%	3.3%	100	3%
					ROCHE	674,965	36.7%	5.3%	100	7%
					JANSSEN PHARMA	249,807	13.6%	42.2%	135	26%
					NOVARTIS PHARMA	227,624	12.4%	11.9%	106	8%
					ASTRAZENECA	92,955	5.1%	10.2%	105	-4%
					BMS PHARMA	78,876	4.3%	-25.1%	71	22%
					Brand Manufacturers Subtotal	1,838,770	92.2%	5.1%	100	8%
4	3	3	3	3	30000:ONCOLOGY Subtotal	1,993,331	7.8%	4.6%	101	8%
					SERVIER LAB.	330,309	36.7%	12.3%	109	13%
					PFIZER	126,490	14.1%	-4.1%	93	-5%
					MERCK CANADA INC	102,062	11.3%	9.7%	106	-1%
					BAYER HEALTHCARE	74,333	8.3%	4.3%	101	0%
					VALEANT PHARMA	56,580	6.3%	-3.8%	93	-5%
					Brand Manufacturers Subtotal	900,062	54.7%	3.4%	102	-1%
2	4	4	5	4	31000:CARDIOVASCULARS Subtotal	1,645,713	6.4%	1.7%	99	-2%

T22 | TOP 15 THERAPEUTIC CLASSES AND LEADING BRAND-NAME MANUFACTURERS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					MERCK CANADA INC	380,692	25.9%	16.1%	101	20%
					NOVO NORDISK CDA	313,224	21.3%	-0.3%	87	5%
					SANOFI-AVENTIS	278,784	18.9%	10.7%	96	16%
					ASTRAZENECA	131,968	9.0%	33.6%	116	46%
					LILLY	129,573	8.8%	7.3%	93	3%
					Brand Manufacturers Subtotal	1,471,516	93.3%	15.1%	101	17%
9	7	6	6	5	39000:DIABETES THERAPY Subtotal	1,577,598	6.1%	13.9%	110	13%
					GILEAD SCIENCES	877,783	60.1%	-18.5%	98	55%
					VIIV HEALTHCARE ULC	166,356	11.4%	21.7%	146	16%
					ABBVIE	111,789	7.7%	18.2%	142	11%
					JANSSEN PHARMA	72,687	5.0%	-3.4%	116	9%
					BMS-GILEAD	64,240	4.4%	-18.3%	98	-10%
					Brand Manufacturers Subtotal	1,461,225	94.3%	-16.7%	97	19%
11	11	8	4	6	81000:ANTI-VIRALS Subtotal	1,549,439	6.0%	-14.0%	83	18%
					GLAXOSMITHKLINE	513,003	41.5%	-0.8%	97	0%
					ASTRAZENECA	295,277	23.9%	6.1%	103	7%
					BOEHRINGER ING	198,452	16.1%	-8.8%	89	-2%
					NOVARTIS PHARMA	154,013	12.5%	27.3%	124	43%
					MERCK CANADA INC	48,465	3.9%	9.2%	106	6%
					Brand Manufacturers Subtotal	1,236,225	93.0%	2.5%	100	4%
7	6	5	7	7	28000:RESPIRATORY THERAPY Subtotal	1,328,662	5.2%	2.9%	100	4%
					TAKEDA PHARMA NA	102,457	20.2%	-51.6%	64	-5%
					ASTRAZENECA	94,312	18.6%	-12.6%	115	-20%
					NOVARTIS PHARMA	86,912	17.2%	4.8%	138	8%
					JANSSEN PHARMA	33,672	6.7%	-2.5%	128	1%
					TAKEDA PHARMA USA	33,118	6.5%	-3.0%	127	-6%
					Brand Manufacturers Subtotal	506,298	47.9%	-23.8%	86	-9%
5	5	7	8	8	23000:GASTROINTESTINAL/ GENITOURINARY Subtotal	1,057,966	4.1%	-11.5%	86	-6%

T22 | TOP 15 THERAPEUTIC CLASSES AND LEADING BRAND-NAME MANUFACTURERS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					NOVARTIS PHARMA	349,600	36.8%	-25.9%	71	5%
					BAYER HEALTHCARE	246,329	26.0%	154.1%	244	-
					ALLERGAN	132,612	14.0%	6.8%	103	15%
					ALCON CANADA	129,591	13.7%	-0.4%	96	1%
					BAUSCH & LOMB	19,209	2.0%	9.2%	105	5%
					Brand Manufacturers Subtotal	949,186	94.5%	4.0%	99	12%
13	13	11	10	9	61000:OPHTHALMICS Subtotal	1,004,950	3.9%	4.7%	101	13%
					PURDUE PHARMA	269,013	48.5%	-1.9%	102	-5%
					MCNEIL CONSUMER	66,452	12.0%	-11.0%	92	-5%
					JANSSEN PHARMA	37,683	6.8%	-11.7%	91	-3%
					PALADIN	29,631	5.3%	-5.9%	97	0%
					NOVARTIS CONS HEALTH	29,150	5.3%	12.8%	117	19%
					Brand Manufacturers Subtotal	554,730	57.1%	-3.4%	97	-4%
10	10	9	9	10	02000:ANALGESICS Subtotal	971,124	3.8%	-0.7%	96	0%
					NOVARTIS PHARMA	133,669	27.3%	8.9%	103	16%
					BIOGEN IDEC	106,039	21.7%	7.3%	102	168%
					TEVA CDN INNOVATION	90,938	18.6%	-1.2%	94	-3%
					PFIZER	48,594	9.9%	-8.6%	87	-40%
					UCB PHARMA CANADA	31,103	6.4%	12.1%	106	17%
					Brand Manufacturers Subtotal	489,318	52.6%	5.5%	101	-7%
8	9	12	11	11	20000:NEUROLOGICAL DISORDERS, MISC Subtotal	930,980	3.6%	4.0%	101	-1%
					AMGEN	123,341	18.0%	19.1%	117	39%
					MERCK CANADA INC	76,382	11.1%	-21.5%	77	-11%
					PFIZER	58,391	8.5%	12.4%	110	6%
					NOVO NORDISK CDA	52,317	7.6%	10.1%	108	15%
					WARNER CHILCOTT	41,990	6.1%	-2.8%	95	-9%
					Brand Manufacturers Subtotal	686,757	76.8%	2.0%	98	3%
12	12	13	12	12	52000:HORMONES Subtotal	893,756	3.5%	3.9%	101	3%

T22 | TOP 15 THERAPEUTIC CLASSES AND LEADING BRAND-NAME MANUFACTURERS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					JANSSEN PHARMA	195,537	24.3%	33.4%	110	32%
					ASTELLAS PHARMA	102,127	12.7%	6.8%	88	8%
					BIOGEN IDEC	101,101	12.6%	0.8%	83	-2%
					NOVARTIS PHARMA	90,540	11.3%	26.9%	104	12%
					GENZYME CORP	86,440	10.7%	52.4%	125	-
					Brand Manufacturers Subtotal	804,635	95.0%	21.6%	100	11%
15	15	15	15	13	86000:IMMUNOLOGIC AGENTS Subtotal	847,059	3.3%	21.7%	118	11%
					BAYER HEALTHCARE	179,886	24.2%	19.3%	105	71%
					BMS PHARMA	141,508	19.0%	63.8%	144	137%
					PFIZER	110,690	14.9%	3.9%	92	4%
					BOEHRINGER ING	87,287	11.7%	-7.2%	82	-3%
					ROCHE	66,043	8.9%	9.1%	96	6%
					Brand Manufacturers Subtotal	744,743	91.2%	13.5%	102	12%
14	14	14	14	14	11000:HEMOSTATIC MODIFIERS Subtotal	816,436	3.2%	11.4%	108	9%
					ASTRAZENECA	145,125	51.1%	0.3%	103	-23%
					PFIZER	66,161	23.3%	-6.1%	96	-10%
					PENDOPHARM	16,077	5.7%	4.3%	107	4%
					MERCK CANADA INC	15,653	5.5%	-32.8%	69	-46%
					VALEANT PHARMA	14,831	5.2%	19.8%	123	107%
					Brand Manufacturers Subtotal	283,896	36.4%	-2.6%	97	-22%
6	8	10	13	15	32000:ANTIHYPERLIPIDEMIC AGENTS Subtotal	779,892	3.0%	0.4%	97	-13%

T 23 | TOP 15 THERAPEUTIC CLASSES AND LEADING GENERIC MANUFACTURERS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
Total Ethical Market						25,713,985	100.0%	3.2%	100	4%
					APOTEX INC	47,759	27.3%	11.3%	110	9%
					TEVA CANADA LTD	22,840	13.0%	-6.7%	92	13%
					PRIVATE LABEL	19,939	11.4%	-5.3%	93	2%
					GENMED	12,299	7.0%	286.1%	380	-
					SANDOZ CANADA INC	9,082	5.2%	14.3%	112	-4%
					Generic Manufacturers Subtotal	175,053	6.8%	1.6%	92	10%
3	2	1	1	1	09000:ANTIARTHRITICS Subtotal	2,555,754	9.9%	10.8%	107	11%
					APOTEX INC	157,287	20.2%	18.8%	109	3%
					TEVA CANADA LTD	147,660	19.0%	-5.3%	87	-7%
					SANIS HEALTH INC	80,508	10.3%	46.1%	135	3%
					MYLAN PHARMA	73,936	9.5%	5.7%	97	7%
					PHARMASCIENCE	71,750	9.2%	1.2%	93	-4%
					Generic Manufacturers Subtotal	778,641	36.2%	8.6%	105	1%
1	1	2	2	2	64000:PSYCHOTHERAPEUTICS Subtotal	2,148,879	8.4%	3.3%	100	3%
					HOSPIRA	39,238	25.4%	-10.9%	90	-11%
					TEVA CANADA LTD	37,172	24.1%	-20.9%	80	4%
					ACTAVIS PHARMA	17,668	11.4%	41.2%	142	219%
					APOTEX INC	13,055	8.4%	7.1%	108	71%
					SANDOZ CANADA INC	10,723	6.9%	26.8%	128	-2%
					Generic Manufacturers Subtotal	154,562	7.8%	-0.6%	95	5%
4	3	3	3	3	30000:ONCOLOGY Subtotal	1,993,331	7.8%	4.6%	101	8%
					SANDOZ CANADA INC	159,165	21.3%	-3.0%	97	2%
					APOTEX INC	113,423	15.2%	0.5%	101	-13%
					TEVA CANADA LTD	85,447	11.5%	1.7%	102	-10%
					PHARMASCIENCE	73,014	9.8%	2.4%	103	-6%
					MYLAN PHARMA	68,120	9.1%	-14.6%	86	-9%
					Generic Manufacturers Subtotal	745,651	45.3%	-0.2%	98	-4%
2	4	4	5	4	31000:CARDIOVASCULARS Subtotal	1,645,713	6.4%	1.7%	99	-2%

T23 | TOP 15 THERAPEUTIC CLASSES AND LEADING GENERIC MANUFACTURERS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					APOTEX INC	27,053	25.5%	7.3%	107	-6%
					SANDOZ CANADA INC	22,244	21.0%	19.7%	120	13%
					TEVA CANADA LTD	11,523	10.9%	-3.9%	96	-21%
					ACTAVIS PHARMA	9,537	9.0%	-14.6%	85	-16%
					MINT PHARMACEUTICALS	7,570	7.1%	45.5%	145	22%
					Generic Manufacturers Subtotal	106,082	6.7%	0.0%	88	-11%
9	7	6	6	5	39000:DIABETES THERAPY Subtotal	1,577,598	6.1%	13.9%	110	13%
					APOTEX INC	30,575	34.7%	87.8%	103	20%
					PHARMASCIENCE	25,433	28.8%	130.8%	127	-2%
					MYLAN PHARMA	10,929	12.4%	113.4%	117	-1%
					TEVA CANADA LTD	3,671	4.2%	-11.1%	49	18%
					ACTAVIS PHARMA	3,353	3.8%	-8.5%	50	86%
					Generic Manufacturers Subtotal	88,213	5.7%	81.9%	212	8%
11	11	8	4	6	81000:ANTI-VIRALS Subtotal	1,549,439	6.0%	-14.0%	83	18%
					TEVA CANADA LTD	33,916	36.7%	16.1%	108	3%
					SANDOZ CANADA INC	13,338	14.4%	69.9%	157	14%
					APOTEX INC	12,584	13.6%	11.3%	103	-12%
					PHARMASCIENCE	9,749	10.5%	-16.8%	77	-8%
					SANIS HEALTH INC	9,389	10.2%	2.0%	94	80%
					Generic Manufacturers Subtotal	92,438	7.0%	8.0%	105	5%
7	6	5	7	7	28000:RESPIRATORY THERAPY Subtotal	1,328,662	5.2%	2.9%	100	4%
					APOTEX INC	157,127	28.5%	-9.4%	87	-8%
					SANDOZ CANADA INC	112,921	20.5%	8.8%	105	4%
					TEVA CANADA LTD	63,927	11.6%	18.2%	114	-14%
					SANIS HEALTH INC	39,259	7.1%	7.5%	103	-1%
					MYLAN PHARMA	37,024	6.7%	49.3%	143	0%
					Generic Manufacturers Subtotal	551,667	52.1%	4.1%	118	-3%
5	5	7	8	8	23000:GASTROINTESTINAL/ GENITOURINARY Subtotal	1,057,966	4.1%	-11.5%	86	-6%

T23 | TOP 15 THERAPEUTIC CLASSES AND LEADING GENERIC MANUFACTURERS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					SANDOZ CANADA INC	26,595	47.7%	54.6%	132	80%
					APOTEX INC	7,345	13.2%	13.3%	97	-12%
					COBALT PHARMA	5,004	9.0%	-1.7%	84	24%
					ACTAVIS PHARMA	4,392	7.9%	-10.0%	77	-
					AA PHARMA INC	3,970	7.1%	23.1%	105	39%
					Generic Manufacturers Subtotal	55,763	5.5%	17.3%	112	20%
13	13	11	10	9	61000:OPHTHALMICS Subtotal	1,004,950	3.9%	4.7%	101	13%
					TEVA CANADA LTD	121,571	29.2%	0.3%	97	1%
					SANDOZ CANADA INC	95,206	22.9%	4.0%	101	10%
					APOTEX INC	55,908	13.4%	3.8%	101	5%
					PHARMASCIENCE	33,016	7.9%	-4.4%	93	5%
					PRIVATE LABEL	18,849	4.5%	-2.5%	94	-3%
					Generic Manufacturers Subtotal	416,393	42.9%	3.3%	104	7%
10	10	9	9	10	02000:ANALGESICS Subtotal	971,124	3.8%	-0.7%	96	0%
					PHARMASCIENCE	88,492	20.0%	5.5%	103	9%
					APOTEX INC	80,720	18.3%	4.9%	102	0%
					TEVA CANADA LTD	56,083	12.7%	-1.6%	96	6%
					SANIS HEALTH INC	45,949	10.4%	37.2%	134	23%
					ACTAVIS PHARMA	27,628	6.3%	-10.4%	87	8%
					Generic Manufacturers Subtotal	441,663	47.4%	2.4%	98	9%
8	9	12	11	11	20000:NEUROLOGICAL DISORDERS, MISC Subtotal	930,980	3.6%	4.0%	101	-1%
					TEVA CANADA LTD	65,865	31.8%	21.5%	110	6%
					TARO PHARMACEUTICALS	44,152	21.3%	8.8%	99	14%
					APOTEX INC	19,426	9.4%	11.9%	101	-17%
					SANDOZ CANADA INC	14,339	6.9%	10.2%	100	6%
					PHARMASCIENCE	11,452	5.5%	-12.2%	80	-13%
					Generic Manufacturers Subtotal	206,999	23.2%	10.4%	106	2%
12	12	13	12	12	52000:HORMONES Subtotal	893,756	3.5%	3.9%	101	3%

T23 | TOP 15 THERAPEUTIC CLASSES AND LEADING GENERIC MANUFACTURERS BY TOTAL ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					APOTEX INC	19,327	45.6%	40.4%	114	22%
					SANDOZ CANADA INC	16,088	37.9%	39.0%	113	29%
					TEVA CANADA LTD	6,141	14.5%	-25.4%	61	15%
					PRO DOC	474	1.1%	3.2%	84	10%
					JAMP PHARMA	261	0.6%	-20.5%	65	262%
					Generic Manufacturers Subtotal	42,424	5.0%	23.2%	101	17%
15	15	15	15	13	86000:IMMUNOLOGIC AGENTS Subtotal	847,059	3.3%	21.7%	118	11%
					APOTEX INC	24,935	34.8%	-4.1%	103	-11%
					TARO PHARMACEUTICALS	12,356	17.2%	-10.6%	96	-4%
					SANDOZ CANADA INC	6,522	9.1%	-12.3%	94	-14%
					PHARMASCIENCE	6,295	8.8%	16.9%	125	22%
					TEVA CANADA LTD	4,242	5.9%	-21.3%	84	0%
					Generic Manufacturers Subtotal	71,693	8.8%	-6.5%	84	-8%
14	14	14	14	14	11000:HEMOSTATIC MODIFIERS Subtotal	816,436	3.2%	11.4%	108	9%
					APOTEX INC	174,809	35.2%	5.7%	103	-3%
					SANIS HEALTH INC	68,580	13.8%	37.4%	135	10%
					TEVA CANADA LTD	63,680	12.8%	-12.5%	86	-8%
					SANDOZ CANADA INC	38,871	7.8%	3.7%	102	12%
					PRO DOC	33,623	6.8%	-0.2%	98	2%
					Generic Manufacturers Subtotal	495,996	63.6%	2.1%	102	-4%
6	8	10	13	15	32000:ANTIHYPERTENSIVE AGENTS Subtotal	779,892	3.0%	0.4%	97	-13%

T24 | TOP 15 THERAPEUTIC CLASSES AND LEADING BRAND-NAME MANUFACTURERS BY TOTAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
TOTAL ETHICAL MARKET						649,746	100.0%	3.7%	100	4%
					SERVIER LAB.	7,879	42.1%	11.4%	110	13%
					MERCK CANADA INC	2,102	11.2%	4.4%	103	-6%
					BAYER HEALTHCARE	1,577	8.4%	-3.6%	95	-5%
					PFIZER	1,471	7.9%	-5.3%	93	-11%
					PENDOPHARM	1,392	7.4%	-5.7%	93	-4%
					Brand Manufacturers Subtotal	18,711	20.5%	1.4%	100	-4%
1	1	1	1	1	31000:CARDIOVASCULARS Subtotal	91,183	14.0%	1.9%	98	2%
					PFIZER	2,974	18.3%	-5.8%	97	-7%
					JANSSEN PHARMA	2,230	13.7%	6.6%	109	7%
					BMS PHARMA	1,946	12.0%	12.4%	115	24%
					SHIRE CANADA INC	1,829	11.2%	14.5%	117	22%
					LILLY	1,800	11.1%	-34.2%	68	-2%
					Brand Manufacturers Subtotal	16,264	18.4%	-2.6%	93	-4%
2	2	2	2	2	64000:PSYCHOTHERAPEUTICS Subtotal	88,250	13.6%	4.7%	101	4%
					TAKEDA PHARMA NA	3,813	44.7%	-43.5%	82	5%
					ASTRAZENECA	776	9.1%	-18.8%	118	-30%
					ASTELLAS PHARMA	630	7.4%	-36.6%	92	4%
					PFIZER	615	7.2%	-36.5%	92	-9%
					PENDOPHARM	528	6.2%	5.3%	153	19%
					Brand Manufacturers Subtotal	8,524	16.9%	-31.3%	66	-9%
3	3	3	3	3	23000:GASTROINTESTINAL/ GENITOURINARY Subtotal	50,417	7.8%	4.1%	100	4%
					ASTRAZENECA	1,644	52.8%	-5.6%	106	-30%
					PFIZER	602	19.3%	-11.9%	99	-17%
					MERCK CANADA INC	190	6.1%	-39.7%	68	-46%
					PENDOPHARM	188	6.0%	3.3%	116	3%
					BGP PHARMA ULC	179	5.7%	-22.7%	87	-24%
					Brand Manufacturers Subtotal	3,113	7.4%	-10.7%	87	-28%
4	4	4	4	4	32000:ANTIHYPERTENSIVE AGENTS Subtotal	42,309	6.5%	2.2%	99	2%

T24 | TOP 15 THERAPEUTIC CLASSES AND LEADING BRAND-NAME MANUFACTURERS BY TOTAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					MERCK CANADA INC	3,580	25.1%	17.5%	112	22%
					NOVO NORDISK CDA	2,355	16.5%	-3.5%	92	-2%
					SANOFI-AVENTIS	1,988	13.9%	8.4%	103	11%
					ASTRAZENECA	1,669	11.7%	24.3%	118	46%
					LILLY	1,494	10.5%	1.1%	96	0%
					Brand Manufacturers Subtotal	14,259	44.0%	5.2%	100	11%
7	6	6	6	5	39000:DIABETES THERAPY Subtotal	32,433	5.0%	5.3%	102	5%
					PFIZER	1,367	33.8%	-7.5%	93	-31%
					PENDOPHARM	1,119	27.7%	-0.9%	100	10%
					NOVARTIS PHARMA	386	9.5%	-3.8%	97	-3%
					UCB PHARMA CANADA	160	4.0%	17.8%	119	12%
					ALLERGAN	156	3.9%	11.4%	113	14%
					Brand Manufacturers Subtotal	4,045	12.8%	-1.1%	94	-17%
8	8	7	7	6	20000:NEUROLOGICAL DISORDERS, MISC Subtotal	31,587	4.9%	5.1%	101	6%
					PURDUE PHARMA	3,938	39.4%	3.5%	107	1%
					JANSSEN PHARMA	1,657	16.6%	-21.8%	81	-12%
					PALADIN	1,108	11.1%	2.7%	106	0%
					NOVARTIS CONS HEALTH	1,070	10.7%	6.9%	110	13%
					ETHYPHARM INC	421	4.2%	-1.9%	101	2%
					Brand Manufacturers Subtotal	9,992	31.9%	-3.0%	97	-2%
5	5	5	5	7	02000:ANALGESICS Subtotal	31,330	4.8%	0.3%	97	2%
					PFIZER	1,850	15.9%	-1.5%	101	1%
					ALCON CANADA	1,513	13.0%	3.7%	106	5%
					MERCK CANADA INC	1,509	12.9%	-15.4%	87	-15%
					ACERUS PHARMA CORP	943	8.1%	-20.6%	81	-6%
					WARNER CHILCOTT	686	5.9%	-5.6%	97	-9%
					Brand Manufacturers Subtotal	11,666	42.5%	-2.4%	97	-2%
6	7	8	8	8	52000:HORMONES Subtotal	27,481	4.2%	0.7%	97	0%

T24 | TOP 15 THERAPEUTIC CLASSES AND LEADING BRAND-NAME MANUFACTURERS BY TOTAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate	
						WARNER CHILCOTT	1,414	42.6%	2.8%	108	4%
						BAYER HEALTHCARE	230	6.9%	-65.0%	37	-32%
						APTALIS PHARMA	221	6.7%	-3.2%	102	-1%
						GLAXOSMITHKLINE	207	6.2%	59.8%	168	12%
						SHIRE CANADA INC	165	5.0%	14.2%	120	16%
						Brand Manufacturers Subtotal	3,320	13.2%	-4.8%	94	-8%
9	9	9	9	9		15000:ANTI-INFECTIVES Subtotal	25,171	3.9%	1.7%	98	0%
						BGP PHARMA ULC	17,887	87.0%	5.3%	101	5%
						TRITON PHARMA INC	2,176	10.6%	-7.6%	89	-3%
						PALADIN	233	1.1%	5.2%	101	4%
						ERFA CANADA INC	177	0.9%	10.6%	107	14%
						PFIZER	82	0.4%	5.6%	102	5%
						Brand Manufacturers Subtotal	20,554	100.0%	3.8%	100	4%
12	12	12	11	10		72000:THYROID THERAPY Subtotal	20,555	3.2%	3.8%	100	4%
						PFIZER	182	45.5%	-22.1%	85	-9%
						SANOFI-AVENTIS	182	45.4%	8.3%	118	2%
						SERVIER LAB.	23	5.8%	1.4%	110	-8%
						VALEANT PHARMA	8	1.9%	4.3%	113	8%
						LEO PHARMA INC	4	0.9%	16.8%	127	8%
						Brand Manufacturers Subtotal	400	2.0%	-8.1%	91	-4%
10	10	10	10	11		41000:DIURETICS AND AQUARETICS Subtotal	20,181	3.1%	1.5%	98	1%
						GLAXOSMITHKLINE	5,987	45.7%	-9.2%	93	-5%
						ASTRAZENECA	3,330	25.4%	4.8%	108	6%
						BOEHRINGER ING	2,412	18.4%	-1.6%	101	-1%
						NOVARTIS PHARMA	601	4.6%	24.2%	128	109%
						MERCK CANADA INC	481	3.7%	7.5%	110	-2%
						Brand Manufacturers Subtotal	13,090	65.5%	-2.7%	95	-1%
11	11	11	12	12		28000:RESPIRATORY THERAPY Subtotal	19,992	3.1%	2.4%	99	2%

T24 | TOP 15 THERAPEUTIC CLASSES AND LEADING BRAND-NAME MANUFACTURERS BY TOTAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					ASTRAZENECA	699	32.6%	5.7%	118	24%
					ABBVIE	348	16.2%	12.5%	126	14%
					JANSSEN PHARMA	302	14.1%	18.4%	132	16%
					PFIZER	278	13.0%	-57.9%	47	-48%
					AMGEN	181	8.4%	-0.4%	111	1%
					Brand Manufacturers Subtotal	2,145	13.6%	-10.5%	88	-19%
13	13	13	13	13	09000:ANTIARTHRITICS Subtotal	15,831	2.4%	2.2%	99	1%
					WEBBER	1,654	35.0%	11.7%	106	17%
					JAMIESON	890	18.8%	-5.5%	90	-2%
					ALCON CANADA	737	15.6%	9.8%	105	5%
					PFIZER CPD	314	6.7%	10.4%	105	0%
					SWISS HERB REMEDIES	291	6.2%	1.7%	97	1%
					Brand Manufacturers Subtotal	4,725	30.4%	4.9%	95	5%
15	15	14	14	14	76000:VITAMINS, ETHICAL Subtotal	15,543	2.4%	10.4%	107	14%
					WEBBER	671	29.0%	33.0%	118	48%
					JAMIESON	549	23.7%	14.4%	102	16%
					NOVARTIS PHARMA	304	13.1%	-10.7%	79	-6%
					SWISS HERB REMEDIES	161	7.0%	23.3%	110	31%
					PENDOPHARM	138	6.0%	8.8%	97	16%
					Brand Manufacturers Subtotal	2,312	16.6%	12.4%	107	7%
14	14	15	15	15	60000:NUTRIENTS&SUPPLEMENTS Subtotal	13,913	2.1%	5.4%	102	8%

T25 | TOP 15 THERAPEUTIC CLASSES AND LEADING GENERIC MANUFACTURERS BY TOTAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
TOTAL ETHICAL MARKET						649,746	100.0%	3.7%	100	4%
					SANDOZ CANADA INC	13,447	18.6%	3.9%	102	9%
					APOTEX INC	11,440	15.8%	0.4%	98	-7%
					TEVA CANADA LTD	8,960	12.4%	0.9%	99	-5%
					PHARMASCIENCE	8,741	12.1%	13.3%	111	2%
					PRO DOC	6,654	9.2%	1.8%	100	12%
					Generic Manufacturers Subtotal	72,472	79.5%	2.0%	100	4%
1	1	1	1	1	31000:CARDIOVASCULARS Subtotal	91,183	14.0%	1.9%	98	2%
					APOTEX INC	14,973	20.8%	6.1%	100	1%
					TEVA CANADA LTD	14,661	20.4%	6.2%	100	4%
					PHARMASCIENCE	9,907	13.8%	10.1%	103	8%
					PRO DOC	6,181	8.6%	7.0%	100	10%
					SANIS HEALTH INC	5,840	8.1%	33.0%	125	16%
					Generic Manufacturers Subtotal	71,987	81.6%	6.5%	102	7%
2	2	2	2	2	64000:PSYCHOTHERAPEUTICS Subtotal	88,250	13.6%	4.7%	101	4%
					SANDOZ CANADA INC	8,825	21.1%	12.4%	97	16%
					APOTEX INC	7,550	18.0%	12.3%	97	0%
					TEVA CANADA LTD	5,605	13.4%	25.7%	108	-5%
					PRO DOC	3,222	7.7%	0.1%	86	15%
					SANIS HEALTH INC	2,957	7.1%	26.8%	109	17%
					Generic Manufacturers Subtotal	41,893	83.1%	16.2%	112	9%
3	3	3	3	3	23000:GASTROINTESTINAL/ GENITOURINARY Subtotal	50,417	7.8%	4.1%	100	4%
					APOTEX INC	10,929	27.9%	7.9%	104	6%
					TEVA CANADA LTD	5,170	13.2%	-1.9%	95	3%
					PRO DOC	4,348	11.1%	0.9%	98	13%
					SANIS HEALTH INC	4,302	11.0%	34.9%	130	26%
					SIVEM PHARMA ULC	3,114	7.9%	-26.4%	71	312%
					Generic Manufacturers Subtotal	39,196	92.6%	3.4%	101	10%
4	4	4	4	4	32000:ANTIHYPERTENSIVE AGENTS Subtotal	42,309	6.5%	2.2%	99	2%

T25 | TOP 15 THERAPEUTIC CLASSES AND LEADING GENERIC MANUFACTURERS BY TOTAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					SANDOZ CANADA INC	3,741	20.6%	49.0%	141	45%
					APOTEX INC	3,504	19.3%	7.2%	102	4%
					TEVA CANADA LTD	2,122	11.7%	4.9%	99	-11%
					PRO DOC	1,996	11.0%	-0.9%	94	1%
					PHARMASCIENCE	1,410	7.8%	18.5%	112	3%
					Generic Manufacturers Subtotal	18,174	56.0%	5.4%	100	2%
7	6	6	6	5	39000:DIABETES THERAPY Subtotal	32,433	5.0%	5.3%	102	5%
					PHARMASCIENCE	7,873	28.6%	8.9%	103	11%
					TEVA CANADA LTD	4,241	15.4%	15.5%	109	11%
					APOTEX INC	4,166	15.1%	-1.3%	93	3%
					PRO DOC	2,186	7.9%	-7.9%	87	16%
					SANIS HEALTH INC	1,575	5.7%	20.8%	114	36%
					Generic Manufacturers Subtotal	27,542	87.2%	6.1%	101	13%
8	8	7	7	6	20000:NEUROLOGICAL DISORDERS, MISC Subtotal	31,587	4.9%	5.1%	101	6%
					TEVA CANADA LTD	8,423	39.5%	5.8%	104	2%
					PRO DOC	3,450	16.2%	-2.4%	96	1%
					PHARMASCIENCE	2,475	11.6%	3.0%	101	9%
					APOTEX INC	2,265	10.6%	9.7%	108	1%
					SANDOZ CANADA INC	1,246	5.8%	-4.9%	93	7%
					Generic Manufacturers Subtotal	21,338	68.1%	1.9%	102	5%
5	5	5	5	7	02000:ANALGESICS Subtotal	31,330	4.8%	0.3%	97	2%
					TEVA CANADA LTD	4,080	25.8%	5.9%	103	-2%
					TARO PHARMACEUTICALS	3,603	22.8%	4.5%	101	7%
					APOTEX INC	2,986	18.9%	6.6%	103	-1%
					PHARMASCIENCE	967	6.1%	-9.8%	87	-7%
					PRO DOC	885	5.6%	-3.2%	94	1%
					Generic Manufacturers Subtotal	15,814	57.5%	3.2%	102	2%
6	7	8	8	8	52000:HORMONES Subtotal	27,481	4.2%	0.7%	97	0%

T25 | TOP 15 THERAPEUTIC CLASSES AND LEADING GENERIC MANUFACTURERS BY TOTAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
						6,258	28.6%	-8.7%	89	-3%
						5,597	25.6%	2.6%	100	-1%
						1,651	7.6%	24.5%	121	7%
						1,486	6.8%	2.1%	99	10%
						1,274	5.8%	2.7%	100	15%
					Generic Manufacturers Subtotal	21,851	86.8%	2.8%	101	2%
9	9	9	9	9	15000:ANTI-INFECTIVES Subtotal	25,171	3.9%	1.7%	98	0%
						0	99.6%	-42.9%	101	-14%
						0	0.4%	-	-	-
					Generic Manufacturers Subtotal	0	0.0%	-43.3%	55	-14%
12	12	12	11	10	72000:THYROID THERAPY Subtotal	20,555	3.2%	3.8%	100	4%
						7,416	37.5%	8.7%	107	9%
						6,360	32.2%	-0.1%	98	-6%
						2,625	13.3%	-16.9%	82	0%
						1,567	7.9%	0.2%	99	1%
						1,191	6.0%	15.3%	113	15%
					Generic Manufacturers Subtotal	19,781	98.0%	1.7%	100	2%
10	10	10	10	11	41000:DIURETICS AND AQUARETICS Subtotal	20,181	3.1%	1.5%	98	1%
						3,119	45.2%	23.4%	109	19%
						1,789	25.9%	8.1%	95	-9%
						987	14.3%	10.8%	98	151%
						291	4.2%	-9.9%	79	-2%
						196	2.8%	41.7%	125	11%
					Generic Manufacturers Subtotal	6,902	34.5%	13.5%	111	10%
11	11	11	12	12	28000:RESPIRATORY THERAPY Subtotal	19,992	3.1%	2.4%	99	2%

T25 | TOP 15 THERAPEUTIC CLASSES AND LEADING GENERIC MANUFACTURERS BY TOTAL PRESCRIPTIONS

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		# of Rx (000s)	% Share of Market	% Change	Evolution Index	4-Yr Avg Compound Growth Rate
					APOTEX INC	4,071	29.7%	8.6%	104	7%
					TEVA CANADA LTD	2,125	15.5%	-1.9%	94	10%
					MARCAN PHARMA INC	1,103	8.1%	7.7%	103	-
					PRO DOC	936	6.8%	6.0%	101	14%
					SANIS HEALTH INC	791	5.8%	17.7%	113	20%
					Generic Manufacturers Subtotal	13,686	86.4%	4.6%	102	9%
13	13	13	13	13	09000:ANTIARTHRITICS Subtotal	15,831	2.4%	2.2%	99	1%
					JAMP PHARMA	5,125	47.4%	16.3%	103	43%
					RIVA	3,242	30.0%	5.9%	94	3%
					SANDOZ CANADA INC	1,298	12.0%	1.3%	90	7%
					PRO DOC	555	5.1%	28.3%	114	>999.9%
					MANTRA PHARMA	321	3.0%	116.8%	192	-
					Generic Manufacturers Subtotal	10,819	69.6%	13.0%	102	20%
15	15	14	14	14	76000:VITAMINS, ETHICAL Subtotal	15,543	2.4%	10.4%	107	14%
					JAMP PHARMA	3,947	34.0%	19.4%	115	28%
					MANTRA PHARMA	1,483	12.8%	24.7%	120	23%
					PRO DOC	1,394	12.0%	-3.3%	93	1%
					SANDOZ CANADA INC	1,324	11.4%	-11.4%	85	6%
					RIVA	895	7.7%	-6.3%	90	-8%
					Generic Manufacturers Subtotal	11,600	83.4%	4.1%	99	8%
14	14	15	15	15	60000:NUTRIENTS&SUPPLEMENTS Subtotal	13,913	2.1%	5.4%	102	8%

T26 | TOP 15 THERAPEUTIC CLASSES AND LEADING CORPORATIONS BY JOURNAL AD EXPENDITURES

	Journal Ad Expenditures (\$000s)	% Share of Market	% Change	% Share of Total Promotional Dollars
TOTAL JOURNAL AD EXPENDITURES	12,465	100.0%	-1.3%	3.0%
ASTRAZENECA	752	27.1%	6.7%	4.6%
BOEHRINGER ING	520	18.7%	19.7%	6.2%
MERCK CANADA INC	513	18.5%	>999.9%	5.4%
LILLY	395	14.2%	491.6%	5.0%
SANOFI-AVENTIS	365	13.1%	132.2%	7.3%
1 39000:DIABETES THERAPY Subtotal	2,775	22.3%	71.1%	4.2%
GLAXOSMITHKLINE	1,128	56.0%	22.0%	4.1%
ASTRAZENECA	244	12.1%	-67.4%	1.2%
BOEHRINGER ING	239	11.9%	-64.8%	2.3%
MERCK CANADA INC	230	11.4%	156.7%	4.0%
NOVARTIS	174	8.6%	-15.4%	2.1%
2 28000:RESPIRATORY THERAPY Subtotal	2,015	16.2%	-24.1%	2.8%
PFIZER	618	47.3%	42.7%	11.6%
H LUNDBECK A/S	447	34.3%	30.7%	4.3%
SHIRE CANADA INC	168	12.8%	11.5%	3.6%
PURDUE PHARMA	73	5.6%	-68.2%	2.7%
3 64000:PSYCHOTHERAPEUTICS Subtotal	1,306	10.5%	6.6%	3.3%
PURDUE PHARMA	261	25.2%	23.6%	48.5%
TEVA CANADA LTD	117	11.3%	185.8%	77.0%
LILLY	106	10.2%	-18.7%	13.4%
ASTRAZENECA	104	10.0%	-27.8%	3.4%
BOEHRINGER ING	100	9.6%	-44.6%	5.4%
4 78000:MISCELLANEOUS ETHICAL Subtotal	1,037	8.3%	-8.8%	3.5%
ASTELLAS PHARMA	373	40.7%	50.3%	6.0%
TAKEDA PHARMA NA	194	21.3%	-40.1%	3.4%
FOREST LAB CANADA	181	19.8%	-53.5%	14.5%
PFIZER	86	9.5%	-42.2%	2.5%
ALLERGAN	80	8.7%	-	3.4%
5 23000:GASTROINTESTINAL/GENITOURINARY Subtotal	914	7.3%	-18.0%	3.9%

T26 | TOP 15 THERAPEUTIC CLASSES AND LEADING CORPORATIONS BY JOURNAL AD EXPENDITURES

		Journal Ad Expenditures (\$000s)	% Share of Market	% Change	% Share of Total Promotional Dollars
	PURDUE PHARMA	450	88.1%	-24.0%	13.1%
	NOVARTIS	61	11.9%	-7.4%	43.8%
6	02000:ANALGESICS Subtotal	511	4.1%	-22.4%	6.0%
	AMGEN	149	33.7%	-26.1%	4.3%
	BGP PHARMA ULC	142	32.0%	44.4%	15.2%
	PFIZER	47	10.6%	-32.9%	33.5%
	CIPHER PHARMA	36	8.1%	-	80.9%
	NOVO NORDISK CDA	34	7.7%	-	2.7%
7	52000:HORMONES Subtotal	443	3.6%	-35.1%	3.6%
	H LUNDBECK A/S	102	23.2%	92.9%	74.6%
	J & J	69	15.7%	-	19.1%
	BAYER INC	63	14.4%	19.2%	100.0%
	PFIZER	57	12.9%	-	64.5%
	ASTELLAS PHARMA	38	8.7%	-59.8%	15.0%
8	30000:ONCOLOGY Subtotal	440	3.5%	20.4%	19.7%
	SERVIER LAB.	350	81.5%	86.7%	1.4%
	NOVARTIS	63	14.6%	-	3.0%
	PFIZER	17	3.9%	280.1%	0.9%
9	31000:CARDIOVASCULARS Subtotal	430	3.4%	123.9%	1.1%
	ABBVIE	269	64.6%	-8.3%	17.7%
	PFIZER	60	14.4%	-63.0%	4.7%
	NOVARTIS	36	8.7%	-	100.0%
	J & J	26	6.2%	-89.1%	2.5%
	AMGEN	26	6.1%	-	6.0%
10	09000:ANTIARTHRITICS Subtotal	416	3.3%	-39.9%	4.1%
	GLAXOSMITHKLINE	201	51.3%	3.9%	14.9%
	NOVARTIS VACCINES	109	27.8%	161.7%	100.0%
	MERCK CANADA INC	58	14.7%	-	1.2%
	SANOFI-AVENTIS	24	6.2%	-	15.7%
11	27000:BIOLOGICALS Subtotal	392	3.1%	66.6%	4.9%

T26 | TOP 15 THERAPEUTIC CLASSES AND LEADING CORPORATIONS BY JOURNAL AD EXPENDITURES

	Journal Ad Expenditures (\$000s)	% Share of Market	% Change	% Share of Total Promotional Dollars
GALDERMA	148	40.1%	-7.0%	5.3%
VALEANT PHARMA	136	37.0%	>999.9%	2.3%
CIPHER PHARMA	71	19.2%	128.5%	43.5%
BLISTEX	8	2.2%	-	100.0%
LEO PHARMA INC	6	1.5%	-97.5%	0.3%
12 37000:DERMATOLOGICALS Subtotal	368	3.0%	-41.6%	2.7%
LILLY	69	24.3%	-	35.8%
CELGENE	59	21.0%	-16.4%	14.8%
J & J	56	19.8%	-	16.5%
BIOGEN IDEC	54	18.9%	-	14.3%
NOVARTIS	45	16.0%	-23.3%	7.1%
13 86000:IMMUNOLOGIC AGENTS Subtotal	283	2.3%	73.3%	7.7%
ASTRAZENECA	153	56.8%	-54.1%	12.9%
BAYER INC	69	25.5%	39.3%	0.6%
BOEHRINGER ING	43	16.0%	13.3%	1.0%
BRISTOL-MYERS SQUIBB	5	1.7%	-	0.1%
14 11000:HEMOSTATIC MODIFIERS Subtotal	270	2.2%	-35.9%	1.1%
AMGEN	171	68.5%	-	6.0%
SANOFI-AVENTIS	78	31.5%	-	6.4%
15 32000:ANTIHYPERTENSIVE AGENTS Subtotal	249	2.0%	-	3.1%

T27 | TOP 15 THERAPEUTIC CLASSES AND LEADING CORPORATIONS BY DETAILING AND SAMPLING ACTIVITY

	# of Details (000s)	% Share of Market	% Change	# of Details with Samples (000s)	# of Samples (000s)	% Change
TOTAL NUMBER OF DETAILS	2,877	100.0%	-22.6%	1,415	9,864	-30.3%
GLAXOSMITHKLINE	203	37.3%	4.1%	124	609	4.0%
ASTRAZENECA	155	28.4%	4.6%	112	752	8.4%
BOEHRINGER ING	83	15.3%	-20.4%	45	213	14.5%
NOVARTIS	55	10.1%	-31.0%	14	69	-56.7%
MERCK CANADA INC	44	8.1%	-28.1%	24	144	-28.9%
1 28000:RESPIRATORY THERAPY Subtotal	545	18.9%	-8.7%	320	1,800	-2.8%
ASTRAZENECA	125	26.0%	10.8%	67	426	26.5%
MERCK CANADA INC	76	15.8%	1.8%	30	196	-29.0%
BOEHRINGER ING	62	12.9%	73.6%	38	271	154.8%
J & J	60	12.4%	-18.5%	39	295	43.3%
LILLY	55	11.4%	26.1%	19	119	13.9%
2 39000:DIABETES THERAPY Subtotal	481	16.7%	3.7%	235	1,558	22.0%
SERVIER LAB.	190	62.0%	6.8%	137	868	2.6%
BGP PHARMA ULC	32	10.4%	-38.9%	21	179	-36.7%
MERCK CANADA INC	31	10.0%	15.4%	17	121	4.4%
VALEANT PHARMA	19	6.1%	46.0%	11	76	66.3%
PFIZER	15	5.0%	-25.1%	8	30	-34.0%
3 31000:CARDIOVASCULARS Subtotal	306	10.6%	-5.7%	198	1,304	-7.8%
H LUNDBECK A/S	56	26.3%	-34.5%	28	294	-6.1%
PFIZER	29	13.6%	-54.1%	15	189	-55.2%
SHIRE CANADA INC	25	11.9%	-21.1%	1	7	-75.2%
J & J	25	11.6%	-19.8%	0	1	-88.7%
BRISTOL-MYERS SQUIBB	20	9.6%	-32.7%	6	41	-65.8%
4 64000:PSYCHOTHERAPEUTICS Subtotal	211	7.3%	-36.3%	69	702	-40.3%
TAKEDA PHARMA NA	36	22.8%	-52.1%	26	299	-44.2%
ASTELLAS PHARMA	35	22.1%	-34.3%	25	208	-10.3%
PFIZER	26	16.5%	-12.0%	17	129	4.7%
ALLERGAN	21	13.2%	308.6%	14	112	>999.9%
ACTAVIS GRP PTC EHF	10	6.5%	-72.9%	7	49	-62.6%
5 23000:GASTROINTESTINAL/GENITOURINARY Subtotal	160	5.5%	-38.7%	105	915	-25.4%

T27 | TOP 15 THERAPEUTIC CLASSES AND LEADING CORPORATIONS BY DETAILING AND SAMPLING ACTIVITY

		# of Details (000s)	% Share of Market	% Change	# of Details with Samples (000s)	# of Samples (000s)	% Change
	MERCK CANADA INC	20	12.6%	-1.9%	0	0	-100.0%
	ASTRAZENECA	16	10.2%	57.5%	0	0	-
	BOEHRINGER ING	11	6.6%	132.5%	0	0	-
	PFIZER	10	6.6%	7.3%	0	0	-100.0%
	GLAXOSMITHKLINE	8	5.1%	94.0%	0	0	-
6	78000:MISCELLANEOUS ETHICAL Subtotal	159	5.5%	3.5%	2	12	-75.1%
	BAYER INC	70	47.6%	8.4%	37	329	50.8%
	BOEHRINGER ING	28	19.2%	4.4%	15	81	18.9%
	PFIZER	24	16.2%	-23.4%	12	99	-5.2%
	BRISTOL-MYERS SQUIBB	18	12.1%	5.2%	8	83	183.4%
	ASTRAZENECA	5	3.5%	-27.2%	2	17	4.3%
7	11000:HEMOSTATIC MODIFIERS Subtotal	147	5.1%	-4.5%	74	609	39.4%
	VALEANT PHARMA	51	46.9%	-16.5%	13	59	-79.9%
	GALDERMA	22	20.1%	-53.5%	10	54	-80.3%
	LEO PHARMA INC	17	15.6%	-19.5%	9	34	8.5%
	PEDIAPHARM INC	3	2.5%	32.9%	2	21	-23.3%
	BEIERSDORF CANADA	3	2.3%	-46.5%	2	16	-72.9%
8	37000:DERMATOLOGICALS Subtotal	109	3.8%	-40.3%	47	237	-78.4%
	AMGEN	21	27.6%	-44.6%	0	0	50.5%
	NOVO NORDISK CDA	8	10.7%	-46.0%	5	40	-6.3%
	SEARCHLIGHT PHARMA	7	9.3%	33.8%	6	36	166.9%
	BGP PHARMA ULC	6	8.6%	-38.2%	1	5	-59.5%
	ACTAVIS GRP PTC EHF	5	7.3%	-66.2%	3	28	-49.7%
9	52000:HORMONES Subtotal	74	2.6%	-55.4%	33	186	-64.4%
	BAYER INC	24	35.5%	-32.0%	3	26	22.6%
	ALLERGAN	12	17.9%	840.7%	10	60	810.5%
	ACTAVIS GRP PTC EHF	10	14.1%	-80.4%	9	59	-77.8%
	PFIZER	6	8.9%	-57.6%	4	39	-79.6%
	MYLAN PHARMA	6	8.2%	-	3	18	-
10	33000:CONTRACEPTIVES Subtotal	68	2.4%	-49.7%	36	235	-62.6%

T27 | TOP 15 THERAPEUTIC CLASSES AND LEADING CORPORATIONS BY DETAILING AND SAMPLING ACTIVITY

	# of Details (000s)	% Share of Market	% Change	# of Details with Samples (000s)	# of Samples (000s)	% Change
ASTRAZENECA	26	40.5%	-39.0%	24	220	-34.3%
TAKEDA PHARMA NA	9	14.1%	-24.5%	7	41	-0.7%
PFIZER	7	11.7%	-71.6%	5	27	-86.4%
ABBVIE	6	8.9%	-19.7%	0	1	-18.6%
J & J	5	7.9%	-55.2%	0	0	-100.0%
11 09000:ANTIARTHRITICS Subtotal	64	2.2%	-42.4%	37	296	-56.6%
PURDUE PHARMA	25	43.9%	-54.9%	0	1	-90.4%
TRIBUTE PHARMA	8	13.5%	-44.5%	6	46	-41.8%
BGP PHARMA ULC	6	11.1%	-	0	0	-
J & J	5	8.7%	-62.2%	3	19	-95.9%
BAYER INC	3	5.9%	44.8%	3	33	20.0%
12 02000:ANALGESICS Subtotal	56	2.0%	-53.7%	19	124	-84.0%
VALEANT PHARMA	22	41.4%	-27.5%	14	104	12.9%
AMGEN	18	32.9%	258.3%	0	0	-
SANOFI-AVENTIS	6	12.0%	-	0	0	-
ASTRAZENECA	2	4.6%	130.1%	0	1	-63.5%
PFIZER	2	3.5%	-78.6%	0	1	-93.0%
13 32000:ANTIHYPERLIPIDEMIC AGENTS Subtotal	53	1.9%	-4.1%	16	123	-16.0%
MERCK CANADA INC	34	63.8%	-14.5%	0	0	-
PFIZER	11	20.9%	-5.7%	0	0	-
GLAXOSMITHKLINE	7	13.7%	-11.3%	0	0	-
SANOFI-AVENTIS	1	1.3%	-67.7%	0	0	-
ASTRAZENECA	0	0.3%	-44.4%	0	0	-
14 27000:BIOLOGICALS Subtotal	52	1.8%	-14.7%	0	0	-
GLAXOSMITHKLINE	23	43.7%	-33.9%	22	211	-21.9%
ASTRAZENECA	13	24.9%	-48.4%	11	96	-44.7%
MEDA	8	15.3%	-	4	7	-
MERCK CANADA INC	3	5.5%	-66.8%	3	20	-57.6%
BAYER INC	2	4.7%	49.3%	2	13	-31.8%
15 34000:COUGH/COLD PREPS, ETHICAL Subtotal	52	1.8%	-28.1%	44	370	-31.7%



Diagnoses and Therapies

T28 | PROFILE OF LEADING DIAGNOSES

Profile Element	All Diagnoses	Essential Hypertension (Unspecified)	Diabetes Mellitus (Without Complications)	Health Check-Up*	Depressive Disorders (NEC)	Anxiety	Acute Upper Respiratory Infections (Unspecified Sites)	Normal Pregnancy Supervision	Hyperlipidemia	Esophagitis	Other Unknown and Unspecified Causes
Patient Visits (000s)	335,171	20,034	11,202	9,089	8,420	7,336	4,985	4,959	4,869	4,442	4,407
Patient Visits With Drugs (%)	60	84	76	3	84	69	43	16	89	90	100
Most Often Recommended Therapy	*****	Norvasc	Metformin	Vitamin D	Cipralext	Ativan	Amoxil	Materna	Crestor	Tecta	Pantoloc
Patient Gender Profile Male/Female (%)	44/56	54/45	58/42	48/52	33/67	33/67	44/56	100	60/40	46/54	46/54
Age Group (%)**											
Under 10		<1	<1	48	<1	2	34	-	-	6	4
10-19 years		<1	<1	6	5	9	12	3	<1	3	2
20-39 years		4	5	9	26	29	24	94	3	14	11
40-59 years		29	33	18	43	37	16	3	34	36	28
60-64 years		15	15	6	9	8	4	-	16	12	11
65 +		52	45	13	17	16	9	-	47	30	44
Most Productive Specialty	GP	GP	Internal Medicine	Pediatrician	Psych/Neuro	Psych/Neuro	Pediatrician	OB/Gyn	Internal Medicine	ENT/Opth	Internal Medicine
First Visit/Subsequent Visits (%)	46/54	20/80	16/84	68/32	18/82	32/68	81/19	21/79	26/74	40/60	29/71
Most Desired Action of Therapy	*****	Lower Blood Pressure	Control Diabetes	Vitamin Mineral Supplement	Anti-depressant	Reduce Anxiety	Antibiotic	Prenatal Vitamin	Reduce Lipid Level	Digestion Aid	Symptomatic

* Health check-up is comprised of Diagnoses: V20.2 Routine Child Health Check-up and V70.0 Routine General Medical Exam and Health Check-up

** Percentages may not add up to 100% due to rounding

T29 | PROFILE OF LEADING RECOMMENDED DRUG THERAPIES

Drug	Manufacturer	Drug Mentions 2016 (000s)	% Change Over 2015	% Used Alone	Most Productive Specialty	Drug Mentions per Physician per Year in Most Productive Specialty	New/Cont'd Therapy %	First/Subsequent Visits %
TOTAL		255,491	5.7%					
Metformin	Manufacturer Not Stated	5,087	7.1%	49%	GP and Internal Medicine	109	12/88	15/85
Crestor	AstraZeneca	4,748	18.7%	67%	Internal Medicine	132	13/87	21/79
Ventolin HFA	GlaxoSmithKline	3,461	11.0%	23%	Pediatrician	151	34/66	48/52
Synthroid	BGP Pharma ULC	3,458	1.0%	100%	GP	77	14/86	24/76
Amoxil	Pfizer	3,165	-6.2%	83%	Pediatrician	112	97/3	75/25
Cipralex	Lundbeck Canada Inc	3,038	10.0%	67%	Psych/Neuro	158	23/77	21/79
Norvasc	Pfizer	2,950	7.1%	35%	GP	64	17/83	25/75
Lipitor	Pfizer	2,813	-8.2%	55%	Internal Medicine	73	8/92	22/78
ASA	Manufacturer Not Stated	2,800	-9.3%	15%	Internal Medicine	144	16/84	36/64
Coversyl	Servier Laboratories	2,724	-2.4%	55%	GP	64	20/80	15/85
Prednisone	Manufacturer Not Stated	2,016	1.7%	43%	Internal Medicine	77	65/35	40/60
Hydrochlorothiazide	Manufacturer Not Stated	1,964	-0.7%	27%	GP	43	19/81	18/82
Nasonex	Merck Canada Inc	1,853	10.6%	60%	ENT/Opth	231	76/24	71/29
Effexor XR	Pfizer	1,753	-6.7%	62%	Psych/Neuro	102	21/79	23/77
Symbicort	AstraZeneca	1,738	2.4%	45%	Internal Medicine	72	34/66	40/60
Tylenol with Codeine #3	Janssen Pharma	1,659	12.0%	66%	GP and ENT/Opth	38	53/47	36/64
Metoprolol	Manufacturer Not Stated	1,645	3.5%	25%	Internal Medicine	67	11/89	23/77
Ativan	Pfizer	1,616	11.6%	67%	Psych/Neuro	59	41/59	36/64
Zithromax	Pfizer	1,591	1.8%	73%	GP	41	96/4	77/23
Ramipril	Manufacturer Not Stated	1,582	11.1%	35%	Internal Medicine	48	12/88	24/76

...the first of these is the fact that the ...

...the second of these is the fact that the ...

...the third of these is the fact that the ...

...the fourth of these is the fact that the ...

...the fifth of these is the fact that the ...

...the sixth of these is the fact that the ...

...the seventh of these is the fact that the ...

...the eighth of these is the fact that the ...

...the ninth of these is the fact that the ...

...the tenth of these is the fact that the ...

...the eleventh of these is the fact that the ...

...the twelfth of these is the fact that the ...

...the thirteenth of these is the fact that the ...

...the fourteenth of these is the fact that the ...

...the fifteenth of these is the fact that the ...

...the sixteenth of these is the fact that the ...

...the seventeenth of these is the fact that the ...

...the eighteenth of these is the fact that the ...



Generic Manufacturers

T30 | LEADING 10 GENERIC MANUFACTURERS AND TOP FIVE PRODUCTS BY ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change
TOTAL ETHICAL GENERIC MARKET						5,666,001	100.0%	4.6%
1	2	2	1	1	APO-ATORVASTATIN : ATX : 05/10	101,345	8.5%	4.0%
2	1	1	2	2	APO-ESOMEPRAZOLE : ATX : 03/11	60,956	5.1%	-31.9%
3	3	3	3	3	APO-ROSUVASTATIN : ATX : 04/12	45,531	3.8%	11.0%
-	5	4	4	4	APO-MOMETASONE : ATX : 03/13	40,834	3.4%	4.7%
4	4	5	5	5	APO-OMEPRAZOLE : ATX : 02/04	35,066	2.9%	3.8%
APOTEX INC Subtotal						1,192,097	21.0%	6.7%
1	3	3	3	1	TEVA-VENLAFAXINE XR : TEV : 12/06	38,767	4.3%	4.6%
2	2	2	2	2	TEVA-FENTANYL : TEV : 08/06	34,060	3.8%	-8.8%
3	1	1	1	3	TEVA-ROSUVASTATIN : TEV : 04/12	28,386	3.2%	-27.8%
5	5	5	5	4	TEVA-CEPHALEXIN : TEV : 02/80	27,821	3.1%	26.0%
4	4	4	4	5	RATIO-OXYCOCET : TEV : 04/84	25,041	2.8%	3.3%
TEVA CANADA LTD Subtotal						900,518	15.9%	-1.2%
1	1	4	1	1	SANDOZ PANTOPRAZOLE : SDZ : 06/08	32,664	4.4%	13.9%
3	4	2	2	2	SANDOZ-RABEPRAZOLE : SDZ : 09/08	29,997	4.1%	4.6%
4	2	1	3	3	SANDOZ-AMLODIPINE : SDZ : 07/09	22,649	3.1%	-17.4%
5	5	5	5	4	SANDOZ-METFORMIN FC : SDZ : 12/97	20,101	2.7%	24.6%
2	3	3	4	5	SANDOZ VALSARTAN : SDZ : 02/11	19,228	2.6%	5.0%
SANDOZ CANADA INC Subtotal						738,692	13.0%	7.8%
-	2	3	3	1	PMS-PREGABALIN : P8I : 02/13	31,853	6.1%	43.9%
1	1	1	1	2	PMS-ZOPICLONE : P8I : 09/99	21,404	4.1%	-23.3%
4	4	2	2	3	PMS-CETIRIZINE : P8I : 12/08	20,832	4.0%	-12.4%
2	3	5	5	4	PMS-VALACYCLOVIR : P8I : 05/08	20,591	3.9%	195.3%
3	5	4	4	5	PMS-HYDROMORPHONE : P8I : 07/91	16,530	3.2%	2.2%
PHARMASCIENCE Subtotal						522,356	9.2%	-0.4%
-	4	2	2	1	ROSUVASTATIN : S1H : 09/13	30,448	7.6%	120.6%
1	1	1	1	2	ATORVASTATIN : S1H : 06/10	26,854	6.7%	2.7%
-	5	5	4	3	PREGABALIN : S1H : 09/13	21,346	5.4%	100.2%
3	3	3	3	4	ZOPICLONE : S1H : 08/10	18,009	4.5%	55.5%
2	2	4	5	5	AMLODIPINE : S1H : 02/11	16,485	4.1%	77.0%
SANIS HEALTH INC Subtotal						398,480	7.0%	27.2%

T30 | LEADING 10 GENERIC MANUFACTURERS AND TOP FIVE PRODUCTS BY ETHICAL PURCHASES

Rank 2012	Rank 2013	Rank 2014	Rank 2015	Rank 2016		Ethical Purchases (\$000s)	% Share of Market	% Change
-	3	2	2	1	MYLAN-BUPROPION XL : MYN : 10/13	38,101	13.5%	4.5%
1	1	1	1	2	MYLAN-NIFEDIPINE : MYN : 01/09	33,271	11.8%	-16.3%
2	2	3	3	3	GEN-CLOZAPINE : MYN : 03/03	22,366	7.9%	-0.2%
-	4	4	4	4	MYLAN-NITRO PATCH : MYN : 11/13	12,926	4.6%	1.3%
-	-	-	5	5	MYLAN-PANTOPRAZOLE T : MYN : 10/15	12,454	4.4%	332.4%
MYLAN PHARMA Subtotal						282,226	5.0%	1.3%
2	2	1	1	1	ACT LEVETIRACETAM : AAV : 05/06	18,314	8.1%	-3.8%
1	1	2	2	2	ACT ATORVASTATIN : AAV : 05/10	15,243	6.8%	-4.9%
-	-	-	5	3	ACT AMPHETAMINE XR : AAV : 10/15	14,580	6.5%	451.9%
4	4	3	3	4	ACT AMLODIPINE : AAV : 07/09	13,967	6.2%	14.7%
3	3	4	4	5	ACT SERTRALINE : AAV : 02/07	9,229	4.1%	-18.3%
ACTAVIS PHARMA Subtotal						225,577	4.0%	-3.7%
1	1	1	1	1	ATORVASTATIN : PDO : 08/10	17,223	8.3%	-6.9%
2	2	2	2	2	PANTOPRAZOLE : PDO : 05/09	11,057	5.4%	-6.3%
-	5	5	4	3	PREGABALIN : PDO : 03/13	8,999	4.4%	8.4%
4	4	4	5	4	ROSUVASTATIN : PDO : 07/12	8,996	4.4%	13.4%
3	3	3	3	5	AMLODIPINE : PDO : 09/09	8,538	4.1%	2.1%
PRO DOC Subtotal						206,664	3.6%	0.0%
2	1	1	1	1	ATORVASTATIN : SVM : 12/12	9,261	5.3%	-40.7%
-	3	2	3	2	PREGABALIN : SVM : 07/13	8,853	5.1%	-16.8%
-	-	5	2	3	PANTOPRAZOLE-40 : SVM : 11/14	8,035	4.6%	-34.5%
1	2	3	4	4	AMLODIPINE : SVM : 10/12	7,467	4.3%	-16.8%
3	4	4	5	5	VENLAFAXINE XR : SVM : 12/12	5,914	3.4%	-12.8%
SIVEM PHARMA ULC Subtotal						174,435	3.1%	-9.1%
1	1	1	1	1	IBUPROFEN : PRL : 01/95	18,394	13.9%	-5.4%
2	2	2	2	2	ACETAMINOPHEN : PRL : 04/82	11,168	8.4%	-1.8%
4	4	3	3	3	NICOTINE : PRL : 11/02	11,140	8.4%	5.4%
3	3	4	4	4	ALLERGY RELIEF : PRL : 07/90	4,956	3.7%	-15.8%
5	5	5	5	5	VIT D : PRL : 01/96	4,439	3.4%	-4.2%
PRIVATE LABEL Subtotal						132,434	2.3%	-5.7%

T31 | LEADING 10 BRAND AND GENERIC DRUG MANUFACTURERS AND TOP FIVE PROVINCES BY TOTAL ETHICAL PRESCRIPTIONS

	# of Rx (000s)	% Share of Market
TOTAL ETHICAL PRESCRIPTIONS	649,746	100.0%
QUEBEC	10,783	52.1%
ONTARIO	4,704	22.7%
BRITISH COLUMBIA	1,773	8.6%
ALBERTA	1,533	7.4%
MANITOBA	513	2.5%
BGP PHARMA ULC Subtotal	20,691	10.6%
QUEBEC	6,200	45.1%
ONTARIO	3,992	29.1%
BRITISH COLUMBIA	1,255	9.1%
ALBERTA	1,049	7.6%
SASKATCHEWAN	317	2.3%
PFIZER Subtotal	13,735	7.1%
QUEBEC	4,964	45.8%
ONTARIO	3,790	35.0%
ALBERTA	692	6.4%
BRITISH COLUMBIA	596	5.5%
SASKATCHEWAN	247	2.3%
MERCK CANADA INC Subtotal	10,830	5.6%
ONTARIO	4,149	39.7%
QUEBEC	3,721	35.6%
BRITISH COLUMBIA	895	8.6%
ALBERTA	766	7.3%
SASKATCHEWAN	264	2.5%
ASTRAZENECA Subtotal	10,460	5.4%
ONTARIO	3,168	35.8%
QUEBEC	2,812	31.8%
ALBERTA	875	9.9%
BRITISH COLUMBIA	822	9.3%
MANITOBA	263	3.0%
GLAXOSMITHKLINE Subtotal	8,840	4.5%

T31 | LEADING 10 BRAND AND GENERIC DRUG MANUFACTURERS AND TOP FIVE PROVINCES BY TOTAL ETHICAL PRESCRIPTIONS

	# of Rx (000s)	% Share of Market
QUEBEC	3,337	38.6%
ONTARIO	3,125	36.1%
ALBERTA	621	7.2%
BRITISH COLUMBIA	461	5.3%
SASKATCHEWAN	352	4.1%
SERVIER LAB. Subtotal	8,649	4.4%
ONTARIO	3,854	45.8%
BRITISH COLUMBIA	2,350	27.9%
PEI AND NFLD	848	10.1%
NEW BRUNSWICK	688	8.2%
ALBERTA	409	4.9%
MALLINCKRODT Subtotal	8,418	4.3%
QUEBEC	2,768	35.8%
ONTARIO	2,001	25.8%
ALBERTA	933	12.0%
BRITISH COLUMBIA	907	11.7%
MANITOBA	377	4.9%
JANSSEN PHARMA Subtotal	7,741	4.0%
ONTARIO	3,049	47.7%
QUEBEC	1,752	27.4%
ALBERTA	496	7.8%
BRITISH COLUMBIA	424	6.6%
SASKATCHEWAN	154	2.4%
PURDUE PHARMA Subtotal	6,394	3.3%
QUEBEC	2,697	46.0%
ONTARIO	1,793	30.6%
BRITISH COLUMBIA	471	8.0%
ALBERTA	373	6.4%
MANITOBA	150	2.6%
PENDOPHARM Subtotal	5,859	3.0%
BRAND Subtotal	194,504	29.9%

T31 | LEADING 10 BRAND AND GENERIC DRUG MANUFACTURERS AND TOP FIVE PROVINCES BY TOTAL ETHICAL PRESCRIPTIONS

	# of Rx (000s)	% Share of Market
ONTARIO	38,894	43.3%
QUEBEC	22,617	25.2%
ALBERTA	7,826	8.7%
BRITISH COLUMBIA	7,710	8.6%
MANITOBA	3,849	4.3%
APOTEX INC Subtotal	89,878	19.8%
ONTARIO	33,596	44.6%
QUEBEC	22,779	30.2%
BRITISH COLUMBIA	5,283	7.0%
ALBERTA	4,712	6.3%
MANITOBA	2,092	2.8%
TEVA CANADA LTD Subtotal	75,373	16.6%
QUEBEC	22,966	45.7%
ONTARIO	13,512	26.9%
BRITISH COLUMBIA	4,504	9.0%
ALBERTA	3,224	6.4%
SASKATCHEWAN	1,645	3.3%
PHARMASCIENCE Subtotal	50,225	11.0%
ONTARIO	19,109	42.1%
QUEBEC	15,693	34.6%
BRITISH COLUMBIA	3,211	7.1%
ALBERTA	2,878	6.3%
SASKATCHEWAN	1,370	3.0%
SANDOZ CANADA INC Subtotal	45,363	10.0%
QUEBEC	36,466	100.0%
ALBERTA	0	0.0%
ONTARIO	0	0.0%
PEI AND NFLD	0	0.0%
NEW BRUNSWICK	0	0.0%
PRO DOC Subtotal	36,467	8.0%

T31 | LEADING 10 BRAND AND GENERIC DRUG MANUFACTURERS AND TOP FIVE PROVINCES BY TOTAL ETHICAL PRESCRIPTIONS

	# of Rx (000s)	% Share of Market
QUEBEC	10,302	34.8%
BRITISH COLUMBIA	5,061	17.1%
ALBERTA	4,244	14.4%
ONTARIO	3,556	12.0%
SASKATCHEWAN	1,534	5.2%
SANIS HEALTH INC Subtotal	29,572	6.5%
QUEBEC	13,629	72.6%
ALBERTA	1,690	9.0%
BRITISH COLUMBIA	1,308	7.0%
MANITOBA	614	3.3%
NEW BRUNSWICK	519	2.8%
SIVEM PHARMA ULC Subtotal	18,781	4.1%
QUEBEC	16,004	86.6%
ONTARIO	1,271	6.9%
BRITISH COLUMBIA	564	3.1%
ALBERTA	270	1.5%
SASKATCHEWAN	133	0.7%
JAMP PHARMA Subtotal	18,481	4.1%
ONTARIO	6,683	46.4%
QUEBEC	3,415	23.7%
BRITISH COLUMBIA	1,503	10.4%
ALBERTA	1,273	8.8%
MANITOBA	388	2.7%
MYLAN PHARMA Subtotal	14,402	3.2%
ONTARIO	5,947	47.9%
QUEBEC	2,879	23.2%
BRITISH COLUMBIA	1,331	10.7%
ALBERTA	981	7.9%
MANITOBA	429	3.5%
ACTAVIS PHARMA Subtotal	12,426	2.7%
GENERIC Subtotal	454,968	70.0%

T32 | SHARE OF PRESCRIPTION MARKET BY PROVINCE, BRAND VS. GENERIC MANUFACTURERS

	# of Rx (000s)	% Share of Market	Average Rx Size (# of Extended Units)	Average Rx Price (\$)
TOTAL ETHICAL PRESCRIPTIONS	649,746	100.0%	48.1	43.30
Generic Manufacturers	197,963	72.3%	28.4	15.04
Brand Manufacturers	75,825	27.7%	41.7	67.65
QUEBEC Subtotal	273,917	42.2%	32.1	29.63
Generic Manufacturers	140,653	68.4%	54.2	22.90
Brand Manufacturers	64,958	31.6%	63.0	117.99
ONTARIO Subtotal	205,721	31.7%	57.0	52.97
Generic Manufacturers	36,370	66.9%	60.0	26.25
Brand Manufacturers	17,981	33.1%	56.0	100.28
BRITISH COLUMBIA Subtotal	54,361	8.4%	58.7	50.75
Generic Manufacturers	30,815	67.4%	64.5	29.45
Brand Manufacturers	14,903	32.6%	71.8	119.71
ALBERTA Subtotal	45,726	7.0%	66.9	58.88
Generic Manufacturers	12,454	73.2%	59.2	26.18
Brand Manufacturers	4,549	26.7%	60.0	110.12
MANITOBA Subtotal	17,005	2.6%	59.4	48.64
Generic Manufacturers	11,402	70.9%	54.1	25.92
Brand Manufacturers	4,682	29.1%	57.3	102.36
SASKATCHEWAN Subtotal	16,089	2.5%	55.1	48.19
Generic Manufacturers	8,962	69.2%	75.0	31.63
Brand Manufacturers	3,982	30.8%	74.9	126.72
NOVA SCOTIA Subtotal	12,946	2.0%	75.0	60.89
Generic Manufacturers	8,691	69.0%	68.7	28.04
Brand Manufacturers	3,904	31.0%	63.5	119.24
NEW BRUNSWICK Subtotal	12,598	1.9%	67.1	56.32
Generic Manufacturers	7,659	67.3%	70.7	28.79
Brand Manufacturers	3,720	32.7%	61.0	94.03
PEI AND NFLD Subtotal	11,382	1.8%	67.5	50.13

T33 | TOTAL ETHICAL PURCHASES FOR THE FIVE LEADING BRAND AND GENERIC MANUFACTURERS BY PROVINCE

	Ethical Purchases (\$'000s)	% Share of Market 2012	% Share of Market 2013	% Share of Market 2014	% Share of Market 2015	% Share of Market 2016
TOTAL ETHICAL MARKET	25,713,985	100.0%	100.0%	100.0%	100.0%	100.0%
Brand Manufacturers	20,047,974	75.7%	76.7%	77.6%	78.3%	78.0%
JANSSEN PHARMA	854,439	7.6%	8.5%	9.3%	9.5%	10.5%
MERCK CANADA INC	577,109	7.3%	7.8%	7.0%	6.0%	7.1%
NOVARTIS PHARMA	539,449	5.9%	6.8%	7.4%	7.0%	6.6%
ASTRAZENECA	398,923	6.9%	4.9%	4.8%	4.8%	4.9%
PFIZER	353,301	8.6%	7.9%	5.9%	4.6%	4.3%
ONTARIO Subtotal	8,152,791	38.4%	39.6%	40.0%	39.9%	40.7%
JANSSEN PHARMA	619,111	8.0%	9.7%	10.8%	11.1%	12.3%
NOVARTIS PHARMA	348,760	5.4%	6.3%	6.4%	6.7%	6.9%
MERCK CANADA INC	278,275	6.4%	6.6%	6.2%	5.3%	5.5%
ROCHE	233,857	4.4%	4.8%	4.7%	4.6%	4.7%
ASTRAZENECA	228,768	9.9%	5.6%	4.8%	4.6%	4.6%
QUEBEC Subtotal	5,023,286	28.6%	26.6%	26.3%	25.3%	25.1%
JANSSEN PHARMA	275,753	8.7%	9.9%	10.6%	10.8%	12.1%
GILEAD SCIENCES	184,175	1.7%	1.9%	2.9%	10.3%	8.1%
ABBVIE	116,532	3.4%	3.7%	3.8%	4.0%	5.1%
ROCHE	115,289	5.4%	5.5%	5.6%	5.0%	5.0%
ASTRAZENECA	109,176	6.6%	4.9%	4.7%	4.4%	4.8%
BRITISH COLUMBIA Subtotal	2,285,873	11.0%	11.2%	11.0%	11.5%	11.4%
JANSSEN PHARMA	267,568	8.6%	9.8%	9.9%	10.5%	13.1%
NOVARTIS PHARMA	100,208	5.3%	6.0%	6.8%	6.6%	4.9%
GILEAD SCIENCES	100,051	0.7%	0.9%	2.3%	6.3%	4.9%
ABBVIE	97,516	3.4%	3.3%	3.5%	4.1%	4.8%
ASTRAZENECA	92,054	5.7%	4.2%	4.2%	4.2%	4.5%
ALBERTA Subtotal	2,047,087	9.7%	10.1%	10.3%	10.5%	10.2%
JANSSEN PHARMA	93,768	10.3%	12.5%	13.6%	14.7%	16.5%
ROCHE	31,485	6.0%	6.1%	6.1%	5.8%	5.5%
ABBVIE	29,573	3.8%	4.3%	4.6%	4.6%	5.2%
GILEAD SCIENCES	28,988	0.9%	1.0%	1.4%	6.0%	5.1%
PFIZER	26,774	8.1%	7.8%	6.3%	4.8%	4.7%
MANITOBA Subtotal	568,744	2.8%	2.7%	2.7%	2.8%	2.8%

T33 | TOTAL ETHICAL PURCHASES FOR THE FIVE LEADING BRAND AND GENERIC MANUFACTURERS BY PROVINCE

	Ethical Purchases (\$000s)	% Share of Market 2012	% Share of Market 2013	% Share of Market 2014	% Share of Market 2015	% Share of Market 2016
JANSSEN PHARMA	74,692	9.4%	10.3%	11.8%	12.5%	13.3%
ABBVIE	35,242	4.7%	5.1%	5.5%	5.4%	6.3%
ASTRAZENECA	29,636	7.2%	5.3%	5.2%	5.0%	5.3%
NOVARTIS PHARMA	27,956	3.3%	3.8%	4.1%	4.6%	5.0%
AMGEN	25,225	5.1%	5.2%	5.2%	4.6%	4.5%
NOVA SCOTIA Subtotal	562,902	2.8%	2.8%	2.8%	2.9%	2.8%
JANSSEN PHARMA	81,687	10.1%	11.4%	12.5%	13.5%	15.0%
GILEAD SCIENCES	36,240	0.5%	0.9%	1.6%	4.8%	6.7%
ABBVIE	28,914	4.5%	4.8%	4.6%	4.7%	5.3%
ROCHE	27,584	5.4%	5.2%	5.6%	5.3%	5.1%
GLAXOSMITHKLINE	23,843	5.0%	5.0%	4.9%	5.1%	4.4%
SASKATCHEWAN Subtotal	544,002	2.6%	2.7%	2.7%	2.7%	2.7%
JANSSEN PHARMA	78,240	8.2%	10.8%	12.4%	13.9%	16.1%
ABBVIE	28,647	3.7%	4.1%	4.5%	5.1%	5.9%
AMGEN	28,603	6.8%	6.9%	6.8%	6.0%	5.9%
NOVARTIS PHARMA	27,014	4.2%	4.5%	4.5%	5.0%	5.6%
ROCHE	23,991	5.4%	5.3%	5.4%	4.9%	4.9%
NEW BRUNSWICK Subtotal	484,781	2.3%	2.3%	2.3%	2.4%	2.4%
JANSSEN PHARMA	54,187	10.0%	11.1%	12.3%	13.1%	14.3%
ABBVIE	25,603	4.5%	4.9%	5.6%	6.1%	6.8%
ROCHE	23,032	6.0%	6.5%	6.1%	5.6%	6.1%
AMGEN	17,075	4.2%	4.6%	4.7%	4.7%	4.5%
GLAXOSMITHKLINE	16,139	4.5%	4.5%	4.5%	4.7%	4.3%
PEI AND NFLD Subtotal	378,508	1.9%	1.9%	1.8%	1.9%	1.9%

T33 | TOTAL ETHICAL PURCHASES FOR THE FIVE LEADING BRAND AND GENERIC MANUFACTURERS BY PROVINCE

	Ethical Purchases (\$'000s)	% Share of Market 2012	% Share of Market 2013	% Share of Market 2014	% Share of Market 2015	% Share of Market 2016
Generic Manufacturers	5,666,001	24.3%	23.3%	22.4%	21.7%	22.0%
APOTEX INC	559,862	30.7%	29.9%	28.6%	26.6%	26.6%
TEVA CANADA LTD	399,294	21.7%	22.5%	21.8%	21.3%	19.0%
SANDOZ CANADA INC	331,312	10.8%	12.3%	13.9%	15.7%	15.7%
PHARMASCIENCE	176,571	8.4%	9.1%	8.9%	8.6%	8.4%
MYLAN PHARMA	121,594	8.2%	5.7%	5.6%	5.7%	5.8%
ONTARIO Subtotal	2,106,534	34.6%	35.9%	37.0%	37.2%	37.2%
PRO DOC	206,660	14.1%	14.2%	15.3%	15.4%	14.6%
TEVA CANADA LTD	174,953	18.5%	14.3%	13.1%	11.3%	12.3%
APOTEX INC	173,151	15.5%	13.7%	11.4%	10.8%	12.2%
SANDOZ CANADA INC	149,881	11.2%	9.8%	10.3%	10.2%	10.6%
PHARMASCIENCE	148,261	12.0%	10.9%	10.1%	10.4%	10.5%
QUEBEC Subtotal	1,418,323	21.2%	25.1%	24.8%	24.8%	25.0%
APOTEX INC	129,353	19.6%	20.7%	21.2%	19.4%	19.8%
TEVA CANADA LTD	88,473	15.7%	15.1%	13.4%	13.5%	13.6%
SANDOZ CANADA INC	84,052	12.5%	12.9%	12.7%	12.3%	12.9%
SANIS HEALTH INC	72,720	10.4%	9.4%	9.7%	11.0%	11.2%
PHARMASCIENCE	66,516	11.5%	11.7%	12.0%	11.7%	10.2%
BRITISH COLUMBIA Subtotal	652,093	12.9%	11.7%	11.5%	11.6%	11.5%
APOTEX INC	127,045	24.6%	25.1%	23.5%	21.3%	21.1%
TEVA CANADA LTD	84,158	16.2%	16.2%	14.8%	14.8%	14.0%
SANIS HEALTH INC	79,219	11.6%	10.2%	10.6%	13.4%	13.2%
SANDOZ CANADA INC	72,042	11.4%	11.1%	10.6%	11.1%	12.0%
PHARMASCIENCE	50,422	8.9%	9.4%	8.6%	8.7%	8.4%
ALBERTA Subtotal	601,378	12.8%	10.3%	10.3%	10.4%	10.6%
APOTEX INC	56,170	23.9%	27.3%	28.0%	26.4%	26.0%
TEVA CANADA LTD	34,016	22.4%	21.4%	18.9%	18.7%	15.7%
SANDOZ CANADA INC	25,702	9.9%	9.7%	10.0%	10.4%	11.9%
SANIS HEALTH INC	21,519	0.1%	1.3%	6.5%	9.4%	10.0%
PHARMASCIENCE	16,319	7.1%	8.7%	8.4%	8.4%	7.5%
MANITOBA Subtotal	216,239	4.4%	4.3%	4.1%	3.9%	3.8%

T33 | TOTAL ETHICAL PURCHASES FOR THE FIVE LEADING BRAND AND GENERIC MANUFACTURERS BY PROVINCE

	Ethical Purchases (\$000s)	% Share of Market 2012	% Share of Market 2013	% Share of Market 2014	% Share of Market 2015	% Share of Market 2016
APOTEX INC	40,379	19.5%	19.4%	21.2%	20.1%	20.8%
TEVA CANADA LTD	37,398	22.3%	22.6%	18.4%	19.5%	19.3%
SANDOZ CANADA INC	22,602	10.0%	9.7%	9.7%	10.7%	11.7%
SANIS HEALTH INC	21,374	10.3%	8.5%	9.3%	10.9%	11.0%
PHARMASCIENCE	18,524	11.3%	12.9%	12.3%	10.6%	9.6%
NOVA SCOTIA Subtotal	193,909	4.0%	4.0%	3.8%	3.5%	3.4%
APOTEX INC	38,740	16.3%	16.2%	20.8%	20.6%	22.1%
TEVA CANADA LTD	31,004	21.9%	22.3%	18.7%	20.4%	17.7%
SANDOZ CANADA INC	23,263	12.2%	12.7%	12.4%	12.8%	13.3%
PHARMASCIENCE	20,254	13.6%	15.3%	14.3%	12.5%	11.5%
SANIS HEALTH INC	17,436	9.3%	9.2%	9.4%	10.4%	9.9%
SASKATCHEWAN Subtotal	175,534	3.2%	3.2%	3.2%	3.1%	3.1%
APOTEX INC	33,628	24.1%	25.1%	22.4%	21.5%	21.3%
SANIS HEALTH INC	24,028	12.5%	11.4%	12.4%	14.8%	15.2%
TEVA CANADA LTD	22,492	19.5%	18.4%	16.5%	14.3%	14.3%
SANDOZ CANADA INC	13,510	8.9%	8.8%	8.7%	8.5%	8.6%
PHARMASCIENCE	13,426	12.0%	12.2%	10.4%	9.6%	8.5%
NEW BRUNSWICK Subtotal	157,590	3.7%	2.9%	2.8%	2.8%	2.8%
APOTEX INC	33,769	21.3%	24.2%	23.5%	23.2%	23.4%
TEVA CANADA LTD	28,729	21.7%	21.7%	20.7%	20.8%	19.9%
SANIS HEALTH INC	16,695	9.0%	9.2%	10.0%	11.1%	11.6%
SANDOZ CANADA INC	16,328	9.8%	8.9%	9.5%	10.5%	11.3%
PHARMASCIENCE	12,063	12.5%	12.2%	10.5%	10.1%	8.4%
PEI AND NFLD Subtotal	144,401	3.1%	2.6%	2.5%	2.6%	2.5%

T34 | TOP 25 GENERIC MOLECULES AND TOP FIVE PRODUCTS BY TOTAL ETHICAL PURCHASES

	Ethical Purchases (\$000s)	% Share of Market	% Change
TOTAL ETHICAL MARKET	25,713,985	100.0%	3.2%
APO-ATORVASTATIN : ATX : 05/10	101,345	47.0%	4.0%
ATORVASTATIN : S1H : 06/10	26,854	12.5%	2.7%
ATORVASTATIN : PDO : 08/10	17,223	8.0%	-6.9%
RATIO-ATORVASTATIN : TEV : 05/10	15,362	7.1%	44.3%
ACT ATORVASTATIN : AAV : 05/10	15,243	7.1%	-4.9%
1 ATORVASTATIN Subtotal	215,570	3.8%	1.5%
SANDOZ PANTOPRAZOLE : SDZ : 06/08	32,664	19.7%	13.9%
APO-PANTOPRAZOLE : ATX : 03/08	17,923	10.8%	8.9%
TEVA-PANTOPRAZOLE MAGNES : TEV : 11/15	14,067	8.5%	>999.9%
TEVA-PANTOPRAZOLE : TEV : 04/08	13,887	8.4%	-0.6%
MYLAN-PANTOPRAZOLE T : MYN : 10/15	12,454	7.5%	332.4%
2 PANTOPRAZOLE Subtotal	165,451	2.9%	29.1%
APO-ROSUVASTATIN : ATX : 04/12	45,531	28.9%	11.0%
ROSUVASTATIN : S1H : 09/13	30,448	19.3%	120.6%
TEVA-ROSUVASTATIN : TEV : 04/12	28,386	18.0%	-27.8%
SANDOZ-ROSUVASTATIN : SDZ : 04/12	11,589	7.3%	43.8%
ROSUVASTATIN : PDO : 07/12	8,996	5.7%	13.4%
3 ROSUVASTATIN Subtotal	157,757	2.8%	8.5%
SANDOZ-AMLODIPINE : SDZ : 07/09	22,649	19.8%	-17.4%
APO-AMLODIPINE : ATX : 07/09	21,900	19.1%	5.1%
AMLODIPINE : S1H : 02/11	16,485	14.4%	77.0%
ACT AMLODIPINE : AAV : 07/09	13,967	12.2%	14.7%
PMS-AMLODIPINE : P8I : 07/09	8,820	7.7%	16.0%
4 AMLODIPINE Subtotal	114,595	2.0%	6.0%
PMS-PREGABALIN : P8I : 02/13	31,853	28.5%	43.9%
PREGABALIN : S1H : 09/13	21,346	19.1%	100.2%
TEVA-PREGABALIN : TEV : 02/13	18,990	17.0%	-6.9%
PREGABALIN : PDO : 03/13	8,999	8.1%	8.4%
PREGABALIN : SVM : 07/13	8,853	7.9%	-16.8%
5 PREGABALIN Subtotal	111,710	2.0%	15.9%

T34 | TOP 25 GENERIC MOLECULES AND TOP FIVE PRODUCTS BY TOTAL ETHICAL PURCHASES

	Ethical Purchases (\$000s)	% Share of Market	% Change
APO-ESOMEPRAZOLE : ATX : 03/11	60,956	66.1%	-31.9%
MYLAN-ESOMEPRAZOLE : MYN : 08/12	12,025	13.0%	22.3%
ESOMEPRAZOLE : S1H : 12/14	6,974	7.6%	-23.9%
ESOMEPRAZOLE : SVM : 11/15	4,226	4.6%	662.6%
ESOMEPRAZOLE : PDO : 10/13	4,224	4.6%	-45.0%
6 ESOMEPRAZOLE Subtotal	92,203	1.6%	-21.5%
TEVA-VENLAFAXINE XR : TEV : 12/06	38,767	50.0%	4.6%
VENLAFAXINE XR : S1H : 11/10	12,664	16.3%	25.9%
VENLAFAXINE XR : SVM : 12/12	5,914	7.6%	-12.8%
ACT VENLAFAXINE XR : AAV : 04/08	5,613	7.2%	-7.6%
SANDOZ-VENLAFAXINE XR : SDZ : 07/08	4,325	5.6%	12.9%
7 VENLAFAXINE Subtotal	77,511	1.4%	5.3%
TEVA-ESCITALOPRAM : TEV : 09/14	18,873	26.4%	-11.6%
APO-ESCITALOPRAM : ATX : 09/14	16,770	23.4%	23.4%
ESCITALOPRAM : S1H : 12/14	11,559	16.2%	121.3%
RAN-ESCITALOPRAM : RBY : 09/14	4,908	6.9%	-32.6%
CO ESCITALOPRAM : CBT : 09/14	3,561	5.0%	15.9%
8 ESCITALOPRAM Subtotal	71,554	1.3%	15.8%
APO-GABAPENTIN : ATX : 11/01	19,548	29.0%	-8.9%
PMS-GABAPENTIN : P8I : 02/01	14,952	22.2%	-0.6%
GABAPENTIN : S1H : 11/10	10,339	15.3%	21.7%
TEVA-GABAPENTIN : TEV : 06/02	9,458	14.0%	-10.7%
GABAPENTIN : SVM : 10/12	5,795	8.6%	5.7%
9 GABAPENTIN Subtotal	67,503	1.2%	-3.0%
PMS-ZOPICLONE : P8I : 09/99	21,404	31.8%	-23.3%
ZOPICLONE : S1H : 08/10	18,009	26.8%	55.5%
APO-ZOPICLONE : ATX : 11/96	6,179	9.2%	-32.6%
ACT ZOPICLONE : AAV : 01/06	4,027	6.0%	-5.5%
ZOPICLONE : SVM : 10/12	3,902	5.8%	-17.8%
10 ZOPICLONE Subtotal	67,294	1.2%	-9.7%

T34 | TOP 25 GENERIC MOLECULES AND TOP FIVE PRODUCTS BY TOTAL ETHICAL PURCHASES

	Ethical Purchases (\$000s)	% Share of Market	% Change
TEVA-QUETIAPINE XR : TEV : 03/13	16,574	24.8%	-3.7%
PMS-QUETIAPINE : P8I : 09/08	7,765	11.6%	-15.1%
ACT QUETIAPINE : AAV : 09/08	7,253	10.9%	1.2%
SANDOZ QUETIAPINE XRT : SDZ : 08/13	7,227	10.8%	18.4%
TEVA-QUETIAPINE : TEV : 09/08	5,221	7.8%	-5.0%
11 QUETIAPINE Subtotal	66,836	1.2%	-9.1%
RAMIPRIL : S1H : 01/12	14,210	21.5%	104.2%
APO-RAMIPRIL : ATX : 01/07	13,116	19.9%	-4.8%
PMS-RAMIPRIL : P8I : 04/08	10,498	15.9%	-3.9%
TEVA-RAMIPRIL : TEV : 05/07	7,499	11.3%	30.5%
ACT RAMIPRIL : AAV : 12/07	5,411	8.2%	-61.7%
12 RAMIPRIL Subtotal	66,075	1.2%	-1.5%
TEVA-FENTANYL : TEV : 08/06	34,060	55.0%	-8.8%
FENTANYL CITRATE : SDZ : 03/00	9,023	14.6%	19.7%
SANDOZ-FENTANYL MTX : SDZ : 10/09	8,830	14.3%	-8.5%
MYLAN-FENTANYL MATRIX : MYN : 02/13	5,049	8.2%	9.4%
RAN-FENTANYL MATRIX : RBY : 01/10	2,429	3.9%	-28.4%
13 FENTANYL Subtotal	61,936	1.1%	-6.1%
SANDOZ-METFORMIN FC : SDZ : 12/97	20,101	34.2%	24.6%
RATIO-METFORMIN : TEV : 06/01	7,630	13.0%	4.2%
ACT METFORMIN : AAV : 11/04	6,619	11.3%	-10.0%
APO-METFORMIN : ATX : 09/95	5,490	9.4%	-2.5%
PMS-METFORMIN : P8I : 02/97	4,100	7.0%	4.9%
14 METFORMIN Subtotal	58,708	1.0%	-2.9%
APO-MOMETASONE : ATX : 03/13	40,834	75.5%	4.7%
TARO-MOMETASONE : TAR : 08/05	10,846	20.1%	-2.3%
RATIO-MOMETASONE : TEV : 02/04	1,940	3.6%	11.1%
SANDOZ MOMETASONE : SDZ : 08/16	450	0.8%	-
15 MOMETASONE Subtotal	54,071	1.0%	4.3%

* Please note that this table reports on Combined Molecules.

T34 | TOP 25 GENERIC MOLECULES AND TOP FIVE PRODUCTS BY TOTAL ETHICAL PURCHASES

	Ethical Purchases (\$000s)	% Share of Market	% Change
APO-SERTRALINE : ATX : 09/99	10,388	19.4%	7.7%
ACT SERTRALINE : AAV : 02/07	9,229	17.3%	-18.3%
TEVA-SERTRALINE : TEV : 08/99	9,182	17.2%	96.4%
SERTRALINE : S1H : 11/10	8,432	15.8%	32.4%
PMS-SERTRALINE : P8I : 08/02	7,261	13.6%	11.4%
16 SERTRALINE Subtotal	53,492	0.9%	14.9%
APO-AMOXI : ATX : 08/84	18,293	34.2%	-3.8%
TEVA-AMOXICILLIN : TEV : 01/79	17,889	33.5%	4.0%
AMOXICILLIN : S1H : 09/10	7,372	13.8%	5.7%
PRO-AMOX : PDO : 11/85	3,382	6.3%	10.5%
AMOXICILLIN : SVM : 06/13	2,765	5.2%	2.8%
17 AMOXICILLIN Subtotal	53,465	0.9%	3.9%
APO-OMEPRAZOLE : ATX : 02/04	35,066	67.5%	3.8%
TEVA-OMEPRAZOLE : TEV : 07/13	2,912	5.6%	-22.1%
OMEPRAZOLE MAGNESIUM DR : A6D : 09/14	2,599	5.0%	3.3%
PMS-OMEPRAZOLE : P8I : 05/09	2,570	4.9%	-28.4%
OMEPRAZOLE-20 : SVM : 01/14	2,412	4.6%	37.5%
18 OMEPRAZOLE Subtotal	51,934	0.9%	-2.8%
TEVA-OLANZAPINE : TEV : 06/07	10,641	21.2%	-27.8%
OLANZAPINE : S1H : 12/11	8,066	16.1%	58.7%
APO-OLANZAPINE : ATX : 10/09	6,708	13.4%	-11.7%
OLANZAPINE : SVM : 10/12	3,422	6.8%	-17.8%
CO OLANZAPINE ODT : CBT : 12/09	3,137	6.3%	-13.6%
19 OLANZAPINE Subtotal	50,188	0.9%	-10.5%
PMS-HYDROMORPHONE : P8I : 07/91	16,530	35.3%	2.2%
HYDROMORPHONE HCL : SDZ : 06/95	14,540	31.0%	44.6%
HYDROMORPHONE HP 10 : SDZ : 06/95	4,452	9.5%	19.0%
APO-HYDROMORPHONE : ATX : 12/12	4,061	8.7%	22.4%
HYDROMORPHONE HP 50 : SDZ : 07/95	3,706	7.9%	-3.9%
20 HYDROMORPHONE Subtotal	46,865	0.8%	11.3%

T34 | TOP 25 GENERIC MOLECULES AND TOP FIVE PRODUCTS BY TOTAL ETHICAL PURCHASES

	Ethical Purchases (\$000s)	% Share of Market	% Change
CITALOPRAM : S1H : 11/10	10,329	22.5%	87.2%
PMS-CITALOPRAM : P8I : 01/04	9,322	20.3%	13.8%
APO-CITALOPRAM : ATX : 01/04	4,772	10.4%	-7.3%
TEVA-CITALOPRAM : TEV : 08/04	4,547	9.9%	18.8%
CITALOPRAM : SVM : 10/12	3,703	8.1%	-12.5%
21 CITALOPRAM Subtotal	45,840	0.8%	1.5%
MYLAN-BUPROPION XL : MYN : 10/13	38,101	83.1%	4.5%
SANDOZ-BUPROPION SR : SDZ : 06/06	5,377	11.7%	5.4%
BUPROPION SR : S1H : 01/13	1,131	2.5%	16.6%
ACT BUPROPION XL : AAV : 07/16	653	1.4%	-
BUPROPION SR : PDO : 06/10	258	0.6%	-16.1%
22 BUPROPION Subtotal	45,825	0.8%	5.2%
SANDOZ-RABEPRAZOLE : SDZ : 09/08	29,997	66.0%	4.6%
RABEPRAZOLE EC : S1H : 03/11	4,682	10.3%	1.3%
TEVA-RABEPRAZOLE : TEV : 11/07	2,884	6.3%	-24.1%
RABEPRAZOLE : SVM : 12/12	2,344	5.2%	14.5%
RAN-RABEPRAZOLE : RBY : 12/07	2,278	5.0%	-18.1%
23 RABEPRAZOLE SODIUM Subtotal	45,441	0.8%	-1.1%
PMS-VALACYCLOVIR : P8I : 05/08	20,591	46.0%	195.3%
APO-VALACYCLOVIR : ATX : 06/08	8,281	18.5%	392.5%
MYLAN-VALACYCLOVIR : MYN : 08/10	7,215	16.1%	358.4%
PRO-VALACYCLOVIR : PDO : 05/09	1,973	4.4%	291.7%
VALACYCLOVIR : SVM : 11/15	1,892	4.2%	>999.9%
24 VALACYCLOVIR Subtotal	44,807	0.8%	228.2%
APO-CLOPIDOGREL : ATX : 12/11	22,340	50.3%	-7.2%
PMS-CLOPIDOGREL : P8I : 12/11	5,414	12.2%	13.0%
TEVA-CLOPIDOGREL : TEV : 01/12	4,231	9.5%	-21.1%
CLOPIDOGREL : S1H : 06/13	4,138	9.3%	-9.0%
CLOPIDOGREL : SVM : 10/12	3,139	7.1%	-25.5%
25 CLOPIDOGREL Subtotal	44,408	0.8%	-9.1%
GENERIC MANUFACTURERS	5,666,001	22.0%	4.6%

T35 | 10 FASTEST GROWING BRAND AND GENERIC MANUFACTURERS (LARGER THAN \$10 MILLION) BY TOTAL ETHICAL PURCHASES

	Ethical Purchases (\$000s)	% Share of Market	% Change	4-yr Avg Compound Growth Rate
BRAND MANUFACTURERS	19,783,307	78.1%	2.8%	5%
OTSUKA	46,542	0.2%	170.0%	128%
CELGENE	25,308	0.1%	169.8%	126%
FOREST LAB CANADA	12,823	0.1%	55.2%	-
SUNOVION PHARMA INC	45,366	0.2%	51.0%	30%
BAYER HEALTHCARE	680,423	2.7%	31.8%	20%
GENZYME CORP	161,232	0.6%	25.8%	107%
EISAI	12,489	0.0%	25.6%	103%
STERIMAX INC	41,726	0.2%	24.1%	38%
MALLINCKRODT	25,729	0.1%	22.2%	-
VIIV HEALTHCARE ULC	166,356	0.7%	21.7%	16%
GENERIC MANUFACTURERS	5,556,169	21.9%	4.5%	1%
AURO PHARMA INC	44,279	0.2%	82.5%	104%
GENMED	28,662	0.1%	73.4%	9%
MINT PHARMACEUTICALS	34,569	0.1%	48.5%	11%
JAMP PHARMA	60,681	0.2%	40.0%	33%
MARCAN PHARMA INC	31,053	0.1%	32.4%	129%
ODAN LAB	22,262	0.1%	29.9%	9%
SANIS HEALTH INC	398,480	1.6%	27.2%	9%
RIVA	36,635	0.1%	22.7%	8%
FRESENIUS KABI CDN	21,045	0.1%	16.4%	17%
TARO PHARMACEUTICALS	94,480	0.4%	15.8%	15%



QuintilesIMS Information Services - Canada

The data used to compile the *Canadian Pharmaceutical Industry Review* were drawn from four information services:

CANADIAN DRUGSTORE AND HOSPITAL PURCHASES AUDIT (CDH)

The Canadian Drugstore and Hospital Purchases audit (CDH) estimates the dollar value and unit volume of Canadian pharmaceutical purchases by the major types of outlets within the retail and hospital sectors. Its main focus is on prescription products, although it also tracks many over-the-counter (OTC) and self-diagnostic products as handled by these same types of outlets. However, CDH excludes projection of sales to some of the more specialized types that are less typical and not as conducive to syndicated reporting. Internet pharmacy sales are also excluded from CDH.

Sampling is excellent for this projected audit, covering over one-third of the retail universe and 88% of the hospital universe, which includes government and long-term care categories. Our CDH panel currently consists of over 2,800 drug store sector outlets and 680 hospital sector outlets.

The drugstore sample and universe are stratified by size (small, medium, large) and region (B.C., Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Nova Scotia, New Brunswick and Newfoundland/P.E.I.). The hospital sample and universe are stratified by region and type (general, long-term care, pediatric, psychiatric, cancer centers, government and all other specialties). General hospitals and long-term care centers are further stratified by size (small vs. large).

Note: Data for the 2016 edition of *Canadian Pharmaceutical Industry Review* was drawn from February 2017 Data Month CDH. CDH^{NEXT} enhancements will be introduced for June 2017 Data Month.

CANADIAN COMPUSCRIPT AUDIT (CS)

The Canadian CompuScript audit measures the number of prescriptions dispensed by Canadian retail pharmacies at the provincial level. Product information is presented according to therapeutic class, and for each product the following data elements are collected: manufacturer, form, strength, new and refill prescriptions, prescription size and price (includes mark-up and dispensing fees), transaction location, transaction data month, and authorized repeats.

The CompuScript sample is drawn from a panel of over 6,000 pharmacies, representing more than 62% of all retail pharmacies in Canada. These stores are from both chain and independent pharmacies. Records are collected electronically each month for stores with independent computer systems, or via an external software supplier for stores that are part of a data network system. Sample data collected are then projected to the universe in each province and provincial totals are added together to provide a national estimate.

CANADIAN DISEASE AND THERAPEUTIC INDEX (CDTI)

The Canadian Disease and Therapeutic Index collects treatment data from a sample of Canadian office-based physicians and identifies usage and treatment patterns by drug and by physician specialty. Data for CDTI are collected from a sample of 652 office-based physicians stratified by geographic region and representing all major specialties. Every quarter, each physician submits a case record book, detailing information for all patients (excluding patient identity) seen during a 48-hour reporting period during the quarter. The data are then validated, coded and processed.

CHANNELDYNAMICS

ChannelDynamics is a global offering with consistent methodologies that measures the promotional activity of Canadian pharmaceutical companies across brands, therapeutic areas, promotional channels and physician specialties.

ChannelDynamics – Detailing measures the level of detailing activity directed to office-based physicians for new and established products within the competitive marketplace. It also shows, by specialty, the number of samples left for each product during a detailing visit. The ChannelDynamics – Detailing panel currently consists of 488 reporting office-based physicians, stratified by three regions and 12 specialties.

ChannelDynamics – Journal provides advertising spending information through a monthly audit of over 40 journals of medical publications in Canada, including general practice, specialty, pharmacy and nursing journals.

Manufacturer Abbreviations

A20	Aton Pharma Inc	EM+	EMD Canada Inc	OTS	Otsuka America Pharmaceuticals, Inc
A6D	Accord Healthcare	ERF	ERFA Canada Inc	P8I	Pharmascience
A9N	Actelion Pharma Canada	FER	Ferring	PDN	Paladin
AA1	AA Pharma Inc	FOU	Fournier	PDO	Pro Doc
AAI	Amgen	F/S	Forest Laboratories Canada Inc	PE7	PendoPharm
AAV	Actavis Pharma	G7Y	Graceway Pharmaceuticals	PFZ	Pfizer
ABD	Abbott EPD	GKC	GSK Consumer	PRG	P&G Pharmaceuticals Canada Inc
ABT	Abbott	GLD	Galderma	PUF	Purdue Pharma
ACT	Actavis Specialty	GS-	Gilead Sciences	RBV	Ranbaxy Pharma Canada
AES	Astellas Pharma	GSK	GlaxoSmithKline	R-D	Roche Diagnostics
AHP	Abbott SPD	GTC	Genentech	ROC	Roche
ALC	Alcon Canada	GZY	Genzyme Canada	RVA	Riva
ALL	Allergan	HLT	HLS Therapeutics	S.A	sanofi-aventis Canada
ALM	Almirall	HO&	Hospira Healthcare	S/C	Shire Candada Inc
AO+	Abbott Diabetes Care	IBO	ID Biomedical Corp	S/O	Shire Orphan
AS8	Ascensia Diabetes	ILU	Intercell AG	S1H	Sanis Health Inc
ATV	Actavis Group PTC EHF	IPS	Ipsen Ltd	S8R	Sunovion Pharma Inc
ATX	Apotex Inc	ISY	Imclone Systems Inc	SAX	Salix Pharma Inc
AV1	AbbVie Corporation	JAN	Janssen Inc	SDZ	Sandoz
AZH	Aralez Pharma Inc	JMP	Jamp Pharma	SF2	Sanofi-Pasteur
AZN	AstraZeneca	KGP	King Pharma	STF	Stiefel, a GSK company
B.I	Boehringer Ingelheim Ltd	L&B	Labopharm Inc	SVM	Sivem Pharma ULC
B5L	Biovail Pharma	LEO	Leo Pharma Inc	SVR	Servier Laboratories
BAY	Bayer Healthcare	LFS	LifeScan	T3V	Teva Women's Health
BCX	Biocodex	LLY	Lilly	T4T	Triton Pharma Inc
BGE	Biogen Idec	LUI	Luitpold Pharmaceuticals Inc	TAK	Takeda Pharmaceuticals
BGP	BGP Pharma ULC	LUN	Lundbeck Canada Inc	TAR	Taro Pharmaceuticals
BHL	Bausch & Lomb	M5F	Medical Futures	TBU	Tribute Pharmaceuticals
BMG	BMS-Gilead	M8A	Meda AB	TEV	Teva Canada Ltd
BMS	BMS Pharma	M-F	Merck Canada Inc	TVI	Teva Canada Innovation
BRR	Barr Laboratories	MKR	Mallinckrodt Pharmaceuticals	TVN	Teva Neuroscience
BS.	Basilea Pharmaceutica	MM-	MM Therapeutics	UC.	UCB Pharma Canada
BSA	BMS-Sanofi	M-P	Mint Pharmaceuticals	V9P	Valeo Pharma Inc
BY7	Biosyent	MSD	Merck Sharpe & Dohme Corp	VII	ViiV Healthcare
CBT	Cobalt Pharmaceuticals Inc	MYN	Mylan Pharma	VLT	Valeant Pharma
CC5	Celgene	MZ.	Merz Pharmaceuticals GmbH	VRE	Vertex Pharma Inc
CTO	Centocor Inc	N-N	Novo Nordisk Canada	WCT	Warner Chilcott Canada Co
DMI	Dominion Pharmacal	NO9	Novartis Vaccines	WTS	Watson Pharma Company
DUC	Duchesnay Labs	NU-	Nu-Pharm Inc		
EIS	Eisai	NVR	Novartis Pharma		

Glossary

Average compound growth rate: average annual growth rate between any two time periods.

(CPA): co-detailing is reported by adding (CPA) after the product name. This will appear under the company which does the co-detailing.

Dashes: that appear in tables (-) indicate that there is no number for a past year's ranking.

Detail: the presentation of a product to a physician by a sales representative.

Drug mentions: number of times a product is recommended by physicians in the given time period.

Ethical market: ethical products are distinguished from others in that, according to federal and/or provincial legislation, they are not generally advertised to the public, and ethical prescription products are available only in pharmacies and hospitals upon a physician's prescription. Ethical non-prescription products do not require a physician's prescription but are sold only in pharmacies.

Evolution index: growth rate of a specific product, manufacturer or corporation when compared to the growth rate of the class, corporation or market, respectively. For comparison purposes, the growth rate of the class, corporation or market is given an index of 100.

Extended unit: smallest measurable unit of a product depending on the product form, e.g., tablet, millilitre, gram.

Journal ad expenditures: the sum of the costs of ad pages per company, product and therapeutic class over the preceding twelve months.

General discussion: no specific detailing occurs during a representative's visit with a physician.

Institutional: describes company services or research but does not contain product-specific information.

Manufacturer not stated: activity recorded for a product where the manufacturer name is not provided at the collection point.

Molecule: the chemical name for the active ingredient in a product.

Most productive specialty: the specialty or specialty group which makes the highest per capita number of diagnoses or drug recommendations.

Non Pharmaceutical Ingredient: is used for all non-drug products that do not contain chemicals/ molecules.

Patient visits: estimated number of patient/physician contacts in a given time period.

Patient visits with drugs: estimated number of patient/physician contacts where drug therapy is recommended.

Private label: a line of products specially manufactured and labelled for a drug store chain. This category reports the combined activity of private labels for all drug store chains.

Rx: prescription.

Therapeutic class: a classification grouping products exhibiting similar therapeutic properties.

Total "Product Name": shows the sum of the activity for all forms and strengths of the product.

Total promotional dollars: the sum of the costs of detailing and the costs of journal advertising.

Total purchases: the total estimated drug store and hospital purchases measured. This includes all ethical products and some non-ethical (proprietary) products.

QuintilesIMS™

16720 Trans-Canada Highway
Kirkland (Québec) H9H 5M3
(514) 428-6000

535 Legget Drive, Tower C, 7th floor
Kanata, Ontario K2K 3B8
(613) 599-0711

6700 Century Avenue, Suite 300
Mississauga, Ontario L5N 6A4
(905) 816-5000

Contact us at www.quintilesims.com

About QuintilesIMS

CREATING SOLUTIONS FOR YOU TO DRIVE HEALTHCARE FORWARD

QuintilesIMS (NYSE:Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles and IMS Health, QuintilesIMS's approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes and enhanced clinical trial outsourcing through treatment innovations, care provision and access can leverage QuintilesIMS's broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial bringing clients a unique opportunity to realize the full potential of innovations and advance healthcare outcomes.

As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights. Through a wide variety of privacy-enhancing technologies and safeguards, QuintilesIMS protects individual privacy while managing information to drive healthcare forward. These insights and execution capabilities help biotech, medical device, and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders in the development and approval of new therapies, identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes. To learn more, visit www.quintilesims.com.

